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Abstract 
Cancer is the most common cause of the human death in the UK.  Every year 
3.2 million Europeans are diagnosed with cancer, and the figure is projected to 
rise due to the aging population.  Although significant advances are being 
made in the fight against the disease, cancer remains a key public health 
concern and a tremendous burden on UK society in financial and social terms.  
This thesis evaluated two classes of compounds that can be potentially 
developed as anti-cancer agents. 
4-(4-Methyl-2-(methylamino)thiazol-5-yl)-2-(4-methyl-3-
(morpholinosulfonyl)phenylamino)pyrimidine-5-carbonitrile (S-134, 5g) is a 
novel cyclin-dependent kinase 9 (CDK9) inhibitor showing nano-molar growth 
inhibitory potentials in established human cell lines.  Biochemical assays have 
confirmed that S-134 primarily inhibits CDK9 at the protein and cellular levels, 
respectively.  The detailed mechanistic investigation demonstrated that the 
compound caused wild-type p53 stabilisation and cell cycle arrest at the G2/M 
transition.  Cancer cell death induced by S-134 was proven by Annexin-V/PI 
staining, caspase-3 assay and PARP cleavage.  Transcription and expression of 
anti-apoptotic proteins Mcl-1, Bcl-2 and XIAP were reduced by the inhibitor, 
as proved by RT-PCR and Western blots respectively.  
Compound 2-methoxy-5-(3,4,5-trimethoxyphenethyl)phenyl 2,2,5,5-
tetramethyl-2,5-dihydro-1H-pyrrole-3-carboxylate-N-oxide (ZJU-6, 6g) a semi-
synthetic derivative of the natural medicinal compound Erianin (6a) was 
designed to introduce anti-oxidant property and enhance anti-angiogenic 
activity of Erianin.  The study of ZJU-6 revealed that while the effect of 
cellular growth inhibition and the transcription of Bcl-2 were reduced by the 
structural modification, the suppression of tubulin polymerisation and anti-
angiogenic properties were enhanced compared to Erianin. 
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Compound BI 2536, 4-(8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-
tetrahydropteridin-2-ylamino)-3-methoxy-N-(1-methylpiperidin-4-
yl)benzamide (10), is one of the most potent and selective inhibitors of Polo-
like kinase 1 (Plk1) and is a current experimental candidate for the treatment of 
cancer.  A racemic BI 2536 was synthesised using multiple synthesis routes, 
which aimed to use as a lead compound for the discovery of novel Plk1 
inhibitors. 
iii 
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Chapter One 
 
Introduction 
1.1 Cancer 
Cancer refers to a diversity of diseases characterised by the uncontrolled 
proliferation of cells into a different form against the normal complement of 
the organism
1
.  The continuous proliferation of cancer cells develops into 
tumour tissues and may spread across to other organs via circulatory systems 
resulting in metastasis.  There are two types of tumours: those demonstrating 
the properties described above, known as malignant tumours, which result in 
cancer; and those without malignant properties, which are self-limiting, non-
invasive and do not metastasise, known as benign tumours.  It is the metastases 
that are responsible for some 90% of deaths from cancer. 
Cancer may affect humans of all ages.  According to statistics from the 
American Cancer Society (ACS), cancer is the third most lethal disease after 
cardiovascular diseases and infectious and parasitic diseases
2, 3
.  In 2007, 13% 
of total human death worldwide was caused by cancer.  There are 3.2 million 
Europeans diagnosed with cancer every year
4
.  Hence, the medical needs for 
cancer remain one of the most demanding areas in scientific research. 
 
1.1. Cancer 
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1.1.1 Causes of cancers 
Cancer occurs when genetic mutations accumulate in cells during the 
replication of genetic material, allowing cells to undergo transformation.  The 
mutations of three major types of genes: oncogenes, tumour suppressor genes 
and DNA repair genes, play an important role in tumourgenesis.  
Oncogenes are genes whose products have the ability to transform 
eukaryotic cells so that they growth in a manner analogous to tumour cells.  
This class of genes were initially identified as genes carried by virus that 
causes transformation of their target cells.  A major class of the viral oncogenes 
have cellular counterparts that are involved in normal cell functions.  The 
cellular counterparts are known as proto-oncogenes, in certain cases their 
mutation or aberrant activation in the cell to form an oncogene is associated 
with tumour formation.  Oncogenes fall into several groups ranging from 
transmembrane proteins to transcription factors.  The generation of oncogene 
represents a gain-in-function in which a cellular proto-oncogene is 
inappropriately activated
5
.  This can involve a mutational change in protein, or 
constitutive activation, over expression, or failure to turn off expression at the 
appropriate time, which generates a tumourgenic effect in a cell resulting 
cancer. 
Tumour suppressor genes are identified by mutations represent loss-of-
function that contributes to cancer formation.  These genes usually impose 
some constraint on cell cycle procession or cell growth, i.e. checkpoint 
controls.  It is necessary for both copies of the gene to be inactivated in cells
5
, 
the two most important tumour suppressors are retinoblastoma (RB) and p53 
(see section 1.3 for details). 
1.1. Cancer 
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DNA damage happens continuously in all living organisms and there are 
genes acting as a natural defence mechanism to repair these DNA damages (see 
section 1.1.3).  Examples of DNA repairing genes include BRCA1 and BRCA2, 
which involve in the homologous recombination repair
6
.  Although more than 
99.9% of mutations are recognised and corrected by self-repairing systems, 
some cells will escape this monitoring system, thus promoting unlimited 
growth resulting in cancer. 
The genetic mutations may be caused by a number of sources: chemical 
carcinogens, ionising radiation, viral or bacterial infections, hormone 
imbalance, immune system dysfunction and heritable factors
1, 7-9
. 
DNA mutations that lead to cell proliferation are not self-driven, often 
stimulated by external factors or mutagens
5, 10
.  Mutations are usually corrected 
by the DNA repair systems.  Carcinogens, which induce permanent non-
repairable DNA damage include tobacco smoke and asbestos fibres, which are 
respectively associated with 90% of lung cancers and mesothelioma (a rare 
type of cancer for the outer lining of the lungs and internal chest wall)
11
.  
Tobacco smoke may also cause cancers of the lung, larynx, head, neck, 
stomach, bladder, kidney, oesophagus and pancreas, as it contains over fifty 
known carcinogens, including nitrosamines and polycyclic aromatic 
hydrocarbons, and is responsible for about 20% of cancer deaths worldwide.  
Not all carcinogens (agents that cause cancer) are mutagens (agents which 
cause DNA mutations); alcohol is an example of this type
12
.  The carcinogenic 
effects of alcohol are: an increase in the rate of cell division and a reduction in 
the period during which DNA repair enzymes can act.  Hence, the chances for 
mutations to be retained are increased. 
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Ionising radiation consists of subatomic particles or electromagnetic waves 
that are sufficiently energetic to detach electrons from atoms or molecules, i.e. 
they cause ionisation.  The best known example of ionisation radiation is 
ultraviolet light (UV)
13
, a natural source of radiation from the sun which can 
lead to melanoma and other skin malignancies.  Radon gas, X-rays and gamma 
rays are other examples of ionisation radiation which can cause cancer
14
.   
Some cancers can be caused by infection with pathogens
15
.  Viral infections 
are responsible of 15% of all human cancer worldwide, representing the second 
most important risk factor of cancer after tobacco.  The main viruses associated 
with human cancers are papillomavirus, hepatitis B and hepatitis C, Epstein-
Barr and T-lymphotropic virus
12
.  Viral induction of tumours may be via acute 
or slow transformation
16
.  In acute transformation, the virus carries an 
overactive oncogene or viral-oncogene (v-onc); the infected cell is transformed 
as soon as v-onc is expressed.  In contrast, slowly-transforming viruses insert 
their genome into the host cell genome at random.  This insertion occurs near a 
proto-oncogene viral promoter (or other transcription regulation element) and 
induces over-expression of the proto-oncogene, resulting in uncontrolled cell 
division.  Because the insertion is not specific to proto-oncogenes, slowly-
transforming viruses require a much longer time to induce over-expression of 
the proto-oncogene than acutely-transforming viruses.  Bacterial infection has 
also been linked to cancer development, with Helicobacter pylori being the 
best known example, chronic infections of the stomach wall being linked to the 
development of gastric cancer
17
. 
Some hormones can act in a similar manner to non-mutagenic carcinogens 
as they may stimulate excessive cell growth
18
.  A well-established example is 
1.1. Cancer 
5 

the role of hyperoestrogenic states in promoting endometrial cancer.  Immune 
system dysfunction also contributes to an increased risk of cancer 
development.  Human immunodeficiency virus (HIV), a lentivirus (a member 
of the retrovirus family) that leads to acquired immunodeficiency syndrome 
(AIDS), has been associated with a number of malignancies including Kaposi's 
sarcoma and non-Hodgkin's lymphoma, both caused by the breakdown of 
immune surveillance
15, 19
.  Another example, Human papillomavirus (HPV), 
infects the epidermis and mucous membranes of humans and has been 
associated with malignancies such as anal and cervical cancer
20
. 
Cancer is sporadic in most cases, with inheritance playing no role in the 
onset of disease.  However, in a number of recognised syndromes, inherited 
predisposition to cancer due to defects in genes giving protection against 
tumour formation, such as DNA repair genes and tumour suppressor genes, are 
passed to the offspring.  Examples include the BRCA1 and BRCA2 genes, 
which are associated with increased risks of breast and ovarian cancers, 
respectively
21, 22
.  Familial adenomatous polyposis, an inherited mutation of the 
APC gene
23
, leading to early onset of colon carcinoma and retinoblastoma in 
young children, is caused by the inheritance of a mutant retinoblastoma (RB) 
gene
24
. 
 
1.1.2 Prevention of cancers 
Cancer is caused by genomic instability resulting from mutation.  Mutation 
occurs during gene replication and natural repair mechanisms, which act as the 
first line of defence against cancer, operate continuously.   The DNA repair 
mechanisms are divided into various types, including direct repair, base 
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excision repair (BER), nucleotide excision repair (NER), mismatch repair 
(MMR), non-homologous end joining (NHEJ) and homologous recombination 
repair
5
.  Each of these mechanisms repairs different types of DNA damage. 
Direct repair can correct DNA damage without requiring a template; these 
include UV radiation induced thymine dimers and methylation of the bases 
guanine, cytosine and adenine.  
BER, NER and MMR repair single strand breaks, with the unaffected strand 
acting as a template for the repair mechanisms.  BER repairs damage to a 
single base caused by oxidation, alkylation, hydrolysis or deamination.  The 
damaged DNA base is removed by a glycosylase before being resynthesised by 
a polymerase, with ligase performing the nick-sealing step.  NER repairs bulky, 
helix-distorting lesions such as pyrimidine dimers.  This type of damage is 
repaired by a transcription-coupled repair system using a set of NER enzymes 
while the genes are actively transcribed.  Mismatch repair corrects errors 
arising during DNA replication and recombination which result in mis-paired, 
but undamaged, nucleotides.  This also requires template DNA, the damage 
being repaired by enzymes in a similar manner to BER and NER. 
Non-homologous end joining (NHEJ) and homologous recombination repair 
correct double strand breaks.  NHEJ uses DNA ligase IV to recombine both 
ends of the broken strands.  Recombination repair is also an enzymatic process, 
but requires the presence of an identical or nearly identical sequence to be used 
as a template for repair. 
The other aspect of cancer prevention involves voluntary actions which, 
unlike DNA repair, do not occur naturally and automatically.  Active measures 
to reduce the risk of cancer can be achieved by avoiding carcinogens or 
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altering their metabolism by following a lifestyle or diet that modifies cancer-
causing factors and/or medical intervention
25
.  The vast majority of cancer risk 
factors are environmental or lifestyle-related in nature, including tobacco, 
alcohol, physical inactivity and obesity
26
.  The use of exogenous hormones, 
exposure to ionising radiation and ultraviolet radiation as well as certain 
occupational and chemical exposures are other risk factors for cancer 
development.  These factors can be addressed by changes to life style.  
Scientific evidence has already shown that avoiding carcinogens can reduce the 
risk of cancer.  
The consensus of opinion on diet and cancer is that obesity increases the 
risk of developing cancer, although the correlation between reducing obesity 
and reduced risk of cancer remains to be established
27
.  However, certain types 
of food are known to increase the risk of certain cancer types.  Grilled meat 
contains high level of heterocyclic amines through the breakdown of proteins 
under high temperature cooking, these heterocyclic amines act as a source of 
carcinogen that increase the risk of stomach, colon, breast and pancreatic 
cancer
28, 29
.  The consumption of vitamins has been correlated to cancer risk.  
Although for most vitamins the link has not been scientifically proved, 
deficiency of vitamin D is correlated to the increase risk of cancer
30
.  
A new concept of chemoprevention of cancer has come to light in recent 
years, supported by a large number of clinical trials.  An example of this is the 
use of Tamoxifen, an oestrogen antagonist
31
.  Consumption of Tamoxifen for a 
period of five years has been found to significantly reduce the risk of breast 
cancer.  Other chemicals such as polyphenols, naturally occurring agents found 
in green tea and wine, have been suggested to have cancer prevention 
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properties through the presence of anti-oxidants
32, 33
.  The role of natural 
products in cancer prevention will be discussed later in more detail.  
Since the inheritance of genes such as BRCA1 and BRCA2 has been found to 
increase cancer risk, genetic screening for the existence of these genes is one 
way to prevent cancer
34
.  There are commercially available products that allow 
for the rapid screening of clinical specimens to be conducted.  Vaccination 
against viral or bacterial inducers of cancer, such as human papilloma virus 
(HPV) vaccine, is a new measure to reduce cancer risk.  Two vaccines against 
HPV are currently available, Gardasil and Cervarix, which aim to prevent the 
development of cervical cancer and genital warts
35, 36
.  There is also a hepatitis 
B vaccine, which reduces the risk of liver cancer
37
.  A canine melanoma 
vaccine has also been developed
38
. 
 
1.1.3 Treatments of cancers 
In the unfortunate situation where cancer has been diagnosed, there are a 
number of treatments available
39, 40
.   As cancer refers to a class of disease, it is 
unlikely that one single cure for all forms of cancer is possible.  The most 
common methods include surgery, radiation therapy and chemotherapy.  There 
are other methods of treatment such as targeted therapies (monoclonal antibody 
therapy)
41
, immunotherapy
42
 and hormonal therapy
43
.  New methods, 
immunotherapy in particular, which targets specific antigen solely expressed 
by tumour cells, only target cancer and not the healthy cell population, hence 
minimising the adverse effects observed with traditional methods.  
Small molecule inhibitors are sometimes classified as targeted therapy as 
they inhibit specific molecular target(s).  Best example of this is Gleevec, 
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marketed by Novartis, which is the first line treatment of chronic myelogenous 
leukaemia in America
44
.  Gleevec specifically targets the kinase domain of 
three tyrosine kinases, which are the Abelson proto-oncogene (abl), c-kit and 
the platelet-derived growth factor receptor (PDGFR). In leukaemia, the 
translocation between chromosome 9, which contains abl, and chromosome 22, 
which associates with the breakpoint cluster region (bcr) gens, forms the 
Philadelphia chromosome, a new form of chromosome 22.  The Philadelphia 
chromosome encoded a fusion protein termed bcr-abl, a tyrosine kinase.  
Gleevec inhibits the bcr-abl activity in all cell types, however, normal cells 
have other kinases to substitute this activity and maintain normal cellular 
activity.  Alternatively, some tumour cells depend on bcr-abl activity, the 
absence of bcr-abl leads to tumour cell death.  
 
1.2 Kinases 
Kinases are enzymes which transfer a phosphate group from a high energy 
donor, such as adenosine triphosphate (ATP), to a specific substrate; a process 
known as phosphorylation
45
.  There are large varieties of kinase across animal 
and plant species, the largest group being protein kinases.  Protein kinases act 
on and modify the specific activity of a protein, which are used extensively in 
signal transduction and to control complex metabolic processes in cells.  There 
are three outcomes after a protein is phosphorylated: activation or inhibition of 
protein activity, enhancement of the binding of a protein to its substrate, 
initiation or enhancement of degradation through ubiquitination
7
.  Thus protein 
kinases regulate a diverse range of signalling pathways and protein behaviour.  
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The diversity of protein kinases across species is huge in terms of numbers 
and types (Table 1.1)
46
.  So far, more than 500 protein kinases have been 
identified in humans, compared to 130 in yeast and 240 in the Drosophila fly 
(Drosophila melanogaster).  
 
Table 1.1: Distribution of protein kinases across species46.  The second and third columns 
indicate the number of families and subfamilies in general.  The numbers of kinases in yeast, 
worm, fly and human were compared.   A general trend exists with more complex organisms 
having a higher number of kinases.  However, it does not affect the variation in each types, all 
organisms having at least one kinase for each type showing that a minimal function from each 
kinase type is required for intrinsic signalling cascades common to all species to function 
properly (Adapted from Manning et al. Science. 2002, 298, 1912). 
 
Among the 518 protein kinases in humans, 478 belong to a single super 
family whose catalytic domains are related in sequence.  These can be 
clustered into groups, families and subfamilies, based on similarity of amino 
acid sequences and biochemical function.  The kinase dendrograms or tree 
(Figure 1.1) shows the sequence similarity between the catalytic domains of 
kinases - the distance along the branches between two kinases is proportional 
to the divergence between their sequences.  Using this classification system, 
the 478 proteins are divided into seven groups.  Furthermore, protein kinases 
can be divided into two groups based on their ability to remove a phosphate 
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group from ATP and covalently attach it to one of three amino acids of other 
protein that have a free hydroxyl group, e.g. serine, threonine or tyrosine.  Most 
kinases are able to phosphorylate both serine and threonine, known as 
serine/threonine specific kinases; while others act on tyrosine, being classified 
as tyrosine kinases.  Dual-specificity kinases are capable of phosphorylating all 
three amino acids.  The relationships shown on the dendrogram can be used to 
predict protein substrates and biological function for more than 100 
uncharacterised kinases presented.  A further 40 atypical kinases have no 
sequence similarity to typical kinases, but are known or predicted to have the 
enzymatic activity of kinases, and some are predicted to have a structural fold 
similar to typical kinases. 
1.2. Kinases 
12 

 
Figure 1.1: The kinase dendrogram (kinase tree)46.  478 protein kinases which belong to a 
single superfamily are divided into seven groups based on similarity of amino acid sequences 
of the kinases and their biochemical function.  These include PKA, PKG, PKC families 
(AGC); Calcium/calmodulin-dependent protein kinase (CAMK); Casein kinase 1 (CK1); CDK, 
MAPK, GSK3, CLK families (CMGC); homologs of yeast Sterile 7, Sterile 11, Sterile 20 
kinases (STE); Tyrosine kinase (TK) and Tyrosine kinase-like (TKL) family (Adapted from 
Cell Signalling Technology®). 
 
Tyrosine-specific protein kinases are important regulators in signal 
transduction.  They act primarily as growth factor receptors, such as platelet-
derived growth factor receptor (PDGFR) and epidermal growth factor receptor 
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(EGFR), and in downstream signalling from growth factors.  Tyrosine kinases 
consist of a transmembrane receptor with a tyrosine kinase domain projecting 
into the cytoplasm.  These kinases play key roles in regulating cell division, 
cellular differentiation and morphogenesis.  The extracellular part of the kinase 
serves as a ligand binding domain.  Ligand binding triggers the dimerisation of 
two monomer tyrosine kinase receptors and the cascade of linkage events 
results in trans-autophosphorylation of the kinase by other members in the 
kinase complex.  This finally leads to the activation of the kinase domain 
allowing the binding of ATP, hence promoting signal transduction through 
phosphorylation as enzymatic reactions in most cases.  
Serine/threonine-specific protein kinases phosphorylate substrate protein 
based on residues flanking the phosphor-acceptor site which, together, 
comprise the consensus sequence.  As a result, the catalytic domains of kinases 
in this group are highly conserved.  These kinases are regulated by specific 
events (e.g. DNA damage), as well as numerous chemical signals, including 
cAMP/cGMP, diacylglycerol and Ca
2+
/calmodulin.  For clinical interest, 
serine/threonine kinase expression is altered in many types of cancer.  
Therefore, these kinases are important targets for cancer therapy
47
.  One of the 
targets is the cyclin-dependent kinases (CDKs).  
 
1.2.1 Cyclin-Dependent Kinases 
CDKs are one of the most extensively studied Ser/Thr kinases.   Cell division 
cycle 2 (Cdc2) was the first identified member of the CDKs and was originally 
isolated from Saccharomyces cerevisiae.  Initially, Cdc2 was found to regulate 
the cell cycle of yeast.  Later it was found in a range of plants and mammals.  
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The protein identified in human, homologous to Cdc2, is known as CDK1
48, 49
.  
To date, more than 10 types of CDK and 15 types of cyclin genes have been 
identified in the human genome.  Originally, it was thought that CDKs only 
role was to regulate the cell cycle.  However it has since been discovered that 
CDKs also play a major role in the regulation of transcription
46
.  Other 
functions operated by CDKs have been indicated in neuronal signalling, cell 
differentiation, cell death, golgi membrane trafficking, insulin exocytosis by 
pancreatic ȕ-cells and retinal phosphodiesterase regulation.  As mentioned in 
its name, the functions of CDKs depend on its cyclin counterparts (Figure 1.2); 
a different cyclin combination to the same CDK may result in changes or affect 
its function.  Using CDK2 as an example, CDK2/cyclin E functions during the 
cell cycle transition between gap phase I (G1) and DNA synthesis (S) phase, 
while CDK2/cyclin A is required throughout the progression of S phase
50
.  
Cyclin binding causes a confirmation change within the CDK enzyme, 
exposing a cleft complementary to ATP, thus enabling ATP binding, which 
leads to phosphorylation and their activation
51
.  In the regulation of cell cycle, 
CDK-activating kinase (CAK) complex is required to phosphorylate CDK1, 2, 
4 and 6, which enhances their CDK-cyclin binding
52, 53
.  The CAK complex is 
composed of the catalytic subunit CDK7, the regulatory subunit cyclin H, and a 
Menage A Trosi 1 (MAT1) protein subunit, a polypeptide corresponding to 
residues Met 1  Asp 65 of RING finger domain
54
.  In general, CDKs can be 
divided into three groups according to their primary function: CDKs involved 
in cell cycle regulation, which includes CDK1, 2, 3, 4 and 6; CDKs involved in 
regulation of eukaryotic transcription, which includes CDK7, 8, 9 and 11; 
CDKs involved in intra-vascular signalling, such as CDK5.   
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Figure 1.2: Functional diversity of cyclin-dependent kinases in human.  The functions of 10 
human CDKs have been identified50.  These CDKs required the association of various cyclin to 
promote their functions (Adapted from Ferrari. Cell. Mol. Life. Sci. 2006, 63, 781)   
 
1.3 Cell cycle 
The cell cycle refers to a cascade of cellular events leading to the division and 
duplication of cells.  In eukaryotes, the cell cycle can be divided into two 
distinct periods: the interphase and the mitotic (M) phase.  The interphase 
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consists of three phases: gap phase I (G1), responsible for synthesis of 
organelles in most cells; synthesis phase (S), during which DNA is replicated; 
and gap phase II (G2), which is a period in preparation for cell division.  The 
mitotic phase leads to segregation of chromosomes and results in two daughter 
cells, which is the end point of cell division.  Very often, cells become 
quiescent orsenescent after mitosis; this phase of is known as G0.  

Figure 1.3: Schematic diagram of the cell cycle.  Gap phase I (G1), synthesis (S), and gap 
phase II (G2) are collectively known as interphase.  Mitotic (M) phase can subdivided into 
further five phases; cytokinesis is the end point of the phase and of cell division. 
 
Activation of each phase of the cell cycle depends on the progression and 
completion of the previous phase (Figure 1.3).  In theory, cells will undergo G1 
phase for continuous growth after the completion of mitosis.  However, in 
multi-cellular eukaryotes cells very often enter G0 from G1 if they are non-
proliferative.  The time span of G0 can be very long, even indefinite in the case 
of neuron cells and cell types which are fully differentiated.  It is also a phase 
for cellular responses to DNA damage with affected cells becoming senescent, 
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rendering them at a metabolic active state but unable to divide.  It is an 
alternative to programmed cell death i.e. apoptosis
55
. 
G1 phase is the first step in interphase, extending from the end of the 
previous M phase until the beginning of DNA synthesis.  The biosynthetic 
activity of the cell increases from the previous M phase.  The size of the cell 
increases during G1 phase and the synthesis of enzymes required for DNA 
synthesis is the most noticeable product of this phase.  The duration of this 
phase varies across cell types, even within the same species.  S phase 
commences with the synthesis of DNA.  At the end of the S phase, all 
chromosomes are replicated, resulting in two chromatids per chromosome.  
The synthesis of histone is another product in this phase.  During the G2 phase, 
the rate of protein synthesis increases again after falling during the S phase.  
The main product of the G2 phase is microtubules required for the segregation 
of chromosomes, together with other components required during mitosis
56
. 
Cells enter mitosis after interphase is completed.  Mitosis has a relatively 
short length compared to other phases; it consists of karyokinesis and 
cytokinesis, the division of nucleus and cytoplasm, respectively.  In animal 
cells, mitosis is divided into five phases: prophase, premetaphase, metaphase, 
anaphase and telophase.  As plant cells contain large vacuoles which shift 
nuclei to the side of the cells, an extra phase called pre-prophase occurs before 
prophase.  This essential step of moving the nucleus to the middle of a cell 
before the start of prophase occurs with the formation of phragmosome and the 
pre-prophase band (a ring of microtubules and actin filaments).  During 
prophase, the centrosomes (a pair of centrioles) appear near the nucleus.  The 
genetic material, normally appearing as chromatin during interphase, 
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condenses into chromosomes which are lined up with the microtubules formed 
between the centrioles.  Moving into prometaphase, the nuclear membrane is 
degraded and microtubules invade the nuclear space.  These microtubules will 
then either attach themselves to kinetochores formed by the centromere or 
interact with opposing microtubules.  Metaphase is characterised by 
chromosomal alignment in the metaphase plate or equatorial plane.  During 
anaphase, sister chromatins are cleaved; each complete set is pulled towards 
the opposite ends of the cells.  At telophase, cells elongate further and 
microtubules degrade while a new nuclear membrane forms around the 
chromosomes.  Finally, cytokinesis follows, resulting in separation of two 
daughter cells
56
. 
 
1.3.1 Cell cycle checkpoints and CDKs 
In eukaryotic cells, there are three checkpoints operating during the cell cycle: 
G1/S, G2/M, and the metaphase checkpoint.  These checkpoints verify whether 
the processes at each phase of the cell cycle are completed accurately before 
progressing to the next phase.  An important function of these checkpoints is to 
detect any DNA damage using an enzymatic sensor system.  If damage is 
detected, a signalling mechanism is used to induce cell cycle arrest until the 
damage is repaired.  Cells with unrepaired damage will undergo apoptosis, 
which is the effector mechanism of cell cycle control
57
.  Cyclin-dependent 
kinases (CDKs) are key regulators of cell cycle.  CDK4 and CDK6 in complex 
to D-type cyclins together with CDK2/cyclin E1 regulate the transition from 
G1 to S phase, while CDK1/cyclin B1 controls the cell cycle transition from 
G2 phase to mitosis
58
.  Besides their roles in cell cycle regulation, CDKs are 
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involved in other functions depending on the way in which they were activated.  
The failure of these checkpoints leads to diseases such as cancer
59, 60
.  
 
1.3.1.1 CDK2, 4, 6 and the G1/S checkpoint 
The G1/S checkpoint makes the decision whether the cell should divide, delay 
division, or enter a resting phase (i.e. G0).  This restriction point is regulated by 
CDK inhibitor protein p16
61
, a member of INK4 CDK inhibitor family.  Other 
members of the INK4 family including p15, p18 and p19 also play the negative 
regulatory role to CDK4/6
62
.  They inhibit CDK4/6 activity through direct 
binding to prevent the CDK-cyclin associations.  The expression of these CDK 
inhibitor proteins is induced in response to DNA damage allowing cell cycle 
arrest and subsequent DNA repair, or continuously expressed throughout the 
cell cycle providing a threshold level of inhibition which must be overcome. 
CDK4 combined with D-type cyclins control the proliferation of cells 
during G1 phase by altering the phosphorylation state of retinoblastoma (RB) 
protein
63
.  Three different types of type D cyclins are found in humans: cyclin 
D1, D2 and D3
64, 65
.  CDK7 has been reported to play a role in cell cycle 
progression
66
.  CDK7 associates with cyclin H and MAT1 to form the CDK-
activating kinase (CAK) complex
54
.  CAK is a subunit of transcription factor 
TFIIH, a component of the RNA polymerase II (RNAP II) holoenzyme 
complex in mammals.  Phosphorylation of CDK4 on amino acid residue 
threonine 172 and the binding of cyclin is triggered by CAK
67
, which leads to 
the phosphorylation of CDK6 on threonine 177
68, 69
.  CDK4/cyclin D1 or 
CDK6/cyclin D1 phosphorylates the C-terminal of RB protein
70, 71
, this 
phosphorylation leads to the displacement of histone deacetylase and induces 
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E2F dependent transcription
72
. This activation induces the downstream 
phosphorylation of CDK2 and disrupts the pocket structure, which activates 
CDK2 at the end of the G1 phase.  
CDK2 is highly homologous to CDK1 in structure
73
.  In growth stimulated 
normal human fibroblast cells, the mRNA of CDK2 appears in the late G1 or 
early S phase.  In the cell cycle transition, phosphorylation by CAK on 
threonine 170 and the association of cyclin E is required for the activation of 
CDK2
68, 74
.  Protein p27 is a member of Cip/Kip CDK inhibitor family that 
inhibits the activity of CDK2 by associating with the CDK2/cyclin E1 
complex
75
.  At normal cellular levels of ATP, p27 phosphorylates at Thr 187 
modulated by Transforming growth factor beta (TGF-ȕ), which results in the 
ubiquitination of p27.  Another member in the Cip/Kip CDK inhibitor family, 
p21, functions in a similar manner as with p27 inhibiting the activity of 
CDK2/cyclin E1
62
.   
The cell proceeds from G1 to S phase with CDK2/cyclin E1 maintains the 
hyper-phosphorylated state of RB and phosphorylates other substrates required 
for S phase progression such as Histone H1
76
.  During S phase, CDK2 binds 
cyclin A to initiate DNA replication by phosphorylating numerous targets such 
as the DNA polymerase alpha primase, a key enzyme for DNA synthesis
77
.  
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Figure 1.4: Molecular pathways involved in the transition of G1 to S phase in the cell cycle78.  
Environmental stresses induce various negative regulators which suppress the activity of 
CDK4/6 and CDK2.  Removal of these negative regulators and the induction of activators 
restore the function of the CDKs; phosphorylation of downstream substrates such as RB and 
E2F leads to the progression of cell cycle from G1 to S phase (Adapted from Cell Signalling 
Technology®). 
 
1.3.1.2 CDK1 and the G2/M checkpoint 
The second checkpoint operates at the end of G2 phase.  This checkpoint 
triggers the transition from G2 to M phase.  One of the key factors checked is 
the DNA damage.  The main effect protein response to DNA damage is p53.  
In response to DNA damage, active p53 triggers the direct association of CDK 
inhibitor proteins, such as p21, with CDK1/cyclin B1 complex, resulting cell 
cycle arrest
62
. 
CDK1 associates with cyclin A and phosphorylates components that are 
essential for mitosis during late G2 phase of the cell cycle
77
.  CDK1 is then 
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negatively regulated by the phosphorylation of MYT1 kinase at threonine 14 
and tyrosine 15
79
.  Prior the cell cycle transition from G2 to M phase, CDK1 is 
dephosphorylated by cdc25
80
, which allows the association of CDK1 and 
cyclin B1
48
, also known as the maturation promoting factor (MPF)
81
.  
Phosphorylation of MPF on threonine 161 of CDK1 by CAK triggers the 
progression of cell cycle form G2 to M phase
68
. CDK1 also plays a role in 
mitosis by phosphorylating RCC1 (Regulator of Chromosome Condensation 1) 
protein to coordinate spindle assembly
82
.  The activated RCC1 generates 
RanGTP on mitotic chromosomes, which is essential for spindle assembly and 
chromosome segregation. 
 
Figure 1.5: Molecular pathways involved in the transition of G2 to M phase in the cell cycle78.  
DNA is the main object checked in this checkpoint.  p53 is the main effector protein response 
to DNA damage.  Without DNA damage, majority of Cdc2 negative regulators including 
p21will not be induced, which leads the activation if Cdc2 and the progression of cell cycle 
from G2 to M phase (Adapted from Cell Signalling Technology®). 
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1.3.1.3 Metaphase checkpoint 
During mitosis, the metaphase checkpoint monitors the chromosomes 
alignment during metaphase on microtubules before proceeding to the 
anaphase.  Improper attached kinetochores, a substance that responsible to the 
attachment of mitotic chromosomes to microtubules and their movements, 
triggers the arrest of cell cycle at metaphase
5
.  The expression of Budding 
Uninhibited by Benzimidazoles protein 3 (BUB3) is triggered by the improper 
attachment of kinetochores in eukaryotic cells
83
.  BUB3 forms an inhibitory 
complex with several proteins, including Mitotic Arrest Deficient proteins 
(MADs) at the kinetochores, which inhibits the formation of Anaphase-
promoting complex (APC).  The inhibition APC formation is achieved by 
MAD2 proteins, which interact directly with Cell Cycle Division protein 20 
(Cdc20)
84
, an activator of the APC by promoting ubiquitination of an anaphase 
inhibitory protein known as securin
85
.  Without Cdc20, the centromeres extent 
the chromosomal microtubules until kinetochores are properly aligned.   Once 
the kinetochores are aligned properly on the mitotic spindle, MAD2 releases 
Cdc20 which trigger the cascade signalling pathways including the 
ubiquitination of sercurin and the cell proceeds to anaphase. 
 
1.3.2 Cell cycle and cancer 
Cell cycle abnormalities are a common underlying pathology within human 
malignancies.  These abnormalities are caused by alternations at genetic levels, 
which lead to the possible transcription alternation and protein dysfunction, 
resulting uncontrollable cell cycle progression.  Vast and diverse alternations 
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within the cell cycle have been linked with the generation of malignancy in 
cells
62, 86
.  The two major carcinogenic pathways being commonly altered are 
the RB and p53 pathways. 
 
1.3.2.1 The RB pathway  
Retinoblastoma protein (RB), also known as pRB, was the first proto-oncogene 
identified, its mutation links to the onset of many cancers including retinoma
87
.  
It is a key substrate for the CDK-cyclin complexes in the G1/S phase 
checkpoint.  In quiescent cells, or during the first part of G1, RB is bound to 
the transcription factor E2F
5
.  E2F activity is required for transcription of genes 
which are essential in S phase.  The formation of RB-E2F complex is believed 
to be critical for the arrest of cells at G1 phase.  In addition, RB, also interacts 
with chromatins, it binds histone deacetylases, which may initiate the removal 
of acetyl groups at the target promoters, thus inactivating the promoters.  
Components of the chromatin remodelling complex are potential targets of RB.  
Non-phosphorylated RB forms a complex with D-type CDK4 and CDK6, but it 
is also a substrate of CDK2/cyclin E
72
.  Upon phosphorylation at or close to the 
restriction point, phosphorylated RB releases E2F allows transcription of genes 
required for S-phase, and releases suppression of genes suppressed by the RB-
E2F complex, which leads to the progression of cell cycle into S phase. 
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Figure 1.6: The roles of RB in cellular level5, 78.  Under normal circumstances, RB is associated 
with E2F.  Members of INK4 family inhibit the activity of CDK2, 4 and 6 to phosphorylate 
RB.  Phosphorylated RB release E2F, which leads to the E2F dependent transcription.  The 
products of E2F dependent transcripts are essential for the G1/S phase transition of the cell 
cycle to occur.  Components in red have been reported to be alternated in cancer, which 
includes the unregulated CDKs activities and mutation of RB leading to its uncontrolled 
phosphorylation; over expression of cyclin D leads to hyperactive CDK4/6 and the mutation of 
INK4 genes leads to unregulated CDKs activities involved in the G1/S checkpoint. 
 
In cancer, a large number of alternations related to abnormalities in RB 
function.  A common alteration in RB results in the unregulated 
phosphorylation by CDKs operated at the G1/S phase checkpoint (i.e. CDK2, 4 
and 6).  Direct mutation of RB is also possible; the human papilloma virus 
(HPV) is able to cause RB mutation via its E7 reading fame.  This sort of 
mutation can be referred to as a loss-of-function mutation
86
; mutated RB loses 
its ability in binding with E2F, leading to the unregulated E2F transcription and 
the transcription of proteins required for the cell cycle transition from G1 to S 
phase.   
Over expression of cyclin D is required for oncogenic cells to overcome this 
checkpoint by competing for the binding of CDK4/6 with their negative 
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inhibitors
5
.  This causes hyper-phosphorylation of RB, release of active E2F 
and eventually leads to the inappropriate progression of cell cycle. 
Mutations within the INK4 genes locus, which encode CDK inhibitor 
proteins p15, p16, p18 and p19, are other common features within human 
carcinomas.  Depletion or deletion of CDK inhibitor proteins, the most 
prevalent and relevant to the RB pathway is the mutation of p16
88
.  Mutated 
INK4 genes lead to unregulated activities of CDKs function in cell cycle 
checkpoints, resulting inappropriate cell cycle progression and carcinogenesis.  
 
1.3.2.2 The p53 pathway 
p53, one of the best known tumour suppressors, has a key role in response to 
DNA damages and other genomic alteration at a cellular level
89
.  p53 is 
negatively regulated by oncoprotein HDM-2.  Binding of HDM-2 induces the 
ubiquitination and proteasomal degradation of p53 to prevent its accumulation 
in cells
90
.  p53 activation requires the phosphorylation by several different 
protein kinases, including DNA dependent protein kinase, Ataxia-
telangiectasia mutated (ATM) - Ataxia-telangiectasia and RAD3-related (ATR) 
kinases, of Ser 15 and Ser 37 in response to DNA damage
91-93
, resulting the 
dissociation of HDM-2 and accumulation of p53.  Cell cycle checkpoint 
kinases, Chk1 and Chk2, enhance p53 tetramerisation, stability and activity by 
phosphorylating Ser 20 of p53
94, 95
.  Acetylation, which is mediated by p300 
and Creb-binding protein (CBP) acetyltransferases, appears to play a positive 
role in the accumulation of p53 protein in stress response
96
.  Since this 
acetylation effects on p53, it is therefore negatively regulated by HDM-2. 
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Activated p53 triggers the expression of proteins including p21, which 
results in cell cycle arrest at the restriction point or G2 phase by inhibiting 
CDK2/cyclin E or CDK1/cyclin B, respectively.  Following DNA damage, p53 
is acetylated at Lys 382 in human and Lys 379 in mouse
97
, which promotes 
direct binding of p53 to the damaged DNA and triggers the DNA repair 
mechanisms.  Deacetylation of p53 occurs through interaction with the Sirtuin 
1 (SIRT1) protein following DNA repair
98
.  For cells with non-repairable DNA 
damage or under other circumstances in which programmed cell death is 
required, p53 can induce a variety of apoptotic pathways including Bcl-2-
associated X (Bax) dependent apoptosis
99
 (Figure 1.7).   Bax is a pro-apoptotic 
protein; it binds to mitochondria membrane and triggers caspase-dependent 
apoptosis. 
 
Figure 1.7: The roles of p53 in cellular level99.  Under normal circumstances, p53 is associated 
with HDM-2 which leads to the degradation of p53, with ubiquitination as the major pathway.  
In response to the DNA damage of genomic alternation, p53 is phosphorylated at Ser 15 and 
Ser 37 which leads to the dissociation of HDM-2 from p53.  Activated p53 induces cellular 
DNA repair, activates p21 which causes cell cycle arrest, or induces Bax dependent apoptosis.  
The negative feedback loop of p53 increases the translation and expression of HDM-2 which 
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binds to p53 and regulates its activity.  Proteins coloured in blue are reported to be alternated in 
cancers. 
 
In human tumours, the most common form of p53 alternation is the loss of 
p53 function.  This leads to the reduced or complete loss of p21, resulting in 
uncontrolled cell cycle progression and cell proliferation
99
.  Increased 
phosphorylation of p53 at Ser 392 has been reported in human tumours to 
influence the function of growth suppressor, DNA binding and transcriptional 
activation of p53
100
.  Bax expression, the potential primary response gene of 
p53, could be altered by abnormal p53, hence preventing apoptosis
99
.  
Increased expression of HDM-2 has been noticed in many tumour cell lines as 
an indirect mechanism of carcinogenesis
101
.  Other regulatory components in 
the p53 network such as the ATM/ATR kinase may also be altered in 
malignancy.   
 
1.3.3 Apoptosis 
In eukaryotes, some cells must die during development in order to control the 
number of cells.  All cells possess pathways that can cause death, which is 
known as programmed cell death or apoptosis
5
.  Apoptosis requires activation 
of a pathway that leads to suicide of the cell by a characteristic process in 
which the cell becomes more compact, blebbing occurs at the cell membranes, 
chromatin becomes condensed and DNA is fragmented.  Ultimately, the dead 
cells are fragmented and engulfed by cells such as macophages.  However, the 
pathway is activated only by appropriate stimuli, such as irradiation of cells 
which triggers p53 activation which induces apoptosis.  The ability of p53 to 
induce apoptosis is a crucial defence against cancer; apoptosis is also a key to 
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immune defence and elimination of cancerous cells
5
.  Apoptosis can be divided 
into the extrinsic and intrinsic pathways, respectively. 
 The extrinsic pathway requires extracellular signal transduction from 
membrane receptor protein across the plasma membrane.  One of the best 
characterised death receptor families is the Tumour Necrosis Factor (TNF) 
receptors.  Other well known death receptors include Fas and CD95
102
.  The 
binding of ligands to the appropriate death receptors results in receptor 
aggregation which triggers recruitment of the adaptor molecule Fas-associated 
death domain (FADD) and caspase-8. 
Caspases are proteases that are involved in multiple stages of the apoptotic 
pathway and are synthesised as inactive pro-caspases that are activated by 
auto-cleavage to form the active dimer.  ~14 mammalian caspase are identified 
and divided into two groups.  The caspase-1 subfamily is involved in the 
response to inflammation, while the caspase-3 subfamily (consisting of 
caspase-3 and caspases-6 to 10) is involved in apoptosis
5
.  For extrinsic 
apoptosis, the cell surface receptor forms a complex with a receptor binding 
protein, such as TNFR-1/Fas/CD95 with FADD, and caspase-8.  Upon 
interaction between receptors and ligands, caspase-8 is activated through 
oligomierisation by the receptors, which cleave BH3-Interacting Domain death 
agonist protein (BID) to release a C-terminal domain that translocates to the 
mitochondrion, and leads to the release of cytochrome c from mitochondria 
into the cytosol
103
.  Cytochrome c binds to Apoptotic protease activating factor 
1 (Apaf-1) and (pro)-caspase-9 to form the apoptosome.  The apoptosome 
results the activation of caspase-9 by auto-cleavage, which activates other 
caspases downstream of this cascade with caspase-3 as the main target.  
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Activation of caspase-3 and other caspases by auto-cleavage triggers the 
effector phase of apoptosis when cellular structures are destroyed, which 
includes protein degradation, membrane damage and DNA cleavage, resulting 
in cell death
5
. 
The intrinsic apoptotic pathway is characterised by a change in 
mitochondrial membrane permeability, which is regulated by members of Bcl-
2 family, such as Bax
102
.  Subsequent release of cytochrome c from the 
mitochondria triggers formation of the apoptosome and results in activation of 
caspase dependent apoptosis through activation of caspase-9.  Hence, both 
extrinsic and intrinsic apoptotic pathways merge at the mitochondria and 
subsequently employ the same mechanisms to effect programmed cell death. 

Figure 1.8: The roles of anti-cancer drugs on apoptosis.  Anti-cancer drugs employ both 
extrinsic and intrinsic apoptosis.  For extrinsic apoptosis, caspase-8 is activated by auto-
cleavage upon the ligand-receptor binding of death ligand (e.g. TNF-TNFR), which cleaves 
BID protein.  The C-terminal domain of cleaved BID induces the expression of cytochrome c 
from mitochondria.  Intrinsic apoptosis induced cytochrome c expression by changing the 
permeability of mitochondrial membrane.  An example of intrinsic activation is the binding of 
Bax to mitochondrial membrane triggered by p53 activation.  Cytochrome c forms a complex 
known as apoptosome with Apaf-1 and caspase-9.  The activated caspase-9 in apoptosome 
cleaves caspase-3, which leads to the effector phase of apoptosis. 
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Anti-cancers agents employ both extrinsic and intrinsic apoptosis in order to 
induce tumour cell death
102
.  Most of the chemotherapy agents are known to 
activate extrinsic apoptosis.  5-Fluorouracil, a chemotherapy agent for the 
treatment of colon carcinomas, is known to activate CD95 for extrinsic 
apoptosis.  Some chemotherapy agents, such as paclitaxel, are known to have 
an indirect role in activating intrinsic apoptosis by triggering perturbations of 
intermediate metabolism, or by increasing the concentration of pro-apoptotic 
second messengers, such as the activation of p53 leading to the expression of 
Bax (Figure 1.8).   
In tumour cells, anti-apoptotic factors are usually expressed to suppress this 
programmed cell death.  There are two stages where anti-apoptotic proteins 
could suppress this pathway.  Bcl-2, one of the best known anti-apoptotic 
factors, suppresses apoptosis in many cells by inhibiting the release of 
cytochrome c from mitochondria through direct binding to the outer 
mitochondrion membrane
104
.  IAPs are another group of anti-apoptotic proteins 
which inhibit the formation of apoptosome
105
.  Proteins that antagonise IAPs 
may be released from the mitochondrion to overturn the effect of these anti-
apoptotic proteins.  
 
1.3.4 Anti-apoptotic factors 
In tumour cells, transcription of anti-apoptotic factors has been linked to the 
activity of CDK9.  Anti-apoptotic proteins Mcl-1, Bcl-2 and XIAP have been 
reported to be regulated by CDK9 at transcriptional levels by RNAP II
106
. 
Mcl-1 (Myeloid cell leukaemia-1) protein is a member of Bcl-2 family 
which acts as a potent multi-domain anti-apoptotic protein
107, 108
.  Mcl-1 has 
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been found to be over-expressed in malignant human tumours, including non-
small cell lung carcinoma, and cholangiocarcinoma.  Mcl-1 localises to the 
mitochondria and associates with other members of Bcl-2 proteins, such as 
Bax, which forms a heterodimer to inhibit the activity of these proteins (i.e. 
apoptotic induction), hence protects cells against apoptosis
109, 110
.  Mcl-1 has 
also been found to inhibit apoptosis by interfering with the association of p53 
and BAK (Bcl-2 antagonist killer)
111
.  The formation of the p53/BAK complex 
has shown to release Mcl-1.  This indicates that Mcl-1 works as a negative 
regulator of p53 by competing with BAK as a binding partner. 
Bcl-2 (B-cell CLL/Lymphoma 2) is one of the most extensively studied 
anti-apoptotic factors and is a cancer survival gene.  Bcl-2 was first found to be 
over-expressed in follicular lymphoma, localised in the inner mitochondrial 
membrane and suppressing apoptosis of pro-B lymphocytes
112
.  The presence 
of the RAF1 protein kinase in mitochondria improves Bcl-2 activity in resisting 
cell death
113
.  Bcl-2 has also been found in normal human brain tissue, spinal 
cord tissue, cytotoxic (killer) and memory T cells
114-116
.  In addition, Bcl-2 is 
also involved in a huge number of caspase-dependent / -independent apoptotic 
pathways
117
. 
 XIAP (X-linked inhibitor of apoptosis) gene is located on human 
chromosome 23 X (Xq25)
118
.  XIAP shows high homology with the 
baculovirus inhibitor of the apoptosis gene which encodes proteins that 
significantly inhibit apoptotic cell death.  XIAP protein inhibits the activation 
of caspase-3, -7 and -9, all of which are involved in major apoptotic 
pathways
119, 120
.  XIAP is targeted nuclear factor kappa B (NFkB), which leads 
to the inhibition of C-JUN kinase (JNK) resulting cell apoptosis
121
.  
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Ubiquitination of XIAPs, a guided degradation, has been suggested as a critical 
event in apoptosis
122
.  XIAP has also been found to associate with other anti-
apoptotic proteins, such as BIRC5, and interact with protein kinase A to 
promote survival in human cancer cells
123
. 
 
1.4 Eukaryotic transcription and CDKs 
Transcription is a process in cells to synthesise messenger ribonucleic acid 
(mRNA) from genomic DNA; the mRNA is later translated into proteins.  In 
higher eukaryotes including humans, CDK7, CDK8, CDK9 and CDK11 play 
regulatory roles during the processes of transcription initiation and elongation 
by RNA polymerase II (RNAP II).  There are three types of RNA polymerase - 
I, II and III
5
.  In humans, RNAP II is the most abundant.  Ribosomal RNA 
genes are transcribed by RNAP I ribosomal RNA genes, while RNAP III 
transcribes small nuclear and transfer RNA genes. 
Activator signals, such as growth factor proteins, initiate transcription in 
eukaryotic cells.  The activators bind to the sequences adjacent to the promoter 
of a particular gene, these sequences, sometimes known as initiator or distal 
enhancers (Figure 1.9)
124
, can also be located inside the promoter sequence.  
The binding of an activator to the regulatory sequence leads to the assembly of 
RNAP II, general transcription factors (GTFs), including TFIIA, TFIIB, TFIID, 
TFIIE and TFIIH, and a large multi-protein complex mediator which directly 
communicates with other gene-specific regulators
125
.  This assembled protein 
complex is known as the pre-initiation complex (PIC).  PIC assembly is 
directed to the start site by core promoter sequences such as the TATA 
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box
126
, a tandem repeated DNA sequence consisting of 5-TATAAA-3, which 
is recognised primarily by TFIID and other GTFs. 

Figure 1.9: Mechanism in the pre-initiation phase of RNA polymerase II dependent 
transcription124.   Activator binds to upstream promoter region to initiate the formation of pre-
initiation complex (PIC), which includes RNA polymerase II, general transcription factors 
(GTFs) and the Mediator.  TFIID is the predominant GTF involved in PIC.  In some genes, 
chromatin modifying co-factors such as histone acetyltransferase (HAT).  Creb-binding protein 
1 (CBP-1) will also be recruited if histone modification is involved in the regulation of that 
particular gene (Adapted from Blackwell & Walker.  Transcription mechanism.  WormBook. 
2006). 
 
The most fundamental mechanism of PIC recruitment is gene specific 
activation to induce transcription, but PIC assembly is also influenced by 
histone modification and its positioning
127
.  Histones are the basic protein 
building blocks of chromatin, which acts as a reel for DNA coiling and regulate 
gene expression.  At the promoter region of a gene, specific gene activators or 
repressors affect the configuration of chromatin by recruitment of chromatin 
modification or remodelling factors.  Transcription regulation by histone 
modification is a hugely complicated process involving many other signalling 
pathways.  The process of binding of activators to the PIC assembly in the core 
promoter region is known as the pre-initiation phase of transcription. 
From early studies in C. elegans and human cells, it has been shown that the 
process of transcription occurs dominantly through the phosphorylation of 
RNAP II at its large subunit (RPB1) C-terminal domain (CTD) after the 
assembly of PIC.  RNAP II CTD consists of tandem repeats (38 in C. elegans, 
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52 in humans) of a seven amino acids sequence (5'-Tyr-Ser-Pro-Thr-Ser-Pro-
Ser-3')
124
.  RNAP II is recruited to the PIC with the CTD in an 
unphosphorylated state
128
.  The CTD repeat is phosphorylated on Ser 5 by 
CDK7 at the promoter region of the gene.  This phosphorylation is regulated by 
CDK8, which is associated with cyclin C (another component of RNAP II 
holoenzyme complex)
129
 and regulates the activity of CDK7 through the 
phosphorylation of cyclin H1 at Ser 5 and Ser 304, resulted in suppression of 
transcriptional activation by TFIIH
125, 130
.  The phosphorylation of RNAPII by 
CDK8 prevents the RNAP II assembly on to the promoters, therefore prevents 
the initiation of transcription.  The phosphorylation at the Ser 5 of RNAP II in 
the PIC complex by the CDK7 subunit of TFIIH promotes RNAP II to proceed 
from the promoter region to the downstream sequence, a process known as 
promoter clearance.  The RNAP II complex is then arrested at the 5,6-dichloro-
1-ȕ-d-ribofuranosylbenzimidazole (DRB) sensitivity inducing factor (DSIF) - 
negative elongation factor (NELF) complex
131
, which acts as a checkpoint 
allowing and ensuring the association of mRNA capping enzyme (C.E.) to 
RNAP II, which add the 5'cap to the nascent pre-mRNA transcript. 
The RNAP II CTD is subsequently phosphorylated on Ser 2 by CDK9 
(Figure 1.10) which initiates transcription elongation and allows mRNA 
termination and processing factors to be recruited directly to the CTD. At this 
stage, RNA nucleotides assemble at their complementary base on the coding 
DNA through RNAP II.  CDK11/cyclin L is involved in this stage of 
transcription with one of its two isoforms in humans, p110, functioning in 
transcriptional related activity and RNA splicing
132
.  Reduction of p110 in vitro 
has shown a reduction in transcriptional activity, while the re-addition of p110 
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rescued transcriptional activity.  Similarly, immunodepletion of p110 from 
splicing extracts shows profound reduction in the amount of spliced RNA 
transcript produced in vitro
133
. 
 
Figure 1.10: Regulation of transcription initiation and elongation by CDKs124.  CDK7/cyclin H, 
which is regulated by CDK8/cyclin C, phosphorylate RNAP II CTD at Ser 5, which allows 
dissociation of TFIIH from RNAP II and promotes clearance of RNAP II from the core 
promoter.  Capping enzyme (C.E.) binds to RNAP II to generate a 5'cap for the mRNA.  
Phosphorylation of CTD Ser 2 by CDK9 follows and transcription elongation begins.  CDK11 
regulates the transcriptional activity and the mRNA splicing (Adapted from Blackwell & 
Walker.  Transcription mechanism.  WormBook. 2006).  
 
Once RNAP II reaches the terminator sequences on the DNA template, 
RNAP II detaches from the template DNA, proteins recognise the terminator 
sequences cause the cleavage of the nascent RNA from the DNA template 
following the polyadenylation signal
5
.  The addition of a poly-A tail stabilises 
the mRNA which exports outside the nucleus for post-transcriptional 
processing.  
The phosphorylation of the CTD of RNAP II is a key regulatory event of the 
process from transcription initiation to downstream nuclear events which 
include mRNA processing, termination and nuclear export
128
.  CDK7 and 
CDK9 are essential for the initiation and synthesis of mRNA, which leads to 
the nuclear export and translation of mRNA to the synthesis of protein in the 
ribosome. 
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1.5 Natural products 
Natural products refer to chemical compounds or substances naturally 
synthesised by living organisms
133
.  Sometimes, these natural products have 
biological activity against disease and may therefore have potential for use in 
drug discovery and design.  Chemicals that may be synthesised in the 
laboratory, but are found naturally occurring in organisms, are also considered 
as natural products. 
Natural products may be extracted from terrestrial plants, marine organisms 
or micro-organism fermentation broths.  A crude extract from any one of these 
sources typically contains a vast range of novel, structurally diverse chemical 
compounds.  The degree of diversity comes from the geographic and 
environmental diversity of the species habitats, coupled with variation in the 
species themselves.  
The plant kingdom is the most common source of natural products; plants 
having been used for medicinal purposes since the beginning of human 
civilisation and have been successfully exploited in Chinese medicine.  The 
simplicity of plant organisation increases their ability to adapt to the 
environmental changes through variation
134
.  Plants represent a rich source of 
compounds with therapeutic properties, such as morphine, cocaine, digitalis, 
quinine, tubocurarine, nicotine and muscarine.  These compounds very often 
have complex structures and are unlikely to be easily synthesised in 
laboratories.  
Micro-organisms, such as bacteria and fungi, have been invaluable in drug 
discovery.  The most famous example is the discovery of penicillin
135
.  After 
its discovery, water and soil samples were studied intensively to obtain new 
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strains of antibiotic producing microbes, leading to the discovery of 
antibacterial agents such as cephalosporins, tetracyclines, aminoglycosides, 
rifamycins and chloramphenicol.  
Marine organisms have recently received significant attention in natural 
product discovery.  Coral, sponges, fish and other marine microorganisms 
contain potent chemicals with anti-inflammatory, antiviral and anticancer 
activities. Curacin A is a compound obtained from marine cyanobacterium 
with anti-tumour activity
136
.  Animals, their venoms and toxins are other 
sources which have yielded new medicines
137
. 
Sources Drugsbeingdiscovered
Plant morphine,cocaine,digitalis,quinine,tubocurarine,
nicotine,muscarine,paclitaxel,artemisinin
Microbes penicillin,cephalosporins,tetracyclines,
aminoglycosides,rifamycins,asperlicin,lovastatin,
ciclosporin,chloramphenicol
Marine curacinA,eleutherobin,discodermolide,bryostatins,
 dolostatins,cephalostatins
Animal,venomsandtoxins epibatidine,teprotide
 
Table 1.2: Some of the best known drugs discovered from natural sources135-138.  Plants 
contribute the most drugs of all natural sources, their compounds treating a wide range of 
diseases.  Microbes are the second most abundant source for natural product discovery, the 
majority being anti-microbial agents.  There are some exceptions such as asperlicin and 
lovastatin which reduce anxiety and cholesterol levels respectively.  Animals, venoms and 
toxins contribute to drug discovery occasionally, examples being epibatidine and teprotid, an 
extract from the Ecuadorian poison frog and a peptide isolated from the venom of the Brazilian 
viper, which are analgesic and antihypertensive agents respectively. 
 
The complexity of many natural products poses a problem to their study, 
making them far too expensive to synthesise in the laboratory.  Drugs such as 
penicillin, morphine and paclitaxel (Taxol) can only be obtained from natural 
sources
138
.  
In the developed world, almost all clinically used chemotherapeutics have 
been produced by semi- or total chemical synthesis as this is a most efficient 
way to obtain medicine.  However, many non-natural, synthetic drugs induce 
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severe adverse effects unacceptable except in last resort treatments for terminal 
diseases.  Although most natural medicinal products, particular those with anti-
cancer properties, are highly toxic, the use of metabolites discovered in 
medicinal plants and other natural sources still have the possibility avoid the 
adverse effects of synthetic drugs as these compounds may accumulate within 
living cells in the species itself without adverse effects. 
Semi-synthetic procedures often involve harvesting a biosynthetic 
intermediate from the natural source, which can then be converted to the final 
product by conventional synthesis.  There are two advantages in using this 
approach.  Firstly, the intermediate may be more easily extracted in higher 
yield than the final product, an abundant supply being available for conversion 
into the active compound within the species itself.  Secondly, it may allow the 
possibility of synthesising analogues of the final product to generate chemical 
diversity.  Production of penicillins is an illustration of this approach; 
semisynthetic penicillins, which have similar functions to natural penicillins, 
are currently used as medicines
139
. 
The use of natural products is one of the major approaches in drug 
discovery.  A large number of natural products and derivatives were approved 
as registered drugs and contributing currently approximately 50% of marketed 
drugs.  More importantly, there is still enormous scope for the development of 
natural products as, despite their long history of medicinal use, the potential for 
most plant species remains unexplored. 
In recent years, natural products are believed to have an effect on the 
prevention of disease.  Compounds with polyphenolic functions are often 
identified in natural sources, such as grapes and tea
140
.  These polyphenols 
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possess anti-oxidant properties, which are believed to prevent or slow down the 
occurrence of diseases such as cancer.  Among these compounds, the most 
extensively studied polyphenol is Epigallocatechin gallate (EGCG)
32
.  
EGCG is the most abundant catechin (polyphenolic anti-oxidant plant 
metabolite) found in green tea and may have therapeutic properties for many 
disorders, including cancer and AIDS
141
.  Although oxidation is an essential 
process in living organisms, free oxygen radicals are mutagens which cause 
DNA damage and are associated with certain forms of cancer; hence oxidative 
stress may induce cell damage and death
142
.  Therefore, dietary intake of anti-
oxidants, including polyphenols and vitamins, are implicated in the prevention 
of disease.  In the case of EGCG, experimental data have proven that it could 
reduce oxidative stress and may be beneficial in HIV treatment
143
.  However, 
the quantity required to achieve such an effect cannot be achieved through 
normal dietary intake.  Nevertheless, extensive research has been carried out to 
investigate the medicinal use of polyphenols. 
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1.6 Aims and objectives 
The project is divided into three parts:  
x Evaluation of CDK9 inhibition as an anti-cancer strategy using 
chemical biology approaches.  A class of rationally designed inhibitors 
were tested for their anti-proliferative activity against human cancer 
cells.  A lead inhibitor was further selected and used to study the 
detailed cellular mode of action and anti-cancer property.  
x The study of natural product derivatives.  The cellular growth inhibitory 
effect of the product will be investigated.  This includes its effect on 
cell cycle and cell death induction, expression and transcription of anti-
apoptotic, and tumour suppressor proteins, suppression of tubulin 
polymerisation as well as its anti-angiogenic and anti-oxidant properties 
x The synthesis of BI 2536, a known Polo-like kinase 1 (Plk-1) inhibitor, 
was attempted in order to use this compound as a biologic tool for the 
validation of Plk-1 as a pharmacologic target for cancer. 
Drug discovery is a multi-step process; this project involves the synthesis 
phase and in vitro biological evaluation and mechanistic study of small 
molecule inhibitors.  A wide range of biological and chemical techniques are 
also employed.  These techniques are critical at the early stages of drug 
discovery, which determines whether a compound has the potential to become 
a successful drug.  
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Chapter Two 
Mechanism of action of a novel 
CDK9 inhibitor 
2.1 Introduction 
Protein kinases are fundamental regulators of essential molecular pathways in 
live cells.  One of most extensively studied kinase groups is the 
serine/threonine (Ser/Thr) protein kinases.  Some of the best known Ser/Thr 
protein kinase family members include cyclin-dependent kinases (CDKs), 
Polo-like kinase (Plks) and Aurora kinases.  These kinases are involved in the 
progression of the cell cycle and are altered in several diseases including 
cancers. 
 
2.1.1 Cyclin-Dependent Kinase 9 
Cyclin-dependent Kinase 9 (CDK9) was initially identified in mice in 1994.  It 
was first isolated by performing PCR on a mouse embryonic cDNA library, 
using oligonucleotide primers based on regions conserved over CDK1 related 
proteins
144
.  The CDK9 gene was isolated by comparing the PCR product to a 
cDNA library from humans.  The human CDK9 gene was later mapped to be 
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on chromosome 9 (9q34.1).  By performing a northern blot analysis, which 
separates the RNA by size, it was found that the mRNA of CDK9 was 
expressed with a length of 2.8 and 3.2 kb in human.  The highest levels of 
mRNA expression were found in the liver and placenta.  Real time PCR (RT-
PCR) of total RNA from HeLa cells led to the identification of two isoforms of 
CDK9; these were CDK9-55 and CDK9-42 with a calculated molecular weight 
of 55 and 42 kD, respectively.  CDK9-55 contains a 117 amino acids N-
terminal extension with a proline-rich region and a glycine-rich region in 
addition to the 372 amino acids of CDK9-42 (Figure 2.1).  The ratio between 
the two CDK9 isoproteins varies between different tissues, with CDK9-42 
generally a more dominant form over CDK9-55 in most tissues
145
.  Human 
macrophages activated by lipopolysaccharide or infected with HIV are an 
exception with CDK9-55 expressed dominantly. 
 
Figure 2.1: Gene and amino acids sequences of CDK9145.  The genes sequence of CDK9 
encoded both CDK9-55 and CDK9-42.  The gene sequence of CDK9-55 has an extended exon 
1 sequence over CDK9-42. Hence the amino acid sequence of CDK9-55 has an additional 117 
amino acids at the N-terminal of the protein compared to CDK9-42.  
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Comparing the amino acid sequences to other CDKs, CDK9 has shown 41 - 
43% sequence conservation with CDK1, CDK2, CDK4 and CDK5 with CDK2 
most homologous to CDK9
146
.  CDK9 binds to cyclin T1, T2a, T2b or cyclin K 
to become an active unit known as positive transcription factor b (P-TEFb)
147
.  
The association between CDK9 and cyclin T requires the interaction of 
bromodomain containing protein 4 (BRD4)
148
, a transcriptional co-activator.  
Increased expression of BRD4 causes increased phosphorylation of RNAP II 
CTD
149
.  The recruitment of P-TEFb to a promoter is BRD4 dependent and is 
enhanced by the increase of chromatin acetylation.  At the cellular level, half of 
the P-TEFb was negatively regulated by 7SK small nuclear RNA (snRNA) and 
Hexamethylene bis-acetamide-inducible (HEXIM1 or HEXIM2) protein
148, 150
.  
Various stimuli, including stress and hypertrophic signals, induce release of P-
TEFb from the inhibitory complex, which allows the binding of transcription 
factors, such as nuclear factor kappa B (NFkB).  Following the binding of co-
activators (e.g. BRD4), P-TEFb is recruited to the transcription initiation 
complex. 
The function of P-TEFb is to regulate transcription elongation by RNAP II 
through phosphorylation.  P-TEFb phosphorylates the DSIF-NELF complex 
which allows the removal of promoter-proximal pausing on the transcription 
initiation complex.  Subsequent phosphorylation of RNAP II CTD at Ser 2 of 
the tandem repeats (5'-Tyr-Ser-Pro-Thr-Ser-Pro-Ser-3') promotes active 
transcription elongation.  The phosphorylation of Ser 2 also has an indirect role 
in the regulation of RNA splicing, termination and polyadenylation of nascent 
mRNA
151
. 
 
2.1. Introduction 
45 

2.1.2 CDK9 and human pathologies 
Since CDK9 is involved in transcription, an essential process that occurs in 
almost all living cells at some stage, therefore CDK9 has been linked to many 
disease areas, including virology, cardiology and oncology
151
. 
 
2.1.2.1 Virology  
Many viruses require their host transcription system to synthesise proteins 
essential for their replication, particularly the human immunodeficiency virus 
(HIV).  CDK9 was found to be linked to acquired immunodeficiency syndrome 
(AIDS), with its prospective role in (HIV)-1 related to transcription through 
7SK RNA
151
.  In humans, 7SK is an abundant snRNA transcribed by RNA 
polymerase III.  7SK RNA inhibits the activities of P-TEFb and HIV-1 tyrosine 
aminotransferase (Tat)-specific transcription by suppressing the activity of 
CDK9 and preventing recruitment of P-TEFb to the HIV-1 promoter
152
.  
Treating cells with agents that enhance HIV-1 transcription and RNAP II 
phosphorylation such as actinomycin D shows 7SK RNA dissociate from P-
TEFb, enhancing CDK9 activity and transcription.  P-TEFb and 7SK RNA 
association is a specific and reversible interaction.  As CDK9 is crucial for 
HIV-1 transcription, the activity of 7SK snRNA is suppressed in HIV-1.  The 
role of BRD4 in P-TEFb is replaced by Tat in HIV-1; therefore Tat is required 
for the formation of P-TEFb in HIV-1.  Another component of P-TEFb, cyclin 
T1, its C-terminal domain helix shows flexibility that might be critical for 
HIV-1 Tat and HEXIM association that regulates the activity of P-TEFb. 
 
2.1. Introduction 
46 

2.1.2.2 Cardiology 
Over-expression of CDK9 is also linked to cardiac hypertrophy
153
, a syndrome 
with an increase in the size of terminally differentiated cardiomyocytes.  
Increased CDK9 activity against the C-terminal domain of RNAP II subunit A 
(POLR2A) was found in ventricle samples from patients with heart failure 
caused by dilated cardiomyopathy
154
.  Studies from cyclin T1 deficient mice 
have shown that the induction of cyclin T1 expression in cardiomyocytes 
maintained CDK9 activity in mouse hearts, resulting in myocyte enlargement 
and selective suppression of PPAR-gamma co-activator (Pgc1), a master 
regulator of several metabolic processes, including mitochondrial biogenesis 
and respiration.  The ultimate effects of such CDK9 activity induction in 
defective mice were mitochondrial defects, enhanced myocyte apoptosis, 
predisposition to heart failure and early death
155
. 
Another known function of CDK9 is its involvement in myogenesis, the 
generation of muscle cells
156
, including the pacemaker of the heart.  Over-
expression of CDK9/cyclin T2a induced the expression of MyoD and enhanced 
myocyte differentiation.  MyoD also acts as a transcription factor which binds 
to P-TEFb promoting transcription elongation.  Cyclin T2a has also been found 
to induce the expression of other myogenic differentiation factors such as 
myogenin and myosin heavy chain.  P-TEFb was found to selectively activate 
transcription mediated by the myocyte enhancer factor 2 (MEF2) in murine 
C2C12 cells
157
.  Knockdown of endogenous cyclin T1 by siRNA was found to 
reduce the expression of MEF2 dependent reporter genes, which may underlie 
the potential transcription mechanisms in muscle cells. 
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2.1.2.3 Oncology 
The alteration of cell cycle has been linked to the onset of cancer.  As 
described in section 1.3, the unregulated cell cycle CDKs activity leads to the 
alteration and dysfunction of tumour suppressors, such as RB and p53.  
Tumour suppressors dysfunction lead to the unregulated transcription of 
components required for cell cycle progression, or anti-apoptotic factors which 
suppress programmed cell death in oncogenic cells.  CDK9 has been linked to 
the transcription of components in the RB and p53 pathways, such as p21 in 
the INK4 CDK inhibitor family.  CDK9 is also associated with the 
transcription of anti-apoptotic factors Mcl-1 (Myeloid cell leukaemia-1), Bcl-2 
(B-cell CLL/Lymphoma 2), XIAP (X-linked inhibitor of apoptosis) and BAG-1 
(Bcl-2-associated athanogene 1)
106
. 
One of the major applications of CDK9 inhibitors is for the treatment of 
chronic lymphocytic leukaemia (CLL) in B-lymphocytes
106
, a type of cancer 
characterised by combination of blocks in apoptosis, such as the expression of 
Mcl-1 and Bcl-2 (see section 1.3.4).  An inhibitor targeting CDK9 may 
suppress transcription in cancers; this suppression of transcription could reduce 
the synthesis of anti-apoptotic proteins required for the survival of cancer cells, 
which will lead to cell death. 
In normal healthy cells, apoptotic factors such as the Fas ligand (FasL), a 
member of tumour necrosis factor (TNF)
158, 159
, are expressed at low levels.  
Oncogenic transformation refers to the process where normal cells are 
transformed into tumour cells via carcinogenic induction.  After oncogenic 
transformation, a number of apoptotic factors such as TNFs is released, triggers 
a cascade of signalling pathways and the activates caspase-dependent 
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apoptotsis
160
.  Tumour cells are highly mutated cells that may escape 
programmed cell death by expressing anti-apoptotic genes and proteins 
including Bcl-2, Mcl-1, IAPs and survivin
108, 161
. CDK transcriptional 
inhibition can suppress the transcription and expression of anti-apoptotic 
proteins and causes cancer cell death
162
 (Figure 2.2).  
 
Figure 2.2: Rational of targeting transcription as a potential cancer therapy162. The oncogenic 
transformation should increase the sensitivity of cells to apoptotic signals (A).  However, 
tumour cells expression anti-apoptotic factors (I) suppress the function of apoptotic factors 
(AI) and reduce the sensitivity of tumour cells to apoptosis, hence enable tumour cell survival.  
Transcriptional inhibitors should suppress the production of anti-apoptotic factors (I) which 
would lead to tumour cell death.  Normal cells however, do not affected by transcriptional 
inhibition, as majority of normal cells are in G0, i.e. quiescent and do not required transcription 
(Adapted from Koumenis et al. Mol. Cell. Biol. 1997, 17, 7306). 
  
In tumour cells, transcription of anti-apoptotic factors has been linked to the 
activity of CDK9.  Anti-apoptotic proteins Mcl-1, Bcl-2 and XIAP have been 
reported to be regulated by CDK9 at transcription by RNAP II
106
.  The use of 
CDK9 inhibitors for cancer treatment hopes to suppress the expression of these 
anti-apoptotic proteins transcribed in tumours cells
163
, which results in tumour 
cell death. 
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2.1.3 Discovery of CDK9 inhibitors 
CDK9 inhibition has presented as one of the most effective targets for the 
treatment of proliferative diseases.  To identify inhibitor compounds, two 
strategies are frequently used, e.g. kinase structure-based design, or inhibitor 
compound analogue design and modification.  Most kinase inhibitors, 
including Gleevec
44
, are designed as ATP antagonists.  Based on the x-ray 
crystal structure of CDK2, three regions in the ATP-active binding domains are 
crucial for design of the ATP mimetics: the hinge region, the ribose binding 
domain and the hydrophobic binding pocket.  The latter is crucial for designing 
inhibitors with specificity for individual CDKs
164
.  The structure of ATP 
binding domain is conserved among the CDKs, in particular between CDK2 
and CDK9
165
. 
 
Figure 2.3: Binding between the ATP binding pocket of CDK2 and ATP164.  Three hydrogen 
bonds are crucial for this binding in this ATP-CDK complex: NH2: Glu 81 CO; pyrimidine N1: 
Leu 83 NH; pyrimidine H6: Leu 83 CO, respectively.  Most kinase inhibitor-CDK complexes 
have replicated and conserved binding in this form (Adapted from Wang et al. J. Med. Chem. 
2004, 47, 1662). 
 
The crystal structure of CDK9 in complex with cyclin T1 has recently been 
solved (Figure 2.4)
147
.  Docking studies show that ATP antagonists bind to the 
ATP binding site of CDK9 inducing unanticipated structural changes that 
possibly inhibit kinase activity. 
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Figure 2.4: Crystal structure of CDK9 (green) bound to cyclin T1 (brown)147.  The red dot is 
the phospho-threonine residue in the activation segment.  Cyclin T1 consists of 5 helices (H) 
and short N- (NH) and C- terminal (Adapted from Hirose & Ohkuma.  J. Biochem. 2007, 141, 
601).  
 
Our novel CDK9 inhibitors are designed as the ATP antagonists against the 
ATP binding pocket of the kinase domain.  The potency and selectivity were 
optimised based on our advanced medicinal chemistry and structural biology 
techniques.  
A number of CDK9 inhibitors have been reported in the literature, some of 
which are currently undergoing clinical trials
50
 (Figure 2.5).  As they target the 
ATP active binding site, many of these known inhibitors are pan-CDK 
inhibitors
151, 166
. 
 
Figure 2.5: Structures of some of the best known CDK inhibitors.  DRB is regarded as the 
prototype of CDK9 inhibitor, as it is a substance naturally found in eukaryotic transcription.  
DRB is the most selective CDK9 inhibitor.  Flavopiridol and Seliciclib inhibit multiple kinases 
and are currently under clinical evaluation.  
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2.1.3.1 DRB 
5,6-dichloro-1-ȕ-d-ribofuranosylbenzimidazole (DRB) 1 is a substance 
originally identified in the DRB sensitivity inducing factor (DISF) - negative 
elongation factor (NELF) checkpoint, this checkpoint appeared shortly after the 
elongation of pre-mRNA to ensure the addition of 5'cap during transcription
131
.  
DRB can be regarded as the prototype due to its close association with the 
original identification of CDK9 P-TEFb kinase. DRB had long been known to 
suppress the transcription of long mRNA; this property was then related to the 
inhibition of a number of cellular kinases.  To date, DRB is still the most 
selective inhibitor against CDK9 possibly due to its role in nature.  DRB had 
been evaluated as a possible therapy for cancers and HIV
167, 168
.  However due 
to the poor cellular activity and unfavourable pharmaceutical properties (such 
as its inhibition over a large range of human kinases resulting in the lack of 
selectivity), DRB was unable to proceed to clinical trials. 
 
2.1.3.2 Flavopiridol 
Flavopiridol 2, also known as Alvocidib or HMR-1275, is a semi-synthetic 
flavonoid of a natural product Rohitukine, which is isolated from Dysoxylum 
binectariferum
169
.  Flavopiridol works by competing with ATP for binding to 
the active site, thereby inhibiting the activities of CDKs.  In vitro data revealed 
Flavopiridol inhibited the phosphorylation of RNAP II CTD and led to a 
significant reduction in Mcl-1 and XIAP expression, resulting in caspase-3 
dependent apoptosis.  Flavopiridol is most potent CDK9 inhibitor with a Ki 
value of 3 nM in kinase assay; it also inhibits CDK2 and CDK7 but at lower 
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potencies.  Flavopiridol has also shown to inhibition the transcription of 
HIV
170
. 
 Flavopiridol is currently undergoing clinical trials for the treatment of solid 
tumours and chronic lymphocytic leukaemia (CLL)
171
.  However, differential 
protein binding of flavopiridol in humans was observed
172
.  In addition, pro-
inflammatory side effects have been observed within phase I and II clinical 
trials
173
.  In terms of efficiency, Flavopiridol as a monotherapy agent for solid 
tumours has shown partial tumour resolution or reduced tumour progression.  
Combination therapy with traditional cytotoxic agents was shown to increase 
tumour cell death
174
.  From in vivo studies treating tumour cells with anti-
neoplastic agents, such as paclitaxel, followed by flavopiridol, it is thought that 
flavopiridol enhances the anti-tumour activity of anti-neoplastic agents by 
reducing the apoptotic threshold
175
.   
 
2.1.3.3 Seliciclib 
Seliciclib 3, also known as R-roscovitine or CYC202, was developed by 
Cyclacel Ltd.  It was developed from the separation of the two optical isomers 
from Roscovitine, which was originally found to prevent cell division of sea 
urchin embryos
176
.  Seliciclib was developed as a potential treatment for non-
small cell lung cancer (NSCLC), leukaemia, HIV-1 infection, herpes simplex 
infection and chronic inflammation disorders.  Seliciclib inhibits the activity of 
most CDKs, preferably against CDK2/cyclin E, CDK7/cyclin H and 
CDK9/cyclin T1 (see section 2.4).  CDK2 activity is most affected by this 
compound, hence, inducing cell cycle arrest at S phase and G2/M transition in 
treated cells.   
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Seliciclib is currently undergoing Phase IIb clinical trials.  However, a 
number of adverse effects were reported during the Phase I trials, including 
vomiting, transient elevations in serum creatinine and transient hypokalaemia.  
Seliciclib is also undergoing clinical trials for treating B-cell lymphomas, 
relating to its inhibition of CDK9 activity in B-lymphocytes.  The possibility of 
using Seliciclib in the treatment of AIDS and chronic inflammatory diseases, 
such as cystic fibrosis, are currently under evaluation. 
The work described in this chapter investigates the properties of a series of 
novel inhibitors designed to inhibit CDK9 activity in hope of identifying a 
novel selective CDK9 inhibitor which is also a potent inhibitor of cancer cell 
growth.  
 
2.2 Identification of novel CDK inhibitors 
A class of small molecule inhibitors were designed based on the structure of 
2,4-disubstituted pyrimidine 4 CDK inhibitor series164 (Figure 2.6).  

Figure 2.6: The general structures of 2,4-disubstituted pyrimidine 4 and 2,4,5-trisubstituted 
pyrimidine 5. 
 
Both compound series 4 and 5 were designed to work as ATP antagonists of 
CDK9.  Inspection of the binding mode of compound 4 in the ATP binding 
pocket of CDK2 revealed that this compound bind similarly to natural ATP
164
.  
2.2. Identification of novel CDK9 inhibitors 
54 

In both cases, a group of three H-bonds between the ligand and the backbone 
of CDK2 residues Glu 81 and Leu 83 was observed.  The three hydrogen bonds 
formed between 4 and the CDK2 ATP binding pocket were: pyrimidine H6: 
Glu 81 CO; pyrimidine N1: Leu 83 NH; aniline NH: Leu 83 CO, respectively. 
To improve the potency and selectivity for CDK9, a novel class of 2,4,5-
trisubstituted pyrimidines 5 with R1 at the 5C-position of the pyrimidine ring 
was designed, which was expected to interact with the gatekeeper residue Glu 
81 CO (Figure 2.7).  The extension of the heterocyclic system of the molecule 
can also be achieved by introduction of a hydrophobic group, including phenyl, 
tert-butyl or isobutyl groups, in the thiazole ring (R3). 

Figure 2.7: The proposed binding of 2,4,5-trisubstituted pyrimidine 5 to the ATP binding 
pocket of CDK9.  Glu 81 (in red) CO represents the gate keeper residue which should be 
covalently bound with the R1 residue of 5.  Another two H-bonds should be formed between 
pyrimidine N1: Leu 83 NH; aniline NH: Leu 83 CO, respectively. 
 
A number of compounds were tested against MTT proliferation assays with 
72 hours exposure to the compounds, as described in section 6.3, were used to 
estimate the concentration of molecules required to inhibit cell growth by 50% 
(GI50).  Two human cancer cell lines and a human fibroblast cell line were used 
for the screening; the human cancer cell lines used to estimate the effect of our 
molecules on inhibiting cancer cell growth were HCT-116 human colon 
carcinomas cells and MCF-7 human breast adeno-carcinomas cells.  A human 
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embryonic lung fibroblast cell line MRC-5 was used to indicate selectivity of 
compounds between cancer and normal cells.  Many compounds demonstrated 
potent anti-proliferative activity in cancer cells. 
 
Table 2.1:  The structure activity relationship (SAR) of a series of novel CDK9 inhibitors 
based on the GI50 values.  MTT assays were performed following 72 hours exposure to agents 
against HCT-116, MCF-7 can MRC-5 cells.  
 
From Table 2.1, compound 5a to 5g generally demonstrate a 10 times 
selective between cancer cells (HCT-116 and MCF-7) and Fibroblast cell 
(MRC-5) lines.  Although some of these compounds, such as 5b, show a better 
selectivity than 5g, however, their chemical structures are lack of novelty.  
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Other compounds in Table 2.1 (i.e. 5h to 5w) which show better potency and 
selectivity were synthesised almost a year after 5g, therefore, for the interest of 
this project, 5g was selected for further mechanistic studies; we named this 
compound S-134. 

Figure 2.8: Chemical structure of S-134 5g.
 
 
2.3 Cellular growth inhibition of S-134 
HCT-116 and MCF-7 was used for the initial screening.  The GI50 of S-134 5g 
were in a range of 0.07 to 0.39 µM.  The compound was also active against 
MRC-5 with a GI50 values of 0.64 µM.  There was approximately 7.5 fold 
selectivity between HCT-116 human colon carcinomas cells and MRC-5 
human embryonic fibroblast cells.  A total of 13 human cell lines were then 
used to further investigate the effect of S-134 on cancer cell lines derived from 
a wider spectrum of organ sites (Table 2.2).  S-134 was shown to be most 
effective against HCT-116 and A2780 ovarian carcinoma cells (Figure 2.9).  
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Figure 2.9: Growth inhibition of S-134 on HCT-116, A2780, MCF-7 and MRC-5 cells. OD 
reading indicates the viability of cells.  Among the 13 cell line tested, S-134 was most potent in 
HCT-116 and A2780 cells indicated with the rapid decrease of OD.  There was selectivity 
between tumour cells HCT-116 and A2780 cells to MRC-5 fibroblast cells in between 4-8 fold.  
In addition, high concentration of S-134 kills HCT-116 cells as indicated by the OD reading, 
which dropped below initial OD. 
 
S-134 was a nano-molar inhibitor in most of the cell lines tested.  However, 
two cancer cells - U373 and SNB19 which are human astrocytoma and 
malignant glioma cell lines, respectively - were less sensitive to S-134. 
Cellline Origin GI50(µmol/L)
HCT ?116 Humancoloncarcinoma 0.07
MCF ?7 Humanbreastadeno ?carcinoma 0.39
MRC ?5 Humanembryoniclungfibroblast 0.64
WI38 HumanCaucasianfoetallungfibroblast 0.78
A2780 Humanovariancarcinoma 0.15
U373 Humanastrocytoma 7.71
A549 Humancarcinomicalveolarbasalepithelial 0.53
SNB19 Humanmalignantglioma 5.38
HMEC ?1 Humanmicrovascular 0.77
HELA Humancervicalcarcinoma 0.66
MDA ?MB ?231 Humanbreastcarcinoma 0.92
PANCW1 Humanpancreaticcarcinoma 0.37
MIAPaCa ?2 Humanpancreaticcarcinoma 0.47
 
Table 2.2: Summary table of GI50 values of S-134 in the 13 human cell lines. 
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DRB was used as a positive control in this assay; the GI50 of DRB in HCT-
116, A2780, MCF-7 and MRC-5 cells were in a range of 5 to 30 µM, 
respectively.  From the supplier information (Calbiochem), DRB has an IC50 of 
6 µM in cells.  Our MTT assay data has shown similar results to reported data, 
proving that our data is comparable to the literature. 
 
2.4 Effect of S-134 on CDK9, CDK2 and CDK7 
CDK inhibition by S-134 was initially tested by in vitro CDK2 and CDK9 
kinase assays.  Among the CDK cyclin combination of the two CDKs, 
CDK2/cyclin E and CDK9/cyclin T1 were our objective for investigation, as 
both are widely screened with CDK inhibitors. 
This kinase assay was initially done in-house to estimate the effect of S-134 
on CDK9/cyclin T1.  As CDK2 and CDK7, which later became of interest, 
were not available in-house, all kinase assays were eventually done externally 
by Millipore (Billerica, MA, USA). 
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Figure 2.10: Effect of S-134 on CDK2/cyclin E and CDK9/cyclin T1.  The data were given by 
Millipore (Billerica, MA, USA).  For optimal reaction conditions, ATP (120 and 45 µM) was 
used with the CDK2/cyclin E and CDK9/cyclin T1 assay, respectively.  The IC50 values are 
0.23 µM against CDK2/cyclin E and 0.04 µM against CDK9/cyclin T1. 
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The initial kinase assay against CDK9/cyclin T1 carried out in-house with 
100 nM ATP showed that S-134 had an estimated IC50 value of 0.02 µM.  E-29 
5b, a 2,4-disubstitute pyrimidine analogue of S-134, has an IC50 of 0.06 µM.  
The external assay indicated that S-134 has an IC50 of 0.23 µM against 
CDK2/cyclin E and 0.04 µM against CDK9/cyclin T1 (Figure 2.10), using 120 
and 45 µM ATP in the respective kinase assays.  E-29 showed an IC50 of 0.55 
µM against CDK2/cyclin E and 0.05 µM against CDK9/cyclin T1, in the 
external kinase assays.  These results indicated that S-134 has a relatively 
potent effect on CDK9 with E-29 being two times more selective than S-134 
between CDK9/cyclin T1 and CDK2/cyclin E. 
Gathering all our kinase assay and literature data
151
 (Table 2.3), clinical 
compounds such as Seliciclib and Flavopiridol were unable to provide the 
potency for CDK9 inhibition and the selectivity for CDK2 as shown by our 
compounds.  DRB, the most selective CDK9 inhibitor to date, has shown huge 
selectivity against other CDKs, but it is much less potent than S-134 and other 
clinical candidates in inhibiting the activity of CDK9.  Nevertheless, because 
of its selectivity, DRB was be used as a positive control in some of our cellular 
assays to directly compare its activity with S-134. 
Compounds CDKsIC50orKi(µmol/L)
 CDK2/cyclinE CDK7/cyclinH CDK9/cyclinT1
DRB >1 >1 0.34
Flavopiridol(alvocidib) 0.19 0.30 0.003
Seliciclib 0.25 0.25 0.79
S ?1345g 0.23 0.81 0.04
E ?295b 0.55 N/A 0.05
Table 2.3: Summary of kinase activity151.   
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2.5 Effect of S-134 on cell cycle 
Transcription occurs throughout the cell cycle; during S phase, the rate of RNA 
transcription and protein synthesis are reduced.  An exception is the synthesis 
of histone, which is essential for the replication of chromosomes during S 
phase
5
.  Since CDK9 functions as a transcription regulator, S-134 is expected 
to induce cell cycle accumulation at either G1 phase or G2/M transition, where 
transcription is highly active
177
. 
To investigate the effect of S-134 on cell cycle, treated cells were stained 
with propidium iodide (PI).  PI is a fluorescent molecule which passes through 
the cell membrane and intercalates into cellular DNA, which is detectable and 
quantifiable by Fluorescent-activated cell sorting (FACS) using flow 
cytometry.  Hence, the quantity of PI in a cell represents the amount of DNA 
and the cell cycle status of a cell can be determined. 
 
Figure 2.11: Effect of S-134 on the cell cycle of HCT-116 cells.  No effect on the cell cycle 
was observed at the GI50 concentration during a 48 hour time period.  With the compound 
concentration increased to ~10 times GI50 concentration, a G2/M blockage was observed.  
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HCT-116 cells were treated with 0.1 or 1 µM S-134; i.e. ~1 time and ~10 
times GI50 concentration respectively (Figure 2.11).  Samples were harvested at 
4 time points: 12, 24, 36 and 48 hours.  Without the treatment of agents, the 
majority of cells are at G1 phase.  The treatment of S-134 resulted in a G2/M 
transition blockage, indicated by the massive increase in G2/M population 
under 1 µM S-134.  To prove that the G2/M cell cycle arrest was caused by 
CDK9 inhibition, DRB was tested in similar manner to S-134, but at 6 or 60 
µM concentration, corresponding to 1 time GI50 and 10 times GI50 
concentrations (Figure 2.12). 
 
Figure 2.12: Cell cycle effect of DRB on HCT-116 cells.  Treating cells with GI50 
concentration in the 48 hour time period showed DRB has no effect on the cell cycle.  A G2/M 
transition blockage in the cell cycle was observed when the compound concentration increased 
to ~10 times GI50 value.  The results show that CDK9 inhibitors induced G2/M transition block 
in the cell cycle of HCT-116 cells, which also proved S-134 affected the cell cycle in the same 
manner as a CDK9 inhibitor. 
 
The cell cycle data of DRB proved that CDK9 inhibitors induced G2/M cell 
cycle transition blockage in HCT-116 cells.  It also proved that S-134 
performed in the same way as a CDK9 inhibitor.  To make a definite 
conclusion that the G2/M cell cycle transition blockage was caused by S-134, 
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the experiment was repeated with HCT-116 cells with double thymidine block, 
which inhibits the synthesis of DNA and causes synchronisation of cells in 
G1/S phase, before the addition of compound.  HCT-116 cells were treated 
with 1 µM S-134 or 60 µM DRB and harvested at 3, 6, 8, 12 and 24 hours 
(Figure 2.13).  The results again showed that S-134 and DRB act in a similar 
way on the cell cycle of HCT-116 cells.   At 6 hours, cells with DMSO vehicle 
control had moved on to the G2/M transition, while cells with either S-134 or 
DRB were still in transition from S phase to M phase.  This indicated both S-
134 and DRB inhibited cell growth at ~10 times GI50 concentration.  At 8 
hours, cells in all samples entered the G2/M transition phase.  At 12 hours, 
cells with DMSO control moved back to G1, while cells treated with the 
compounds had accumulated at the G2/M transition phase of the cell cycle.  
The cell cycle state of HCT-116 cells at 24 hours was the same as in cells 
without synchronisation - a G2/M transition block had resulted with the 
presence of the compounds. 

Figure 2.13: Cell cycle effect of S-134 and DRB on the synchronised HCT-116 cells.   With 10 
times GI50 concentration of S-134 or DRB, the cell cycle slowed down in the entry of G2/M 
transition as seen in 6 hours.  G2/M transition blockage was observed from 12 hours onwards 
with the presences of compounds.  Cells without compounds managed to return to G1 phase at 
12 hours and continue cell growth. 
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A simple explanation of this G2/M transition accumulation is that S-134 and 
DRB may target other proteins such as CDK7/cyclin H, which phosphorylate 
CDK1 in order to bypass the G2/M checkpoint.  1 µM S-134 is higher than the 
IC50 of CDK7/cyclin H inhibition as determined by kinase assays.  
Alternatively, S-134 inhibits CDK9 only, but cells may manage to complete 
G1 and S phase without CDK9 dependent transcription; however, the 
production of proteins without the natural enzyme are inaccurate.  These 
proteins could not perform normal function and cells arrest at the G2/M 
transition checkpoint, resulting in accumulation and cell death.  This cell cycle 
arrest also suggests p53 may be induced by the compounds, which leads to the 
cell cycle arrest at G2 phase for the repair of DNA (see section 2.9). 
 
2.6 S-134 induces cell death 
With the inhibition of CDK9 activity, the transcription of anti-apoptotic 
proteins such as Mcl-1 and Bcl-2 should be reduced.  This increases the 
sensitivity of cancer cells to the apoptotic signals which leads to programmed 
cell death.  An Annexin-V assay was adopted to observe cell populations 
undergoing early apoptosis and cell death.  HCT-116 cells were treated with 
0.5 or 1 µM S-134 and harvested at 24, 36 and 48 hours (Figure 2.14).  Cells 
were stained with Annexin-V labelled with fluorescein isothiocyanate (FITC) 
and propidium iodide (PI) then analysed by flow cytometry.  Cells undergoing 
cell death externalise phosphatidylserine (PS) on the cell membrane.  FACS 
detects the PS-mediated binding of Annexin-V-FITC to cells and the cellular 
concentration of PI.  Hence, healthy cells are negative for Annexin-V and PI, 
while cells undergoing early apoptosis are Annexin-V positive and PI negative.  
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PI is only able to enter cells through holes on cell membranes.  Therefore, late 
apoptotic or dead cells will have PI inside the cell and Annexin-V expression.  
The graphs generated by FACS represent concentration of Annexin-V (X axis) 
and the PI (Y axis).   
 
Figure 2.14: Effect of S-134 on the cell death in HCT-116 cells.  From the graphs illustrating 
the presence of PI, induction of early apoptosis is shown at 24 hours with 1 µM S-134. A 
significant cell death was observed from 36 hours with 1 µM S-134.  For percentage readings 
of graphs, see Table 2.4. 
 
The results of Annexin-V assay with HCT-116 cells indicated that 1 µM S-
134 (~10 times GI50 concentration) induced early apoptosis by 24 hours.  This 
is indicated by the significant increase of PI in the bottom right quadrant (A4) 
of the graph indicating PI leaks into cells.  From 36 hours, 1 µM S-134 also 
induced a significant increase in cell population containing PI and expressing 
Annexin-V, as indicated by the increase of PI in the top right quadrant (A2) of 
the graph.  This indicates cells were in definite cell death.  The appearance of 
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PI in A4 followed by A2 during the time course indicates that cell death was 
caused by apoptosis. 
 
Figure 2.15: Effect of S-134 on the cell death in MRC-5 cells.  S-134 showed no sign of 
causing cell death during the 48 hour time period as the PI was kept in the bottom left quadrant 
(A3) only, which represented healthy cell population.  For percentage readings of graphs, see 
Table 2.4 
 
To investigate whether S-134 induces apoptosis selectively in cancer cells, 
Annexin-V assay was performed with MRC-5 fibroblast cells and the result is 
shown in Figure 2.15.  Modest effect on MRC-5 cells was observed by S-134 
treatment at the same concentration used with HCT-116 cells.  
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Table 2.4:  Summary of the percentage readings from Annexin-V assays.  Table A) are 
readings from samples of HCT-116 cells, while table B) are readings from samples of MRC-5 
cells.  Quadrant A2 represents the population of death cells, while quadrant A3 represents 
healthy cells population and A4 represents the percentage of cells undergoing apoptosis.   
 
Poly (ADP-ribose) polymerase (PARP), a protein appears to be involved in 
DNA repair in response to environmental stress, hence maintains cell 
viability
178
.  PARP can be cleaved by many caspases in vivo, including 
caspase-3
179
.  The cleavage of PARP facilitates cellular disassembly and serves 
as a marker of cells undergoing apoptosis
180
.  Initially, PARP cleavage was 
detected with HCT-116 cells; however, there were some difficulties in 
observing a detectable signal.  Therefore, for the interest of other experiments, 
A2780 cells were used instead.  Cells were treated with 0.5, 1, 2.5 or 5 µM S-
134 (~4, ~8, ~20 and ~40 times GI50 respectively) for 24 hours.  Cells were 
also treated with 30, 60 or 135 µM DRB (~5, ~10 and ~22 times GI50 
concentration respectively, Figure 2.16).  Western blots were used to detect the 
presence of PARP cleavage from the cell lysates. 
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Figure 2.16: Effect of S-134 on PARP cleavage in A2780 cells at 24 hours.  PARP cleavage 
was induced at 24 hours by S-134 from 2.5 µM.  DRB induced PARP cleavage from 30 µM. 
 
PARP cleavage was observed with S-134 at 2.5 µM and above.  DRB 
generated cleaved PARP at all concentrations tested.  To investigate the 
selectivity on apoptotic induction by S-134 between cancer cells and normal 
cells, the experiment was repeated using MRC-5 cells under the same 
conditions (Figure 2.17).  The result showed PARP cleavage was induced by 5 
µM S-134.  DRB cleaved PARP at 60 and 135 µM.  
 
Figure 2.17: Effect of S-134 on PARP cleavage in MRC-5 cells at 24 hours.  PARP cleavage 
was induced at 24 hours by S-134 at 5 µM only.  DRB induced PARP cleavage from 60 µM. 
 
Apoptosis is caused by the activation of various factors; the major cellular 
apoptotic pathway is the activation of caspase-3.  Other known pathways 
include the activation of pro-caspase-6 and caspase-7.  To investigate which 
apoptotic pathway is activated by S-134, caspase-3 assay was performed on 
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HCT-116 cells to detect the activation of caspase-3 and the result is shown in 
Figure 2.18. 
 
Figure 2.18: S-134 activates caspase-3.  There is a sharp rise of caspase-3 activation in HCT-
116 cell at 48 hours with 1 µM S-134.  The low level of caspase-3 activation at 5 and 10 µM S-
134 was possibly due the reduction in cell number caused by the compound, hence the signals 
were reduced.  Alternatively, other apoptotic pathways may be employed by S-134. 
 
This fluorimetric caspase-3 assay indicated a significant increase in 
activated caspase-3 at 48 hours with 1 µM S-134 in HCT-116 cells.  Western 
blot detection of PARP cleavage indicated significant apoptosis induced at 24 
hours with 2.5 µM S-134 and above.  Cells treated with 1 µM have shown a 
rise in caspase-3 activation.  As the counting of cell number was not involved 
before the analysis of samples, the reduction of signal at a higher concentration 
possibly due to the reduction in cell number caused by S-134 at these time 
points, which is one of the limitation of this assay.  DRB at concentrations of 
30 µM and above resulted in significant caspase-3 activation in a time 
dependent manner. 
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2.7 Cellular CDK inhibition of S-134 
CDK9 regulates transcription elongation by phosphorylating serine 2 (Ser 2) on 
the C-terminal domain (CTD) of RNA polymerase II (RNAP II).  CDK7 
phosphorylates serine 5 (Ser 5) during transcription initiation, the 
phosphorylation of Ser 5 by CDK9 has been observed from HIV-1 related 
transcription
181
.  A selective CDK9 inhibitor should therefore dominantly 
suppress the phosphorylation of Ser 2, with lesser effect on Ser 5.  Selectivity 
between CDK7 and CDK9 is difficult to achieve as both kinases have similar 
amino acid sequences in their kinase domain and operate at the same time.  
Therefore, most of the known CDK9 inhibitors suppress the phosphorylation of 
both Ser 2 and Ser 5 at similar level. 
To verify whether CDK9 is the primary target of S-134 at the cellular level, 
Western blot is the only available method which detects against the expression 
levels of phosphorylated Ser 2 and Ser 5 in the CTD of RNAP II.  A2780 
ovarian carcinoma cells were treated with 0.5, 1, 2.5 or 5 µM S-134.  30, 60 or 
135 µM DRB treatments were used as positive control in this experiment.  
Cells were treated with the compounds for 6 and 24 hours.  Cell lysates were 
subjected to Western blot and antibodies used to detect phosphorylated Ser 2, 
Ser 5 and total level of RNAP II. 
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Figure 2.19: Effect of S-134 on RNA polymerase II at 6 and 24 hours in A2780 cells.  A) At 6 
hours, both S-134 and DRB reduced the phosphorylation of serine 2 (Ser 2) and serine 5 (Ser 
5) in a dose dependent manner.  S-134 reduced phosphorylation of both Ser from 2.5 µM, 
while DRB reduced the phosphorylation of Ser 2 at all concentration and Ser 5from 60 µM.  
The expression level of RNAP II was not affected by either compound.  B) At 24 hours, both 
compounds reduced the phosphorylation of both Ser dose dependently.  S-134 reduced the 
phosphorylation of Ser 2 and Ser 5 from 1 µM and 2.5 µM respectively.  DRB reduces the 
phosphorylation of both Ser in the same manner as at 6 hours.  Again, no effect on the RNAP 
II expression was found with either compound.  
 
At 6 hours (Figure 2.19), a dose dependent reduction in phosphorylation of 
Ser 2 by S-134 was observed starting from 2.5 µM.  The same effect was 
observed with DRB from 30 µM.  The reduction pattern of Ser 2 induced by 
both compounds was also observed with the phosphorylation of Ser 5.  
Comparing the intensity of the bands between Ser 2 and Ser 5, both S-134 and 
DRB have a more profound effect in inhibiting Ser 2 phosphorylation.  This 
indicated that S-134 and DRB primarily targeted CDK9 rather than CDK7 at 6 
hours in A2780 cells. With 5 µM S-134, with the phosphorylation of Ser 5 
more significantly suppressed than Ser 2, which indicates 5 µM S-134 may 
inhibit both CDK7 and CDK9. The effect on CDK7 is more significant could 
due to the order of their phosphorylation during transcription.  There was no 
effect on the expression of RNAP II by both compounds. 
For the 24 hour time point, a dose dependent reduction in phosphorylation 
of Ser 2 by S-134 started from 1 µM treatment, with the Ser 2 phosphorylation 
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completely suppressed with 2.5 and 5 µM S-134.  30 µM DRB reduced 
phosphorylation of Ser 2 with a complete suppression with 60 and 135 µM.  
Reduction in phosphorylation of Ser 5 was observed with S-134, starting from 
a concentration of 2.5 µM with 5 µM completely suppressing phosphorylation.  
60 µM DRB reduced Ser 5 phosphorylation with a complete suppression 
observed at 135 µM.  Similar to the observation at 6 hours, both S-134 and 
DRB have a major effect in suppressing phosphorylation of Ser 2 over Ser 5.  
No effect on the expression of RNAP II was induced by the compounds. 
From these observations, S-134 inhibits CDK9 followed by CDK7 in 
transformed cellular environment.  To investigate whether the selectivity for 
cell death induction between cancer cells and normal cells observed earlier 
were due to the effect of compounds on CDKs, hence phosphorylation of 
RNAP II, the above Western blot experiments were repeated with MRC-5 
cells. 

Figure 2.20: Effect of S-134 on RNA polymerase II at 6 and 24 hours in MRC-5 cells.  A) At 6 
hours, S-134 reduced the phosphorylation of both Ser at 5 µM treatment, while DRB reduced 
phosphorylation of both Ser at all concentrations.  S-134 induced no effect on the expression 
level of RNAP II, but DRB suppressed RNAP II.  B) At 24 hours, 5 µM S-134 reduced the 
phosphorylation of both Ser, as observed at 6 hours.  DRB inhibited phosphorylation of Ser 2 
and reduced phosphorylation of Ser 5 from 60 µM treatment.  Both compounds showed a more 
profound effect on the phosphorylation of Ser 2 over Ser 5.  In addition, both affected the 
expression levels of RNAP II, with S-134 reducing the expression from 2.5 µM treatment and 
DRB across all concentrations. 
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At the 6 hour time point (Figure 2.20), reduction in the phosphorylation of 
both Ser by S-134 was observed with 5 µM treatment.  DRB suppressed Ser 2 
phosphorylation at all concentrations tested.  Phosphorylation of Ser 5 was 
observed with 5 µM S-134.  In DRB treated samples, a dose dependent 
reduction of phosphorylated Ser 5 started from 30 µM.  S-134 was observed to 
have no effect on the expression of RNAP II, but DRB suppressed the 
expression of RNAP II.  This indicates that the reduction of RNAP II 
phosphorylation by DRB could due to its effect on the expression level of 
RNAP II in MRC-5 cells, rather than inhibiting the activity of CDKs. 
At the 24 hour time point, phosphorylation of Ser 2 was reduced by S-134 
with 5 µM treatment and with 60 and 135 µM DRB.  For Ser 5, 
phosphorylation was reduced by 5 µM S-134.  DRB reduced Ser 5 
phosphorylation with 60 µM treatment, a complete suppression observed with 
135 µM.  Similar to the observation at 6 hours, both S-134 and DRB affected 
Ser 2 more severely than Ser 5.  This once again indicates that S-134 and DRB 
primarily target CDK9.  However, in MRC-5 cells, both compounds affected 
the expression of RNAP II at 24 hours.  S-134 reduced RNAP II expression at 
2.5 µM, with DRB affecting RNAP II expression at all concentrations tested.  
This indicates that not only DRB affects the expression of RNAP II, S-134, in a 
lesser extent, if also affects the expression level of RNAP II which may lead to 
the reduction in phosphorylation, rather than CDKs in MRC-5 cells. 
The reduced phosphorylation of Ser 2 was corresponding to the induction of 
PARP cleavage in both cell lines.  Hence, apoptosis of cells could be due to the 
inhibition of CDK9. 
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2.8 S-134 targets anti-apoptotic proteins 
Anti-apoptotic proteins inhibit apoptosis through their interactions with cellular 
components, such as the interaction between Bcl-2 and mitochondria (see 
section 1.3.3), or by inhibiting the function of proteins that induce apoptosis 
through direct binding, such as the relationship between Mcl-1 and Bax (see 
section 1.3.4).  The expression of several anti-apoptotic proteins, including 
Mcl-1, Bcl-2 and XIAP, were found to be regulated by CDK9
106
.  Since S-134 
is a CDK9 inhibitor, the cellular expression of these anti-apoptotic proteins is 
expected to be reduced with the treatment of S-134.  
To prove this hypothesis, Western blots were used to examine the 
expression levels of these anti-apoptotic proteins.  A2780 cells were treated 
with S-134, using DRB as positive control, at the same concentrations used in 
previous experiments (see section 2.7 for details).  Samples were harvested at 6 
and 24 hours.  Cell lysates were detected with antibodies against Mcl-1, Bcl-2 
and XIAP. 

Figure 2.21: Effect of S-134 on the expression of anti-apoptotic proteins at 6 and 24 hours in 
A2780 cells.  A) At 6 hours, S-134 reduced the expression of Mcl-1 at 5 µM with DRB 
affecting the expression of Mcl-1 at all concentrations tested in a dose dependent manner. No 
effect on Bcl-2 was observed with compounds.  A reduction in XIAP was detected only from 
60 µM DRB.  B) At 24 hours, S-134 reduced the expression of Mcl-1 protein in a dose 
dependent manner from the concentration of 1 µM. In comparison to the DMSO control, the 
expression of Bcl-2 was reduced by both compounds.  S-134 reduced the expression of XIAP 
from 1 µM with DRB reducing XIAP expression at all concentration.  The half life of Mcl-1 is 
much short that that of Bcl-2, 1-2 hours and 18 hours, respectively.  Therefore, the effect of S-
134 on Bcl-2 was not as profound as Mcl-1 at both time points.  
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At 6 hours (Figure 2.21), the expression of Mcl-1 protein was suppressed 
with 5 µM S-134 while DRB reduced Mcl-1 expression at all tested 
concentrations in a dose dependent manner.  The reduction of Mcl-1 by both 
compounds corresponds to the reduction pattern of Ser 2 phosphorylation (see 
section 2.7), hence the activity of CDK9.  S-134 had no effect on the protein 
expression of Bcl-2 and XIAP.  Although DRB also has no effect on Bcl-2, a 
reduction of XIAP by DRB started from 60 µM.   
At the 24 hour time point, the expression of Mcl-1 was reduced by both S-
134 and DRB.  S-134 showed a dose dependent reduction on the expression of 
Mcl-1 from 1 µM with a complete suppression observed at 5 µM.  DRB 
reduced Mcl-1 expression dose dependently with a total suppression from 60 
µM.  A low level of reduction in the expression of Bcl-2 by both compounds 
was observed at all concentrations compared to the DMSO vehicle control.  
The expression of XIAP was reduced dose dependently at 24 hours from 1 µM 
S-134 with a total suppression observed at 5 µM.  DRB also reduced the 
expression of XIAP at this time point.  Considering this data together with the 
observation on the effect of compounds on RNAP II phosphorylation; the 
inhibition of CDK9 by S-134 could lead to the reduction of Mcl-1, followed by 
Bcl-2 and finally XIAP. 
To verify the effect of S-134 in normal cells as before, Western blot 
experiments were repeated in MRC-5 cells.  However, the expression of XIAP 
could not be detected in MRC-5 cells.  Although the same total protein 
concentration was used as with A2780 cells, the expression signals of Mcl-1 
and Bcl-2 detected were much weaker than those from A2780 cells.  The weak 
Mcl-1 and Bcl-2 and absence of XIAP signals may be explained by the non-
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essential expression of anti-apoptotic proteins in maintaining the survival of 
normal cells. 

Figure 2.22: Effect of S-134 on the expression of anti-apoptotic proteins at 6 and 24 hours in 
MRC-5 cells.  A) No change in the protein expression levels of Mcl-1 and Bcl-2 was induced 
by compounds at 6 hours.  B) Except that the expression of Mcl-1 was suppressed by DRB 
starting from 60 µM, there was no alteration on the protein expression of Mcl-1 and Bcl-2 by 
the inhibitors at 24 hours. 
 
Reduced phosphorylation of RNAP II Ser 2 in MRC-5 cells with 5 µM S-
134 and 60 µM DRB was observed at 6 hours (see section 2.7).  However, no 
change in the expression levels of Mcl-1 or Bcl-2 proteins was induced by the 
compounds at this time point (Figure 2.22).  At 24 hours, no change in 
expression of Mcl-1 and Bcl-2 was induced by S-134. The protein expression 
of Mcl-1 was reduced starting from 60 µM DRB, with the expression of Bcl-2 
not affected. 
 
2.9 S-134 induces p53 protein 
Anti-apoptotic proteins reduce the sensitivity of cancer cells to apoptotic 
signals.  The loss of anti-apoptotic protein expression would initially allow the 
expression of tumour suppressor proteins to be re-induced, leading to cancer 
cell death.  One of the best known tumour suppressors is p53, which has a key 
role in the cellular response to DNA damages and other genomic alteration at a 
cellular level
89
.  It is important to investigate whether S-134 stabilises p53 (i.e. 
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increases the presence of p53 proteins) and induces p53 activation in cancer 
cells. 
To investigate the effect of S-134 on p53 at the protein level, Western blot 
was carried out on A2780 cells, a cell line expressing wild-type p53.  Cells 
were treated with S-134 and the positive control, DRB, at the same conditions 
as in previous experiments (see section 2.7).  Samples at 6 and 24 hours were 
detected with antibodies against p53 and HDM-2. 
 
Figure 2.23: Effect of S-134 on the protein expression of p53 and HDM-2 at 6 and 24 hours in 
A2780 cells.  A) S-134 and DRB caused a dose dependent increase in the protein expression 
level of p53 at 6 hours.  The level of HDM-2 protein also increased with the exception of 135 
µM DRB.  This indicates that the compounds induced the stabilisation of p53.  B) Both 
compound caused an increase in p53 protein again in a dose dependent manner at 24 hours.  
Compared to the DMSO control, the protein level of HDM-2 had no change until 5 µM S-134 
which reduced the protein expression.  The expression of HDM-2 reduced at all concentrations 
of DRB tested 
 
The results showed the level of p53 protein increased dose dependently by 
the inhibitors at 6 hours (Figure 2.23).   However, the level of HDM-2 
increased as a negative feedback of p53. We observed a suppression of HDM-2 
expression only with 135 µM DRB.  Hence S-134 and DRB only stabilised p53 
at 6 hours.  At 24 hours, the level of p53 protein was increased dose 
dependently by the inhibitors.  The expression of HDM-2 remained constant 
with the DMSO vehicle control and a reduction was observed with 5 µM S-
134.  DRB reduced the expression of HDM-2 at all concentrations.  The results 
indicate that the negative feedback loop of p53 was suppressed.  Hence, the 
p53 expressed at this time point should be functionally active.  As in previous 
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experiments, the effect of compounds on p53 and HDM-2 in normal fibroblast 
cells were investigated. 
Western blot experiments were repeated with MRC-5 cells under the same 
conditions as with A2780 cells.  At 6 hours, the expression level of p53 
remained constant in all samples (Figure 2.24).  Compared to the DMSO 
vehicle control, an increase in the expression of HDM-2 was observed with 0.5 
and 1 µM S-134 with a reduction in the expression of HDM-2 observed with 5 
µM S-134 and 135 µM DRB.  In all other samples, the expression level of 
HDM-2 was the same as in the DMSO control. 
 
Figure 2.24: Effect of S-134 on p53 and HDM-2 proteins at 6 and 24 hours in MRC-5 cells. A) 
At 6 hours, S-134 and DRB have no effect on the protein level of p53.  Compared to DMSO 
vehicle control, the level of HDM-2 protein increased with 0.5 and 1 µM S-134.  There was no 
change in the expression level of HDM-2 with 2.5 µM S-134 as well as 30 and 60 µM DRB.   
A reduction in the HDM-2 protein was observed with 5 µM S-134 and 135 µM DRB.  B) 
Except the observation of a complete suppression of p53 with 5 µM S-134, both inhibitors 
have no effect on p53 at 24 hours.  The level of HDM-2 protein reduced with 5 µM S-134 and 
dose dependently from 60µM DRB. 
 
The observation in the expression level of HDM-2 in MRC-5 cells was 
similar to that in A2780 cells at 6 hours.  However, both inhibitors have no 
effect on p53. Since normal cells should have relatively less genomic alteration 
compared to cancer cells, the results may indicate that MRC-5 cells do not 
require p53 proteins in its growing environment (i.e. p53 surveillance). 
At the 24 hour time point, the expression of p53 was suppressed by 5 µM S-
134.  Compared to DMSO control, no other changes was detected with other 
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samples (Figure 2.24).  The effect of the inhibitors on HDM-2 was similar to 
that in A2780 cells. The expression of HDM-2 protein had no change with a  
reduction observed with 5 µM S-134 and a dose dependent reduction was 
observed with 60 and 135 µM DRB. 
 The reduction of p53 by S-134 at 24 hours reveals that p53 has no role in 
the apoptosis detected by PARP cleavage in MRC-5 cells (see section 2.6). 
Instead, this observation may indicate that S-134 generates p53 independent 
toxicity to normal cells at higher concentrations.   
Since it is clear that S-134 induced the stabilisation of p53 and possibly 
activation at later time points with high concentration in cancer cells, the next 
stage was to compare the effect of S-134 on p53 stabilisation to other novel 
analogues in our CDK9 inhibitor series.  A Cellomic Array Scan was carried 
out to estimate the expression level of p53 proteins by observing the percentage 
of cells in a population having positive stain in cell nucleus with p53 
antibodies.  HCT-116 cells were treated with a serial dilution of compounds for 
8 hours (Figure 2.25).  
 
Figure 2.25: Cellomic Array Scan detecting the stabilisation of p53 protein expression in HCT-
116 cells.  The lead compounds SW-32 and E-29 5b induced >40% cells with p53 positive 
stains at the concentration of 0.37 and 1.11 µM, respectively. S-134 5g stabilised p53 at 0.37 
µM, but the effect was not as profound as the other analogues, such as 5i and 5j at higher 
concentrations.   
2.9. S-134 induces p53 protein 
79 

 
The effect of S-134 5g in stabilising p53 was clearly not as effective as the 
lead compound, SW-32.  S-134 induced a higher percentage of p53 positive 
cells at low concentration, with other analogues (5i and 5j) inducing better 
effect at higher concentration, which is likely due to their potency in cells 
(Table 2.1). 
 
2.10 Effect of S-134 on gene transcription 
Since CDK9 operates at transcription elongation, the inhibition of CDK9 by S-
134 should suppress the synthesis of messenger RNA (mRNA) from genes 
regulated by CDK9.  These genes include anti-apoptotic factors Mcl-1, Bcl-2 
and XIAP.  To prove this hypothesis, reverse transcription polymerase chain 
reaction (RT-PCR) was carried out by extracting RNA from cells treated with 
compounds and synthesising complementary DNA (cDNA) through reverse 
transcription.  The cDNA were amplified by normal PCR with primers 
designed for amplifying specific genes of interest; changes in the intensity of 
the desired cDNA between samples were observed using electrophoresis.  
Since the effect of compounds in the mRNA is our interest, the primers were 
designed based on the available mRNA sequences of the target genes in 
human.  These primers amplify a 125 bp region on the gene between the end of 
exon 1 and the beginning of exon 2; this should solely amplify the mature 
mRNA rather than pre-mature RNA in nucleus. 
A2780 cells were used in this experiment and treated with S-134 or DRB at 
the concentrations used in previous experiments (see section 2.7).  Cells were 
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harvested at 6 and 24 hours.  RNA was extracted from cells for appropriate 
PCR amplification. 
 
Figure 2.26: Effect of S-134 on the transcription of anti-apoptotic genes at 6 hours in A2780 
cells.  A) The amount of cDNA of Mcl-1 was reduced with 5 µM S-134 and 135 µM DRB.  B) 
The amount cDNA of Bcl-2 was reduced dose dependently from 1 µM S-134 and 60 µM DRB.  
C) The level of cDNA of XIAP remained constant with the addition of compounds.  D) The 
mRNA level of ȕ-Actin was constant across all samples. 
 
The changes in the mRNA level of Mcl-1, Bcl-2 and XIAP were investigated 
(Figure 2.26).  In A2780 cells, the cDNA of Mcl-1, synthesised by RT-PCR 
from the mRNA, was reduced by 5 µM S-134 and 135 µM DRB.  Although the 
PCR products are approximately 380 bp, it should only represent our target 
mature mRNA fragment (i.e. exon).  Since the length of intron 1 in the mRNA 
of Mcl-1 is 350 bp, if intron 1 was included in the PCR product, the total size 
of the PCR fragment should be between 450 to 500 bp.  For the transcription of 
Bcl-2, a significant dose dependent reduction was observed from 1 µM S-134 
and 60 µM DRB.  No alteration in the mRNA level of XIAP was induced by 
the compounds. 
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Figure 2.27: Effect of S-134 on the transcription of anti-apoptotic genes at 24 hours in A2780 
cells.  A) A reduction in the amount of cDNA of Mcl-1 was observed with S-134 at all 
concentrations and with 135 µM DRB.  B) The amount cDNA of Bcl-2 was significantly 
suppressed by S-134 from 0.5 µM and 135 µM DRB.  C) For XIAP, the cDNA was reduced 
from 1 µM S-134, which was also observed with DRB.  D) The mRNA level of ȕ-Actin was 
constant across all samples. 
 
At 24 hours (Figure 2.27), the RT-PCR has indicated an alteration in the 
mRNA level of Mcl-1, induced with S-134 at all concentrations.   A complete 
suppression of the transcription of Mcl-1 was caused by 135 µM DRB.  S-134 
inhibited the transcription of Bcl-2 completely from 0.5 µM.  DRB also 
affected the transcription of Bcl-2, a complete suppression was observed with 
135 µM.  The transcription of XIAP was affected by S-134 with a total 
transcription inhibition from 1 µM.  A reduction in the amount of mRNA for 
XIAP was induced by DRB.  The results of RT-PCR at 24 hours matched the 
observation with the Western blot, hence the observation in mRNA links to the 
changes in protein expression.  The effect of compounds on mRNAs was more 
profound than on proteins as CDK9 operates at transcription.  This RT-PCR 
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data also explains the reduction of anti-apoptotic proteins, caused by the 
suppression of their transcription by inhibiting CDK9.   
The effects of compounds on the expression of p53 and HDM-2 proteins 
were investigated in the previous section (see section 2.9).  As a negative 
feedback, the expression of HDM-2 protein increased at 6 hours and reduced at 
24 hours with high concentration of S-134.  The effect of S-134 on the 
transcription of HDM-2 was investigated here and compared with the results 
from Western blot (Figure 2.28). 
 
Figure 2.28: Effect of S-134 on the transcription of HDM-2 in A2780 cells.  A) At 6 hours, the 
transcription of HDM-2 remained unchanged. B) A dose dependent reduction on the 
transcription of HDM-2 by S-134 was detected from 2.5 µM at 24 hours.  DRB reduced HDM-
2 transcription with 135 µM.  The mRNA level of ȕ-Actin was constant in all samples during 
C) 6 hours and D) 24 hours. 
 
According to the RT-PCR data, both inhibitors have no effect on the mRNA 
of HDM-2 at 6 hours.  At 24 hours, a dose dependent reduction in the 
transcription of HDM-2 was detected with 2.5 and 5 µM S-134.  DRB (135 
µM) also affected the transcription of HDM-2.  The effect of DRB on 
transcription and protein expression are similar.  S-134 showed a more 
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profound effect on mRNA than the protein of HDM-2.  In other words, S-134 
suppresses the negative feedback loop of p53 activation by inhibiting the 
transcription of HDM-2 which leads to the reduction in protein expression. 
To compare the effect of S-134 on the transcription between the genes, the 
intensity of the cDNA bands from each set of genes were quantified, which 
represents the trends in the changes of mRNA levels (Figure 2.29).  By 
comparing the gradient of the trend lines, S-134 is most effective in 
suppressing the transcription of Mcl-1, followed by Bcl-2 and XIAP.  This 
quantification further confirms that S-134 affects Mcl-1 and Bcl-2 at both time 
points with XIAP and HDM-2 being affected at 24 hours only.  
 
Figure 2.29: Quantification of the intensities of cDNA with the presence of S-134 at A) 6 and 
B) 24 hours.  The calculated trends assume S-134 induced a linear dose dependent effect on 
transcription.  
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2.11 Conclusion 
To a certain extent, cancer cells should be sensitive to apoptotic signals due to 
their genomic abnormalities. However, anti-apoptotic genes are constantly 
transcribed and translated into anti-apoptotic proteins which provide cancer 
cells with resistance to apoptotic signals and cell death.  Anti-cancer drugs 
which target transcription should inhibit the expression of anti-apoptotic 
proteins and re-induce the expression of tumour suppressors, forcing cancer 
cells to undergo cell death.  For this reason, CDK9, a kinase which regulates 
transcription elongation, is an effective anti-cancer drug target. 
A series of novel inhibitors which were designed to suppress the activity of 
CDK9 were synthesised and growth inhibitory properties tested.  To generate 
SAR data, the compounds were screened against two tumour cell lines, HCT-
116 and MCF-7.  Compounds were tested also against the fibroblast cell line 
MRC-5 to estimate compound selectivity between tumour and normal cells.  
The majority of these novel inhibitors showed high potency in and selectivity 
for cancer cells.  S-134 provided ~10 fold selectivity between HCT-116 and 
MRC-5 cells and was selected for further in vitro mechanism studies.  S-134 
was screened against 13 human cell lines using the MTT assay; this compound 
was particularly potent against HCT-116 colon and A2780 ovarian carcinomas 
cells. 
S-134 was tested in kinase assays for activity against CDK9/cyclin T1, 
CDK2/cyclin E and CDK7/cyclin H, with the IC50 of 0.04 µM, 0.23 µM and 
0.801 µM, respectively.  The result indicated that S-134 was not only effective 
in inhibiting the activity of CDK9, it was also selective against CDK2, the 
closest homologue protein to CDK9, and against CDK7, a kinase which 
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functions in the regulation of transcription as with CDK9.  The selectivity 
between these three CDKs as demonstrated by S-134 was wider than other 
CDK9 inhibitors in clinical trials, such as Seliciclib and Flavopiridol. 
Although CDK9 was not directly involved in the cell cycle, S-134 induced a 
G2/M transition arrest in the cell cycle of HCT-116 cells.  This cell cycle arrest 
was also observed with DRB, another CDK9 inhibitor.  The cell cycle arrest 
could be due to the fact that cells cannot synthesis some key proteins required 
for G2 phase in the absence of CDK9, leading to the inability of the cells to 
bypass the cell cycle checkpoint that regulates mitotic entry.  In addition, 
CDK7 functions during the G2/M cell cycle transition and the concentration of 
S-134 resulted in this cell cycle arrest exceed the IC50 of CDK7/cyclin H 
inhibition in kinase assay, therefore the compounds could inhibit CDK2 at 
higher concentrations resulting in the observed cell cycle arrest. 
The Annexin-V assay shows that apoptosis in HCT-116 cells was induced 
by 1 µM S-134 at 24 hours with a peak level observed at 36 hours.  MRC-5 
cells were treated with S-134 under the same condition as with HCT-116 cells; 
there was no apoptosis detected by the Annexin-V assay.  From the Western 
blots, PARP cleavage was observed in A2780 and MRC-5 cells at 2.5 and 5 
µM S-134, respectively at 24 hours.  The Annexin-V assays and Western blots 
show a therapeutic window can be obtained with S-134, which induced cell 
death in cancer, but not normal cells. 
The effect of S-134 on the phosphorylation of RNA polymerase II (RNAP 
II) was observed by Western blots.  CDK9 and CDK7 phosphorylated Ser 2 
and Ser 5 on the C-terminal domain (CTD) of RNAP II, respectively.  In 
A2780 cells, low concentrations of S-134 reduced the phosphorylation of Ser 
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2, but not Ser 5, at 6 hours.  With higher concentrations of S-134, the 
phosphorylation of Ser 2 was suppressed profoundly at 24 hours by the 
inhibitor, compared to the phosphorylation of Ser 5.  These observations 
indicate that S-134 primarily inhibits the activity of CDK9 followed by CDK7. 
Transcriptional CDKs regulate the level of anti-apoptotic proteins including 
Mcl-1, Bcl-2 and XIAP.  Western blot was carried out to examine the 
expression levels of these anti-apoptotic proteins in cells treated with S-134.  In 
A2780 cells, the expression of Mcl-1 was reduced under the same conditions as 
the inhibition of RNAP II Ser 2 phosphorylation.  The expression of Bcl-2 and 
XIAP were reduced at 24 hours only.  In MRC-5 cells, S-134 affected the 
expression of the three anti-apoptotic proteins at 24 hours only; reduction of 
Mcl-1 and XIAP were observed with high concentration of the inhibitor (5 
µM). 
p53 protein was stabilised by S-134 at all concentrations and time points 
tested in Western blot with A2780 cells, but not in the fibroblast cells.  The 
expression of HDM-2 protein is reduced at 24 hours with 2.5 and 5 µM S-134, 
which is the condition for a definitely active p53.  This activated p53 
corresponds to the induction of PARP cleavage detected in Western blot which 
indicates apoptosis.  HCT-116 cells were used to compare the effect of S-134 
and other novel analogues within the series of inhibitors in stabilising p53 
using a Cellomic Array Scan.  In this assay, S-134 only showed a moderate 
effect in stabilising p53 compared to other analogues. 
The effect of S-134 on the transcription of Mcl-1, Bcl-2 and XIAP in A2780 
cells was examined using reverse transcription PCR.  The transcription of Mcl-
1 was most profoundly suppressed by S-134, followed by the transcription of 
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Bcl-2 and XIAP.  The transcription of HDM-2 was suppressed at 24 hours with 
high doses of S-134, which corresponds to the observation in Western blot. 
Combining all the data, S-134 has been demonstrated to be a promising, 
potent and selective CDK9 inhibitor.  A therapeutic window has been indicated 
for the treatment of cancers. 
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Chapter Three 
Mechanism of action of a novel 
natural product derivative 
3.1 Introduction 
Natural products have a key role in drug discovery; a large number of current 
drugs are natural products or inspired by nature.  In the last few decades, a 
more dominant role for synthetic compounds in anti-cancer drug discovery has 
emerged.  However, since natural products have been found to have cancer 
prevention properties during the last decade, the investigation of natural 
products which possess anti-cancer activity has once again become a favoured 
topic. 
 
3.1.1 Erianin 
Erianin 6a is isolated from the extract of Dendrobium chrysotoxum, a plant 
species found in Southeast Asia
182
.  Erianin (Figure 3.1) shows high cellular 
potency in a range of 0.013 to 0.082 µM.  Literature data has shown that 
Erianin suppresses the growth of Bel7402 human hepatoma and A375 
melanoma xenografts, inducing observable vascular shutdown within 4 hours 
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of administering 100 mg/kg of the compound.  Erianin also demonstrated 
potent anti-angiogenic activities in vitro; it reversed spontaneous or basic 
fibroblast growth factor (FGF) induced neovascularisation in chick embryo.  
The molecule suppressed proliferation of human umbilical vein endothelial 
cells (HUVECs) with an EC50 of 0.034 ± 0.0013 µM, which interrupted the 
formation of endothelial tubules and abolished both migration across collagen 
and adhesion to fibronectin.  In addition, Erianin showed selectivity between 
endothelial cells; quiescent endothelium being less sensitive to Erianin when 
compared with proliferative endothelium and transformed endothelial cells.  
From cytoskeletal studies using fluorescent microscopes with HUVECs, both 
F-actin and ȕ-tubulin were depolymerised by Erianin; the effect of the 
compound was more profound in proliferating than in confluent HUVECs
182
.  
Erianin induced tumour cell death, growth suppression and significant 
vascular shutdown in tumour xenografts; angiogenesis was inhibited in vivo 
and in vitro and disorganisation of endothelial cytoskeletal was found to occur.  
These observations indicate that Erianin has therapeutic potential against 
cancer by inhibiting growth and angiogenesis of tumour tissues
182
. 
 
Figure 3.1: Erianin 6a is a polyphenol identified in a Southeast Asian plant Dendrobium 
chrysotoxum. 
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3.1.2 Prospective mechanism of action of Erianin 
The mechanism of action of Erianin in inducing tumour cell death was 
investigated.  Using HUVECs, Erianin has shown a dose dependent metabolic 
inhibition which was indicated by reduced acidification rate and viability of 
HUVECs
182
.  There is selectivity against endothelial cells.  In addition, Erianin 
reduced lactate production, glucose consumption and intracellular ATP level in 
HUVECs.  Most importantly, Erianin induced a dose and time dependent 
phosphorylation of JNK/SAPK as indicated by Western blot
183
.  This 
mechanism may be involved in the potential anti-tumour and anti-angiogenic 
actions of Erianin
182
. 
From other studies with human HL-60 leukaemia cells, Erianin induced 
cellular DNA fragmentation, this morphological change was observed by 
fluorescence and electron microscopy
184
.  Immunohistochemical analysis 
established that Erianin suppressed Bcl-2 gene and increased Bax gene 
expression.  A cell cycle block at the G2/M transition was also observed.  As 
mentioned in the previous chapter, Bcl-2 is a key anti-apoptotic protein - the 
loss of function in Bcl-2 caused an increased sensitivity of tumour cells to 
apoptotic signals, resulting in tumour cell death. 
Cumulative literature data inferred that Erianin has excellent anti-tumour 
and anti-angiogenic properties.  This compound affected cell cycle by targeting 
pathways and proteins essential for tumour cell survival; the molecular targets 
of Erianin were cell type dependent.  However, Erianin induces severe toxicity 
to patients in clinical trials, which has hampered its clinic development (S. 
Wang personal communication). 
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3.1.3 Novel derivatives of Erianin 
In an attempt to reduce the toxicity and improve the drug-like properties of 
Erianin, various chemical modifications have been made.  However, as Erianin 
is a natural product, the limited availability of the compound for organic 
syntheses and the resulting yield availability for biological testing are major 
challenges.  In this chapter, we demonstrate a series of studies to review the 
mechanism of action of Erianin, and compare its properties to novel synthetic 
derivatives.  
 
3.2 Cellular growth inhibition of novel natural 
product derivatives 
In this section, we review the anti-tumour / growth inhibitory activity of 
Erianin and its novel derivatives.  Six novel compounds were derived 
following modification of Erianin.  Activity was tested using the MTT assay 
following 72 hours exposure, as described in section 6.3, against tumour cell 
lines HCT-116 and MCF-7.  Their activities are summarised below (Table 3.1). 
Compounds GI50(µmol/L)
 HCT ?116 MCF ?7
Erianin6a 0.06± 0.00 0.06± 0.01
ZJU ?16b 6.57± 1.03 5.22± 0.20
ZJU ?26c 53.47± 0.52 8.54±0.08
ZJU ?36d 39.81±7.45 41.18±1.09
ZJU ?46e 36.98±2.72 20.97±3.95
ZJU ?56f >100 44.89±0.14
ZJU ?66g 2.79± 0.31 1.21± 0.35
 
Table 3.1: Cellular activity of novel Erianin derivatives on tumour cell lines HCT-116 and 
MCF-7.  The synthetic analogues demonstrated reduced activity compared with Erianin with 
the GI50 shifted from nano-molar to micro-molar values.  Among these compounds, ZJU-6 6g 
was the most potent molecule and was selected for further screening. 
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The chemical modifications of Erianin reduced the activity of resultant 
analogues from inhibition at nano-molar to micro-molecular values.  The most 
potent compound in this group was ZJU-6 6g (Figure 3.2), followed by ZJU-1 
6b. 
 
Figure 3.2: Chemical structure of 6a (Erianin) and 6g (ZJU-6).  
 
The purpose of ZJU-6 having an oxygen anion is to enhance the anti-
oxidant property of Erianin.  It is proposed that the molecule could protect 
lipids from per-oxidation by free radicals or reactive oxygen species by 
donating its electron without becoming reactive itself
185
 
Cellline Origin GI50(µmol/L)
Erianin ZJU ?6
HCT ?116 Humancoloncarcinoma 0.06±0.00 2.79±0.31
MCF ?7 Humanbreastadeno ?carcinoma 0.06±0.01 1.21±0.35
MRC ?5 Humanembryoniclungfibroblast 0.07±0.01 1.18±0.51
TK10 Humanrenalcellcarcinoma 0.77±0.17 5.89±0.67
HCC ?2998 Humancoloncarcinoma 0.07±0.03 0.07±0.01
U373M Humanastrocytoma 0.02±0.01 0.25±0.08
A549 Humancarcinomicalveolarbasalepithelial 0.07±0.00 0.64±0.04
SNB1evR Humanmalignantglioma 0.08±0.02 0.68±0.10
MDA ?468 Humanbreastcarcinoma 0.04±0.01 0.07±0.01
MIAPaCa ?2 Humanpancreaticcarcinoma 0.01±0.00 0.05±0.01
 
Table 3.2: Growth inhibition of Erianin and ZJU-6 determined by MTT assay (72 hours).  
After 72 hours incubation with compounds, the GI50 of ZJU-6 was reduced between two to 47 
times compared to Erianin in all cell lines tested except HCC-2998. 
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ZJU-6 was selected for further screening against a total of 10 cell lines for 
cellular growth inhibition in parallel with Erianin (Table 3.2).  With the 
exception in HCC-2998, ZJU-6 shows a reduced activity between two to 47 
times compared to Erianin.  Both Erianin and ZJU-6 were most potent in 
human pancreatic carcinoma cell line MIA PaCa-2, with a GI50 value of 0.006 
µM and 0.054 µM, respectively.  ZJU-6 showed similar potency in MDA-468 
cells, a human breast cancer cell line. 
Erianin and ZJU-6 have similar potency on HCC-2998 cells.  Although both 
compounds are potent to this cell line, however, HCC-2998 has been reported 
in the literature to be unpredictable during culture
186
; hence this result may not 
be reliable.  In order to carry out the imaging experiment (section 3.3), a cell 
type with large size is required.  Hence, MCF-7 cells were selected to carry out 
most of the cellular assays for the mechanism studies of ZJU-6 despite the 
lesser potency of the molecule in this cell line. 
 
3.3 Morphological effect of ZJU-6  
Imaging studies were carried out to examine whether ZJU-6 performed in the 
same way as Erianin before proceeding with further specific experiments.  
Erianin has been reported to affect cell cycle by arresting the formation of 
micro-tubulin
182
, therefore, this property is expected to be found with ZJU-6.  
MCF-7 cells were treated with compounds at approximately the four times GI50 
concentration.  Images were taken in short intervals at specific regions of the 
plate.  The results are shown below (Figure 3.3). 
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Figure 3.3: Imaging studies in MCF-7 cells with Erianin and ZJU-6.  With four times GI50 
concentration of either compound, cells were unable to divide as shown at 4 hours.  As a 
consequence, genetic material in cells became disarrayed; cells detached from wells and 
rounded up, followed by cell death.  The scale bar represents 10 µm. 
 
The compound induced no effect during the first few hours of observation.  
At 4 hours, the size of the cells increased, but the cells were unable to divide.  
In vehicle-treated cells, genetic material was observed clearly in nuclear 
regions.  In contrast, a loss of genetic material from nuclei was observed in 
cells treated with either Erianin or ZJU-6.  At 5.5 hours, cells began to round 
up and genetic material was lost.  At 7 hours, cells detached from the culture 
plate indicating cell death.  In contrast, cells exposed to DMSO vehicle grew 
normally and continued to divide during this 24 hour time period. 
From these observations, we can conclude that at four times GI50 
concentration, Erianin and ZJU-6 function in a similar way in causing mitotic 
arrest in MCF-7 cells, followed by the possible disruption of microtubule 
polymerisation resulting in disarray of chromosomes in treated cells, and 
eventually leading to cell death.  Therefore we were now able to carry out 
further experiments to examine cell cycle and tubulin polymerisation and so 
confirm mitotic arrest. 
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3.4 Cell cycle effect of ZJU-6 
MCF-7 cells were treated with either Erianin or ZJU-6 at two or four times 
GI50 concentrations for 24 or 48 hours. The cell cycle effects were analysed by 
FACS which is shown in Figure 3.4. 
 
Figure 3.4: Effect of Erianin and ZJU-6 on the cell cycle of MCF-7 cells.  Cells were treated 
with compounds for 24 or 48 hours.  Significant G2/M transition block was observed with both 
compounds.  However the effect of Erianin was reduced at 48 hours with 0.1 µM, while the 
effect of ZJU-6 at 2.5 µM was the same at both time points.   
 
The G2/M blockage was observed by Erianin or ZJU-6 treatment at all 
concentrations tested.  For 0.1 µM Erianin, cells were predominantly arrested 
at G2/M transition at 24 hours with the G1 population being reintroduced at 48 
hours, while at 0.2 µM the percentage of G2/M cell population at both time 
points remained the same.  In the case of ZJU-6, its effect at 2.5 µM remained 
the same at both time points. 
 
3.5 ZJU-6 induces apoptosis in cancer cells  
From the pre-G1 population indicated in cell cycle analysis, we may 
hypothesise that ZJU-6 is more effective in inducing cell death.  To further test 
this hypothesis, caspase-3 assays were carried out in HCT-116 cells (Figure 
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3.5); MCF-7 cells are inappropriate for caspase-3 assay as the cells do not 
express caspase-3
187
.  HCT-116 cells were treated with either Erianin or ZJU-6 
for 24, 36 or 48 hours.  The level of caspase-3 activation, as an indication of 
apoptotic induction, was measured by optical density (OD). 
 
Figure 3.5: Caspase-3 activation in HCT-116 cells with Erianin and ZJU-6.  Approximately 10 
times GI50 concentration of Erianin was required for significant caspase-3 activation.  
Significant caspase-3 activation was observed with two times GI50 ZJU-6 concentration. 
 
By comparison with the DMSO samples, Erianin only induced a significant 
level of caspase-3 activation at 0.5 µM, with the peak effect observed at 36 
hours.  In the case of ZJU-6, significant caspase-3 activation was induced with 
all concentrations tested and at all time points.  This activation increased in a 
time dependent manner.  The peak activation level was at 36 hours with 10 
times GI50 concentration for both compounds. The caspase-3 assay indicated 
that Erianin was not toxic to cells as it only induced significant apoptosis at 
approximately 10 times GI50 concentration while ZJU-6 induced significant 
apoptosis at all concentrations.  The results further confirmed that ZJU-6 was 
more toxic to cells. 
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To verify the apoptotic effect caused by the compounds in MCF-7 cells, we 
performed Western blot to observe their effect on PARP cleavage (Figure 3.6). 
 
Figure 3.6: Erianin and ZJU-6 cause PARP cleavage.  At 24 hours, PARP cleavage was 
induced at 0.4 µM Erianin in MCF-7 cells.  ZJU-6 induced PARP cleavage from 2.5 to 10 µM. 
This result shows similarity to the caspase-3 assay with HCF-116 cells. 
 
As carried out in the previous chapter, PARP protein was used here, as a 
marker for the detection of apoptosis caused by Erianin and ZJU-6 (see section 
2.6).  MCF-7 cells were treated with either Erianin or ZJU-6 for 24 hours.  
Significant levels of PARP cleavage were caused by 0.4 µM Erianin compared 
to cells treated with DMSO only.  A low level of PARP cleavage was found in 
samples treated with DMSO and 0.1 µM Erianin, possibly due to the over 
growth of cells.  With ZJU-6, although the DMSO sample also revealed 
cleaved PARP as a result of over population, higher levels of PARP cleavage 
were shown in all samples treated with compound ranging from two to eight 
times GI50 concentration.  This observation once again indicates that ZJU-6 is 
more toxic once it has entered the cells, corroborating the results of the 
caspase-3 assays in HCT-116 cells. 
Sample Averagetotalcelldeath(%)
DMSO 4.20±2.51
0.2µMErianin 13.40±2.19
0.4µMErianin 15.43±3.47
1µMErianin 18.23±3.90
5µMZJU ?6 14.80±2.89
10µMZJU ?6 13.97±3.46
 
Table 3.3: Percentage of cell death induced by Erianin and ZJU-6. 
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A further experiment to verify cell death is the Annexin-V assay preformed 
in caspase-3 negative MCF-7 cells.  Cells were treated with 0.2, 0.4 or 1 µM 
Erianin and 5 or 10 µM ZJU-6 for 24 hours.  Both compounds induced 
apoptosis between 3- to 5- fold compared to the control (Figure 3.7).  

Figure 3.7: Effect of Erianin and ZJU-6 on MCF-7 cells death.  Cells were treated with 
compounds based on their GI50 values.  Both compounds induced similar levels of cell death.  
Erianin induced cell death in a dose dependent manner.  ZJU-6 induced a slightly higher level 
of cell death at four times GI50 concentration.  However the difference in cell death between 
four times and eight times GI50 was 0.83%, which is a region within the standard deviation and 
therefore insignificant. 
 
3.6 Effect of ZJU-6 on anti-apoptotic proteins 
ZJU-6 has been shown to be less toxic than Erianin.  However, once cells were 
treated with both compounds at the same GI50 equivalents, which could 
represents the same amount of compounds have entered the cells, the effect of 
ZJU-6 was more profound than Erianin (indicated by the apoptotic assays).  It 
has been reported that Erianin suppresses the transcription of Bcl-2, resulting in 
reduced Bcl-2 mRNA level
184
.  Western blots were used to detect the protein 
expression level of anti-apoptotic proteins Mcl-1 and Bcl-2 (Figure 3.8). 
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Figure 3.8: Effect of Erianin and ZJU-6 on the protein expression of Mcl-1 and Bcl-2.  No 
effect on Mcl-1 was observed by either compound.  Both compounds affect Bcl-2 by inducing 
the expression of an isoform protein with a higher molecular weight, possibly by altering the 
original transcription or translation mechanisms.  Phosphorylation of Bcl-2 resulting in an 
increase in size is another possibility. 
 
MCF-7 cells were treated with either Erianin or ZJU-6 for 24 hours.  
Neither compound suppressed the expression of Mcl-1.  For Bcl-2 expression, 
however, an extra, higher molecular weight band was shown.  This may 
indicate that both compounds induced an alternative isoform of Bcl-2 with a 
larger molecular weight, through alternation of transcription or translation 
mechanisms, which has been observed in lymphoma
188
.    Phosphorylation of 
Bcl-2 is another possibility as the addition of phosphate could increase the 
molecular weight of Bcl-2.  No further clues for the exact mechanism of Bcl-2 
alteration could be obtained by Western blot; further experiments are required 
to understand the mechanisms in detail. 
 
3.7 p53 induction by ZJU-6 
Protein p53 is one of the most important tumour suppressor genes.  The effect 
of Erianin on stabilisation of p53 has not been reported directly; however, since 
Erianin inhibits tubulin polymerisation in cells, which affects the chromosome 
segregation, if could induce the expression of p53.  Here, Western blots were 
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used to determine the effect of Erianin and ZJU-6 on p53 protein, and its 
negative regulator, HDM-2, in MCF-7 cells (Figure 3.9). 
 
Figure 3.9: Effect of Erianin and ZJU-6 on p53 and HDM-2 proteins in MCF-7 cells.  At 24 
hours, both compounds enhanced the expression of p53. However, a biphasic change on HDM-
2 expression, with an increase expression at low concentration followed by a decrease 
expression at high concentration was observed in the presence of both compounds.  
 
MCF-7 cells were treated with both compounds for 24 hours in a range 
between two to eight times GI50 concentrations.  In the presence of either 
compound, p53 protein concentration was increased compared to cells treated 
with DMSO only.  However, the level of HDM-2 protein showed a biphasic 
change with the presence of both compounds.  An increase of HDM-2 
expression was observed with 0.1 and 0.2 µM Erianin, with a decrease 
emerging at higher concentrations (Figure 3.10).  For ZJU-6, a similar trend to 
Erianin was observed.  The result indicated that both Erianin and ZJU-6 
enhanced the synthesis of p53 proteins.  However, they did not suppress the 
negative feedback by HDM-2; hence, we could not confirm whether the p53 
proteins here were active.  Higher concentration of compounds may suppress 
this negative feedback, but for the highest compound concentration here, the 
protein level of HDM-2 was still relatively higher than samples treated with 
DMSO vehicle.  Hence, in this particular experiment, we could only conclude 
that Erianin and ZJU-6 help to stabilise p53. 
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Figure 3.10: Dose dependent effect of compounds on HDM-2 proteins.  Western blot results on 
the effect of HDM-2 expression caused by Eriain-1 and ZJU-6 were used in Image JTM to 
measure the relative grey intensity.  The calculated readings from the measurements of samples 
were calibrated with the readings from the DMSO sample on the corresponding blot.   Both 
compounds have shown a trend to initially increase the expression HDM-2 protein, with a 
suppression observed dose dependently at higher concentration.  ZJU-6 promoted a relatively 
better effect than Erianin in suppressing HDM-2 expression.  However, the expression levels 
still exceed that of DMSO even at the highest compound concentration tested here. 
 
3.8 Effect of ZJU-6 on transcription 
We detected the effect of ZJU-6 on anti-apoptotic proteins Mcl-1 and Bcl-2, 
together with p53 negative regulator HDM-2 through Western blots.  Although 
significant reduction was not found in any of these proteins, Bcl-2 protein 
modification was observed in the presence of these compounds. Consequently, 
we investigated the effect of Erianin and ZJU-6 on the transcription of these 
proteins using RT-PCR (Figure 3.11).  As in Western blot, MCF-7 cells were 
treated with either compound for 24 hours at a range of concentrations based 
on the GI50 values. 
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Figure 3.11: Effect of Erianin and ZJU-6 on transcription in MCF-7 cells.  After 24 hours 
treatment with compounds, A) mRNA of Mcl-1 was affected by ZJU-6 at 10 µM only; Erianin 
had no effect on Mcl-1 transcription.  B) Erianin reduced the transcription of Bcl-2 from 
concentrations of 0.3 µM.  ZJU-6 reduced Bcl-2 mRNA level at 10 µM only.  C) No 
significant effect on transcription of HDM-2 was shown by either compound.  D) Transcription 
of ȕ-Actin remains constant. 
 
The results from RT-PCR have shown that ZJU-6 affected the transcription 
of Mcl-1 at 10 µM concentration. However, from previous experiments, 10 µM 
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ZJU-6 caused significant cell death.  Therefore, this reduction could be a 
consequence of cell death, rather than ZJU-6 specifically targeting Mcl-1 to 
induce cell death.  No effect on the mRNA synthesis of Mcl-1 was induced by 
Erianin.  The transcription of Bcl-2 was reduced by Erianin from 
concentrations of 0.3 µM, matching observations reported in the literature
184
.  
ZJU-6 induced a similar effect on Bcl-2 mRNA as with Mcl-1, reducing 
mRNA levels at 10 µM.  Therefore, Erianin, but not ZJU-6, could induce 
tumour cell death by affecting Bcl-2 transcription.  Both compounds had no 
effect on the transcription of HDM-2, matching Western blot observation.  
 
3.9 Effect of ZJU-6 on polymerisation of tubulin 
Tubulin is involved in the formation of mitotic spindles in the mitotic phase of 
the cell cycle.  Microtubule formation is essential for the segregation of sister 
chromatids and the formation of two daughter cells as the end product of the 
cell cycle.  It has been reported that Erianin is capable of inhibiting tubulin 
polymerisation
182
.  Our cell cycle analysis showed that both ZJU-6 and Erianin 
induced a G2/M transition block in MCF-7 cells, indicating that the compounds 
alter components essential for this phase of the cell cycle.  This cell cycle block 
was suspected to be caused by alteration of tubulin.  Therefore, an in vitro 
biochemical assay which determines the rate of tubulin polymerisation by 
measuring OD was performed to examine the effect of tubulin polymerisation 
induced by Erianin and ZJU-6 (Figure 3.12).  Since ZJU-6 has shown to be the 
more effective compound in the induction of cell cycle arrest, ZJU-6 was 
expected to be more potent than Erianin in inhibiting tubulin polymerisation.  
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Figure 3.12: Effect of compounds on tubulin polymerisation (up to 1 hour).  All compounds 
were used at 0.5 µM.  Paclitaxel and Nocodazole were used as additional controls known to 
enhance tubulin polymerisation and depolymerisation, respectively.  
 
The effect of compounds was compared at 0.5 µM and polymerisation of 
tubulin was allowed to occur for 1 hour.  In this assay, Paclitaxel and 
Nocodazole were the positive and negative controls, respectively.  Paclitaxel, a 
mitotic inhibitor used in cancer chemotherapy, was discovered in 1967 from 
the extract of pacific yew, Taxus brevifolia.  It is well known that Paclitaxel 
binds to tubulin to suppress dissociation of microtubules
189
.  Nocodazole 
functions in a manner opposite to Paclitaxel; it interferes with the 
polymerisation of microtubules by binding to ȕ̻tubulin and preventing 
formation of one of the two interchain disulfide linkages between tubulins.  
After three experimental repeats (Table 3.4), the results indicated that ZJU-6 
has a more potent effect than Erianin in suppressing the polymerisation of 
tubulin. 
Compound
 
DMSO
 
0.5µMPaclitaxel 0.5µMNocodazole 0.5µMZJU ?6 0.5µMErianin 
Vmax
(OD=340nm) 0.37±0.10 0.40±0.12 0.31±0.02 0.29±0.06 0.33±0.04 
 
Table 3.4: Vmax values from the tubulin polymerisation assays.  The results show Paclitaxel 
induced tubulin polymerisation while the other 3 compounds suppressed polymerisation of 
tubulin.  ZJU-6 has a more potent effect than positive control Nocodazole in suppressing the 
polymerisation reaction, while Erianin was less potent. 
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3.10 Effect of ZJU-6 on angiogenesis 
After clonal expansion of tumour cells in vivo, formation of blood vessels is 
essential for further growth of tumours and metastasis.  Oxygen and required 
nutrients are supplied to tumours, and waste removed via the blood.  
Compounds with anti-angiogenic properties suppress new blood vessel 
formation within tumours, hence blocking their oxygen and nutrient supply and 
halting their further development.  It has already been reported that Erianin has 
anti-angiogenic properties based on 48 hours treatment of the compound on 
chick chorioallantoic membrane
182
, we hypothesised that ZJU-6 may also 
possess anti-angiogenic properties.  An ex vivo experiment, the chorioallantoic 
membrane (CAM) assay, was used to test the effect of compounds on 
neovascularisation in fertilised chicken eggs.  The CAM assay allows 
observation of blood vessel formation in the chick embryo over a six day 
incubation period (Figure 3.13).  The effects of vehicle alone, 0.2 µM Erianin 
and 5 µM ZJU-6 on blood vessel formation in chick embryos were compared.  
The concentrations used were four times GI50 concentration in MCF-7 cells. 
 
Figure 3.13: Effect of Erianin and ZJU-6 on angiogenesis in chick embryo.  Based on four 
times GI50 concentration, ZJU-6 has shown a relatively potent anti-angiogenic effect in this 
CAM assay compared to Erianin, almost completely suppressing the formation of blood 
vessels.  The scale bar represents 1 mm. 
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The CAM assay was performed at least three times; all repeats showing 
similar effects.  The results indicated that both Erianin and ZJU-6 have anti-
angiogenic effects on blood vessel formation in chick embryos.  At four times 
GI50 concentration, ZJU-6 demonstrated a more profound anti-angiogenic 
effect than Erianin. 
A number of limitations are associated with the CAM assay, one of which is 
a possible genetic variation between each chick embryo; hence, the time 
required for blood vessel formation may vary between embryos.  In addition, 
anti-infectious agents such as antibiotics could not be used to prevent infection, 
as the embryos would be killed by these agents.  The embryo may become 
infected within a six day period which leads to the low success rate of the 
assays.  The position of the filter paper carrying the compounds may also affect 
the result.  As angiogenesis starts from within the embryo, placing the filter 
paper closer to the embryo may induce a more profound effect.  Another 
challenge is the concentration of compounds used in this assay; four times GI50 
concentration was used to overcome the question of compound delivery while 
being the highest concentration which would not kill the embryo as indicated 
by the earlier assays.  Finally, the mode of compound delivery to the embryo 
was by filter paper followed by diffusion.  The actual concentration of 
compounds in the tissue may be less than the concentration stated.  Hence, the 
effect of compounds may be more profound than reported here. 
 
3.11 Anti-oxidant activity of ZJU-6 
Natural products, particularly polyphenols, are understood to have anti-oxidant 
properties, a possible factor contributing to cancer prevention properties of 
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natural products.  Part of the principles behind the modification of Erianin to 
ZJU-6 with a free radical was to introduce the anti-oxidant effect to the 
molecule.  To examine this hypothesis, we carried out an in vitro biochemical 
assay using 1,1-diphenyl-2-picrylhydrazyl (DPPH) 21.  DPPH (Figure 3.14) is 
a molecule with a free radical in the central nitrogen atom which is readily 
reduced by compounds.  Such reduction is accompanied by a colour change 
which can be monitored spectrophotometrically. 
N N
O2N
NO2
O2N
1,1-diphenyl-2-picrylhydrazyl (DPPH)
7 
Figure 3.14: Molecular structure of DPPH. Free radical in the central nitrogen atom allows 
reduction by anti-oxidant agents.  DPPH reduction results in a colour change from deep violet 
to yellow. 
 
The DPPH assay is commonly used to estimate the anti-oxidant/reducing 
properties of natural products.  From the OD measurements, the estimated IC50 
values of compounds can be determined.  After three assay repeats (each in 
triplicate), the anti-oxidant activities of Erianin and ZJU-6 were plotted (Figure 
3.15) with the IC50 values of 43.69 µM and >100 ȝM were estimated for the 
two compounds respectively.  The positive controls in this assay were ascorbic 
acid and Epigallocatechin gallate (EGCG), the active ingredient in green tea 
with cancer prevention and anti-oxidant properties.  Their IC50 values in this 
assay were 23.58 µM and 3.72 µM, respectively.  Literature data indicated that 
ascorbic acid should have an IC50 value of 19.90 µM in this assay
190
, hence our 
results are comparable. 
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Figure 3.15: Effect of compounds on the reduction of DPPH.  Results of DPPH assay 
measuring the anti-oxidant effects of Erianin and ZJU-6.  EGCG from green tea and ascorbic 
acid were used as positive controls.  The IC50 values of ascorbic acid, EGCG and Erianin in 
this assay were 23.58, 2.58 and 46.23 µM, respectively.  ZJU-6 had an estimated IC50 of >100 
µM. 
 
Further experiments were carried out to investigate whether anti-oxidant 
properties can be demonstrated at a cellular level.  2ƍ,7ƍ-dichlorofluorescein 
diacetate (H2DCFDA) was used to detect the oxidation states of cells.  
H2DCFDA de-esterifies in the presence of intracellular oxidative species and 
turns to highly fluorescent 2ƍ,7ƍ-dichlorofluorescein.  Cellular fluorescence was 
quantified by FACS which estimates the oxidation states of cells. 
Figure 3.16: Effect of compounds in the cellular oxidation state.  H2DCFDA detection has 
shown that Erianin and ZJU-6 had pro-oxidant effect at cellular level with Erianin is more 
potent than ZJU-6.  Although the pro-oxidant effect was reduced between 1 to 6 hours, the 
effect could not be concluded as being anti-oxidant as the fluorescent level was higher than the 
DMSO sample. 
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HCT-116 cells were incubated with Erianin or ZJU-6 for 1, 3, 6 or 24 hours. 
5 µM hydrogen peroxide (H2O2) was used as positive control.  The results 
showed a relative increase in cellular florescence in all Erianin and ZJU-6 
treated samples compared to DMSO treated samples (Figure 3.16), indicating a 
pro-oxidant effect in cells. Erianin had a more profound effect than ZJU-6, 
increasing the cellular oxidation state up to 3-fold during the 24 hours period.  
ZJU-6 had a less significant effect, inducing a maximum ~2-fold increase in 
cellular oxidation level compared to DMSO controls. 

Figure 3.17: Effect of compounds in the prevention of cellular oxidation.  After pre-treating 
cells with hydrogen peroxide, except in the DMSO control, H2DCFDA detection has shown 
that Erianin and ZJU-6 had pro-oxidant effects at cellular level compared to H2O2 treated 
samples.  The results were similar to previous experiments, indicating that Erianin and ZJU-6 
enhanced cellular oxidation states of HCT-116 cells up to 3-fold and around 2-fold, 
respectively.  
 
Since an unexpected result was observed from the H2DCFDA assay, the 
assay method was altered, and all samples (except DMSO control) were pre-
treated with 5 µM H2O2 for 30 minutes before harvesting and FACS analysesis.  
This should have allowed us to observe the effect of test compounds in 
preventing cellular oxidation induced by H2O2 (Figure 3.17).  However, results 
were similar to those obtained in the previous experiment, indicating that both 
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compounds induced pro-oxidant effects.  Since the DPPH assay is a 
biochemical assay, while the H2DCFDA assay is a cellular assay, the results of 
these two assays could suggest that Erianin and ZJU-6 could have anti-oxidant 
properties, but not at cellular levels. 
 
3.12 Conclusion 
Erianin, a natural product obtained from the Southeast Asian plant Dendrobium 
chrysotoxum, is already in phase II clinical trials for treatment of leukaemia (S. 
Wang personal communication).  It inhibits cell growth with GI50 value 
between 12.5 to 81.9 nM in a range of cell lines.  The known properties of 
Erianin include prevention of angiogenesis, disruption of endothelial tube 
formation, abolition of cell migration across collagen and adhesion to 
fibronectin, and depolymerisation of F-actin and ȕ-tubulin.  ZJU-6, a novel 
analogue of Erianin has shown a reduced potency in some cell lines, except 
HCC2998, by at least 20-fold.  The GI50 values of ZJU-6 in the cell lines tested 
were ranging from 0.06 to 2.79 µM (as shown in Table 3.2).   
Both Erianin and ZJU-6 were able to block the segregation of chromosomes 
in MCF-7 cell nuclei following 4 hours treatment with compounds at 
concentration of four times GI50.  The shape of the genetic material inside the 
cell nucleus gave us an early indication that microtubule, possibly tubulin, was 
disrupted by the compounds.  As a consequence, cells become enlarged in size 
and rounded up, followed by detachment from the tissue culture plate and cell 
death. 
The observation of cell enlargement indicated that ZJU-6 possibly induced a 
G2/M phase block in cell cycle.  Cell cycle analysis by FACS confirmed that 
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both Erianin and ZJU-6 induced arrest at G2/M transition, at similar levels 
correlated to their GI50 concentrations.  Profound G2/M cell cycle transition 
arrest has also been observed in other cell lines (HCT 116, A549, MDA-468) 
exposed to Erianin (100 nM, 200 nM, 24 - 48 hours; T.D. Bradshaw personal 
communication). 
ZJU-6 induces tumour cells to undergo apoptosis.  ZJU-6 caused caspase-3 
activation in HCT-116 cells from two times GI50 concentration, while Erianin 
induced caspase-3 activation only at eight times GI50 value.  The peak effect of 
the two compounds was found at 36 hours with eight times their GI50 
concentrations. PARP cleavage was detected by Western blot using MCF-7 
cells treated with compounds; a similar result to the caspase-3 assay was 
observed.  PARP cleavage was detected with ZJU-6 from two times GI50 
concentration, while Erianin only induced PARP cleavage at eight times GI50 
concentration.  These apoptotic assays indicated that ZJU-6 was more effective 
at apoptosis induction, correlating to their GI50 concentrations. 
Since Erianin has been reported in affecting the transcription of Bcl-2, 
expression of anti-apoptotic proteins Mcl-1 and Bcl-2 were examined by 
Western blot in MCF-7 cells treated with the two compounds.  No effect on 
Mcl-1 was induced by either compound.  An isoform of Bcl-2 with a higher 
molecular was detected, which suggests the compounds might affect 
transcription or translation of Bcl-2.  The effect of compounds on p53 has also 
been investigated.  Erianin and ZJU-6 stabilising p53 increasing the protein 
level of both p53 and its negative regulator HDM-2 consequently.  Since 
HDM-2 remains its negative regulatory effect on p53, therefore p53 induced by 
the compounds may not be active.   
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The effect of compounds on transcription of Mcl-1, Bcl-2 and HDM-2 in 
MCF-7 cells was detected by RT-PCR.   Erianin was a better compound for 
inhibiting Bcl-2 transcription, while ZJU-6 was more effective in inhibiting the 
transcription of Mcl-1.  Both compounds have no effect on the transcription of 
HDM-2, which further confirm that p53 expression by the compounds 
observed in Western blot may not be active.  The protein and PCR observations 
suggest ZJU-6 function in similar way as Erianin on Bcl-2, but not Mcl-1.  The 
result also indicated that p53 was not responsible for the cell death, given that 
it may not be active as interpreted from the unchanged HDM-2 levels. 
Tubulin is essential for mitotic spindle formation which is required for 
chromosome segregation during mitosis.  Since literature data reports that 
Erianin arrested tubulin polymerisation
182
, together with our observation on the 
G2/M cell cycle transition arrest with both compounds, ZJU-6 should also 
suppress polymerisation of tubulin.  A biochemical assay was used to estimate 
the effects of Erianin and ZJU-6 on tubulin polymerisation.  Using 0.5 µM 
compounds, ZJU-6 showed a more profound effect than Erianin in suppressing 
tubulin polymerisation.  Furthermore, the ZJU-6 concentration used below its 
GI50 in most of the cell lines tested, it also suggests that inhibition of 
microtubule polymerisation could be the primary action of ZJU-6, but not 
Erianin.  
Erianin has been reported to possess anti-angiogenic properties.  The ex vivo 
chorioallantoic membrane (CAM) using four times GI50 compound 
concentrations on MCF-7 cells proved ZJU-6 to be a more effective anti-
angiogenic compound than Erianin.  However, the sensitivity of chick embryo 
to the compounds is likely to be different to MCF-7 cells.  Perhaps the better 
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anti-angiogenic effect of ZJU-6 was induced by the high concentration of 
compound, i.e. 5 µM ZJU-6 vs. 0.2 µM Erianin. 
Anti-oxidant properties contribute to cancer prevention.  The free radical on 
ZJU-6 was intended to introduce anti-oxidant property.  The in vitro 
biochemical assay using DPPH surprisingly revealed Erianin, which is not a 
polyphenol and do not contain free radicals, to be the more effective anti-
oxidant.  FACS analysis was used to investigate the anti-oxidant effect of both 
compounds in HCT-116 cells; the results, however, indicated that neither 
compound possesses anti-oxidant properties nor low levels of pro-oxidant 
activity were revealed.  Erianin, again, was proven to be more effective than 
ZJU-6 in the possible anti-oxidant property at biochemical level and its pro-
oxidant property at cellular level. 
Gathering all our data, Erianin itself is a potential anti-tumour agent.  As 
mentioned at the beginning of the chapter, Erianin has been found to have 
severe toxicity to patients in clinical trials.  The development of semi-synthetic 
compounds using Erianin as a skeleton could generate a range of novel anti-
tumour agents, such as ZJU-6, to improve the compound property as a clinical 
candidate by reducing its toxicity and possibly its adverse effects. 
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Chapter Four 
Synthesis of a Plk1 inhibitor  
analogue of BI 2536 
4.1 Introduction 
Since the discovery of CDKs, many other kinases, which show evolutionary 
conservation with CDKs in terms of genetic sequence and protein structure, 
have been found to be functionally related to CDKs, such as their roles in cell 
cycle progression.  Examples of these are the Polo-like kinases (Plks).  These 
kinases have also been investigated as potential drug targets in various diseases 
including cancer. 
 
4.1.1 Polo-like kinases 
Polo-like kinases (Plks) are enzymes first discovered in Drosophila 
melanogaster (polo) and Saccharomyces cerevisiae (cdc5) mutant cells that 
failed to undergo normal mitosis
191
.  Subsequently, Plks have been found in 
many eukaryotes
192
.  Human Plk was first cloned in 1993.  This gene encodes a 
polypeptide containing 603 amino acids.  Several nucleotide sequence 
differences were noted among the published sequences, but later these 
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differences were proved to be conservative changes in the amino acid sequence 
and were likely to be polymorphisms.  The molecular weight of the Plk protein 
is 66 kD.  This first identified form of Plk was later denoted as Plk1.  The 
expression of Plk1 was found at a low level during G1 phase of the cell cycle, 
the expression level starting to accumulate during G2/M phase transition.
193
   
Lately discovered members of the Plk family were expressed primarily during 
mitosis.  Hence, Plks are involved in key roles such as cell entry into mitosis, 
bipolar spindle formation, chromosome segregation and cytokinesis
194
. 
There are several different types of Plks, all of which show structural 
similarity, i.e. a canonical serine/threonine kinase domain at the amino 
terminus and a regulatory domain containing two signature motifs, known as 
polo boxes, at the carboxyl terminus.  The genomes of Drosophila 
melanogaster, Saccharomyces cerevisiae and Schizosaccharomyces pombe 
have only one Plk (Polo, Cdc5 and Plo1, respectively), whereas vertebrate 
species have several Plks
194
.  
 
Table 4.1: Different species show variations in Polo-like kinase diversity194, 195.  X. laevis, C. 
elegans and mammals have multiple Plk members.  D. melanogaster, S. pombe and S 
.cerevisiae have only one Plk.  All Plks commonly function during mitosis.  
 
In mammals, there are four Plk family members (Table 4.1)
195
. The function 
of Plk1 will be discussed in detail in section 4.1.2. 
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4.1.1.1 Polo-like kinase 2 
Plk2 also known as serum-inducible kinase (Snk), is a 685 amino acids protein 
(Figure 4.1) with a calculated molecular mass of about 78 kD.  It also contains 
an ATP-binding motif within the kinase domain and a conserved polo box
196
.  
Plk2 was found to be highly expressed in rat organs including adult testis, 
spleen and the occipital lobe, as well as in foetal lung, spleen, kidney and heart 
tissues.  In humans, Plk2 was found to function in normal lung fibroblast cell 
division.  The proposed functions of Plk2 include: DNA damage response, 
synaptic plasticity regulation and regulation of the G1/S cell cycle transition.  
 
Figure 4.1: Structure of human Plk2 polypeptide196.  The red coloured region is the kinase 
domain with a T-loop (T239) which is critical for the regulation of its activity.  There are two 
functional polo-box domains (PBDs) shown here in blue which phosphorylate downstream 
substrate proteins.  This PBD is conserved across the Plk family (Adapted from Strebhardt & 
Ullrich. Nat. Rev. Cancer. 2006, 6, 321). 
 
4.1.1.2 Polo-like kinase 3 
Plk3 has various names including fibroblast-growth-factor-inducible kinase 
(fnk), cytokine-inducible kinase (cnk) and proliferation-related kinase (Prk).  
Plk3 protein has a 646 amino acid sequence containing an N-terminal catalytic 
domain which consists of an ATP-binding site (kinase domain), a central 
putative nuclear targeting signal motif and the polo-box domain (PBD) at the 
C-terminal regulatory domain (Figure 4.2).  It has a conserved sequence with 
other Plk family members, with 91% homology to mouse Fnk, 50% homology 
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to human Plk, 48% homology to D. melanogaster polo and 38% homology to 
S. cerevisiae Cdc5.  Plk3 expression has been found in a limited number of 
human tissues; a moderate level of Plk3 being found in placenta and low levels 
in ovary, lung, and peripheral blood leukocytes
197
.  Reduced expression has 
been found within tumour tissues, significantly in primary lung carcinoma.  
Plk3 regulates the G2/M transition by phosphorylating the C-terminal domain 
of cdc25c, a phosphoprotein found activated in the G2 phase of the cell cycle 
which is critical for the onset of mitosis.  Plk3 is also known to associate with 
centrosomes in several human cell lines which regulate microtubule dynamics 
and centrosomal function.  Other reported functions of Plk3 are similar to those 
of Plk2, which include DNA damage responses and synaptic plasticity 
regulation. 
 
4.1.1.3  Polo-like kinase 4 
The sequence of Plk4 is highly homologous to the mouse Sak gene; therefore, 
it is also referred to as Sak, a kinase consisting of 970 amino acids (Figure 4.2).  
There is suggestion that the lack of Plk4 may be implicated in mitotic infidelity 
tumour development
198
.  It also functions as an upstream regulator for centriole 
formation
199
.  Centrioles are important parts of centrosomes which are involved 
in the organisation of the mitotic spindle and in the completion of cytokinesis.  
Plk4 therefore also has a critical role in the regulation of mitosis and mitotic 
exit.  Abundant Plk4 transcription has been detected in testis and thymus, but 
not in other tissues. 
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Figure 4.2: Structures of human Plk3 and Plk4 polypeptides196.  The structure of Plk3 is similar 
to Plk2 in length, position of T-loop and number of PBDs.  Plk4 is distinguished from other 
members of Plk family by a much longer length, a slightly up front T-loop and only one PBD 
(Adapted from Strebhardt & Ullrich. Nat. Rev. Cancer. 2006, 6, 321).  
 
4.1.2 Polo-like kinase 1 (Plk1) 
Polo-like kinase 1 (Plk1) is the most investigated member of the Plk family.  
Plk1 protein consists of a kinase domain in the N-terminal region and a PBD in 
the C-terminal region
200, 201
.  The kinase domain is responsible for 
phosphorylation; while the PBD is involved in localisation
202, 203
 (Figure 4.3).  
The activity of Plk1 is tightly regulated by cells via phosphorylation within a 
short region of the catalytic kinase domain, known as the T-loop, together with 
the nearby D-box motif
204
. 
 
Figure 4.3: Polypeptide sequence of human Plk1196.  The Plk1 gene encodes a polypeptide 
sequences with 603 amino acids. Plk1 consists of 2 parts: the N-terminal kinase domain and the 
C-terminal polo box domain (PBD).  Three key residues at PBD: Trp414, His538 and Lys540, 
are responsible for phosphor-peptide binding.  T-loop (Thr210) and the D-box motif are 
required for degradation by, for example the APC/C - Cdh1 system205, through 
phosphorylation, which are conserved in all members of Plks(Adapted from Strebhardt & 
Ullrich. Nat. Rev. Cancer. 2006, 6, 321). 
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In mouse, expression of Plk1 is observed in adult thymus tissues, ovaries 
and in foetuses.  In humans, the expression of Plk1 was detected in the 
placenta, but high levels are also found in tumours of various origins.  Studies 
with established growing cell lines show Plk1 transcript level to be low during 
the G1 phase of the cell cycle; accumulating during S phase and reaching 
maximal levels during the G2/M transition
206, 207
. 
To further examine the role of Plk1 during mitosis, recombinant human 
Plk1 expressed in insect cells phosphorylates casein on serine and threonine 
residues.  It also phosphorylates myelin basic protein (MBP) and microtubule 
associated protein 2 (MAP2), but to a lesser extent.  Confocal microscopy 
studies found that Plk1 binds to components of the mitotic spindle at all stages 
of mitosis
208, 209
, but was redistributed as cells progressed from metaphase to 
anaphase.  Specifically, Plk1 is associated with spindle poles up to metaphase, 
before relocating to the equatorial plane, where the spindle microtubules 
overlap, as cells progress through anaphase
210
.  These observations led to the 
conclusion that Plk1 functions in mitotic cells to control spindle dynamics and 
chromosome segregation (Figure 4.4). 
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Figure 4.4: Multiple roles of Plk1 during Mitosis194.  Mammalian Plk1 is believed to regulate 
multiple processes during mitosis.  These include the regulation of mitotic entry by association 
to components of the mitotic spindle; the control of centrosome maturation between prophase 
and prometaphase211; regulation of spindle assembly between prometaphase and metaphase; 
control of the APC/C complex between metaphase and anaphase where a multi-component 
ubiquitin ligase targets proteins for degradation by the proteasome; finally, the control over 
cytokinesis for daughter cell segregation (Adapted from Dai. Oncogene. 2005, 24, 214). 
 
The activity of Plk1 was found to be regulated by Aurora kinase A and its 
co-factor Aurora borealis (BORA) which is also known to control G2/M phase 
cell cycle transition
212
.  BORA accumulates in the G2 phase and promotes 
Aurora A-mediated activation of Plk1 through phosphorylation of T-loop 
Thr210, resulting in the activation of cyclin-dependent kinase 1 (CDK1) and 
mitotic entry.  
During anaphase, Plk1 regulates cytokinesis by localising to the central 
spindle
208, 213
.  This promotes the local activation of RhoA GTPase, which 
induces assembly and ingression of the contractile ring leading to the initiation 
of cytokinesis
214
. 
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4.1.3 Plk1 as a drug target 
In an early study, Plk1 was found to induce mitosis in quiescent NIH 3T3 
mouse embryonic fibroblast cells and caused proliferation in low serum media.  
Microinjection of Plk1 mRNA was later found to produce tumours in nude 
mice
215
.  Plk1 is not expressed in most normal mammalian tissues.  However, 
as expression of Plk1 occurs in many different types of cancer
216
.  Therefore, 
Plk1 has been linked to the promotion or progression of cancer and proposed as 
a diagnostic marker for several tumours. 
As Plk1 is activated during mitosis of dividing tumour cells, it has been 
suggested that inhibiting Plk1 functions may arrest cell proliferation in all 
human cancers regardless of their organ of origin, or oncogene and tumour 
suppressor gene status.  A vector-based RNA interference (RNAi) study 
showed that normal cells can survive with depletion of Plk1
217
, but Plk1 
depleted carcinomas showed inhibition of cell proliferation, decreased viability 
and cell cycle arrest during G2/M transition, eventually leading to apoptosis
47, 
218
.  Caspase-3 activation and the formation of fragmented nuclei which led to 
activation of p53 as a result of DNA damage were all involved in causing 
tumour cell apoptosis by Plk1 depletion
219
. 
In addition to normal quiescent cells do not necessarily require the activity 
of Plk1 to maintain their survival, Plk family has shown no homology to other 
known human kinase families to date.  Therefore, compounds targeting Plk1 
hold potential as effective anticancer agents, as Plk1 inhibitors should have a 
much improved specificity and selectivity compared to chemotherapeutic 
agents
220
.
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4.1.4 Inhibitors targeting Plk1 
Approximately one dozen compounds targeting Plk1 have entered clinical 
trials for treatment of cancers, but none have been approved to date.  With the 
crystal structure of the kinase domain only recently becoming available
221
 
(Figure 4.5), the design of early Plk1 inhibitors relied on compound screening 
and ATP antagonism.  
 
Figure 4.5: Crystal structure of Plk1221.  The CĮ chains of the N-terminal and C-terminal lobes 
are coloured grey and yellow, respectively.  The secondary-structure elements (SSEs) are 
highlighted (cyan for ȕ-strands, red for Į-helices).  The activation segment, which is located in 
the C-terminal domain, is shown in green (Adapted from Cheng et al. The EMBO journal. 
2003, 22, 5757). 
 
The four best known Plk1 inhibitors are Wortmannin, Scytonemin, BI 2536 
and ON01910 (Table 4.2).  Wortmannin 9 is one of the earliest Plk1 inhibitors 
to enter clinical trials; it is a competitive ATP inhibitor.  The disadvantage of 
Wortmannin is poor specificity; in addition to inhibiting Plk1, it also inhibits 
mTOR, DNA-PK, Phosphoinositide-3-kinase (Pl3K), some 
phosphatidylinositol 4-kinases, myosin light chain kinase (MLCK) and 
mitogen-activated protein kinase (MAPK).  Scytonemin 8 has the lowest 
potency against Plk1 compared to the others and inhibits other kinases. 
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Table 4.2: Properties of the four best known Plk1 inhibitors196.  
 
There is one other type of inhibitor which competes for the enzyme 
substrate binding sites by mimicking the structure of substrates binding to Plk1. 
ON01910 11 is a small molecular inhibitor using this mechanism which works 
through competing with the PBD of Plk1
222
.  BI 2536 10 is one of the most 
promising Plk1 inhibitor for the treatment of cancer. 
 
4.1.5 BI 2536 
BI 2536, an ATP-competitive dihydropteridinone derivative that shows 
inhibitory effects on Plk1 both in vitro and in vivo, has at least a 10,000-fold 
level of selectivity for Plk1 against a large panel of other tyrosine and 
serine/threonine kinases
196, 223, 224
.  BI 2536 inhibits Plk1 with an IC50 value of 
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0.83 nM in kinase activity assays.  It also has an EC50 value of 8.3 nM using 
human colon tumour cell line HCT-116 and 9 nM in human breast cancer cell 
line MCF-7, as estimated by Alamar Blue
TM
 proliferation assay with 72 hours 
exposure.  Molecular modelling predicted that BI 2536 binds to Plk1 through 
Leu132 is a unique feature of this inhibitor (Figure 4.6).  It could also be the 
key to inducing conformational changes in the protein pocket which provide 
selectivity for inhibiting Plk1
225
.  According to FACS analysis, treatment with 
BI 2536 arrested HeLa S3 cervix adenocarcinoma cells in the G2/M cell cycle 
transition over a 24 hour period
224
.  Apoptosis was also found in HeLa S3 cells 
48 hours after treatment with BI 2536.  At that time, Western blot was used to 
detect DNA degradation which provided evidence of induction of apoptosis. 
 
Figure 4.6: Proposed binding model for the selective Plk1 inhibitor BI 2536 in Plk1225.  
Computer modelling predicted that BI 2536 (green) would interact with three amino acid 
residues on the Plk1 protein: L132/Y212, C67/V146 and V114/L194 (brown).  These 
interactions suppress the phosphorylation of Plk1 and possibly provide specificity in inhibiting 
Plk1 (Adapted from Kothe. Chemical biology & drug design. 2007, 70, 540). 
 
From the above in vitro biological assay results, BI 2536 is one of the most 
promising Plk1 inhibitors currently undergoing Phase I clinical trials
226
.  For 
this reason, BI 2536 would make an ideal control compound in the 
development of novel Plk1 inhibitors.  Since BI 2536 was not commercially 
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available, it was proposed to synthesise BI 2536 for use as a positive control in 
our in-house biological assays. 
 
4.2 Synthesis of BI 2536 analogue 
Synthesis of BI 2536 is a 9-step process by literature procedures
227
.   However, 
the key starting material, D-alanine ethyl ester, is not commercially available at 
that time.  Therefore, a modified synthetic chemistry was developed as shown 
in Scheme 4.1
227-229
. 
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Scheme 4.1: Synthesis of BI 2536 racemate 25.  Reagents and conditions: (i) CH3COONa, 
(CH3COO)3BHNa, DCM, r.t., 12 hrs; (ii) K2CO3, CH3COCH3, r.t., 12 hrs; (iii) Fe, CH3CO2H, 
70oC, 1 h; 100oC, 1.5 hrs; (iv) CH3I, NaH, DMA, 0
oC, 20 min; r.t., 30 min; (v) LiAlH4, diethyl 
ether, reflux, 17 hrs; (vi) SOCl2, CHCl3, reflux, 3h; (vii) Pyridine, THF, r.t., 2 hrs; reflux, 1.5 
hrs; (viii) Pd/C, EtOH, reflux, 1.5 hrs; (ix) 160oC, overnight. 
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The initial synthesis was focused on the racemic compounds 25 as the low 
cost of starting material 12 was commercially available.  An optical HPLC can 
then be conveniently used to resolve BI 2536 from the racemates 25.  
  
Scheme 4.2: Synthesis of methyl 2-(cyclopentylamino)butanoate.  Reagents and conditions: (i) 
CH3COONa, (CH3COO)3BHNa, DCM, r.t., 12 hrs 
 
DL-alanine ethyl ester hydrochloride 12 was treated with cyclopentanone 13 
and dissolved in dichloromethane at 0
o
C.  Sodium acetate and sodium 
triacetoxyborohydride were added to the reaction mixture which acts as the 
catalysts of this reaction.  After 12 hours at room temperature, 20% aqueous 
sodium hydrogen carbonate solution was added to the reaction mixture until 
hydrogen gas no longer evolved, the excessive amount of carbonate reactions 
with the sodium compounds in the reaction mixture.  The product was obtained 
through extraction of raw reaction mixture with dichloromethane, which was 
evaporated to give methyl 2-(cyclopentylamino)-butanoate 14 with 100% 
yield. 
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Scheme 4.3: Synthesis of the core pyrimidine ring.  Reagents and conditions: (i) K2CO3, 
CH3COCH3, r.t., 12 hrs.  
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The next step was to obtain the core pyrimidine ring of the inhibitor.  To 
prevent undesired reactions, 14 was suspended in acetone in an ice bath prior 
the addition of 2,4-dichloro-5-nitropyrimidine 15 and potassium carbonate.  
Further amounts of 2,4-dichloro-5-nitrpyrimidine were added after 12 hours 
reaction at room temperature.  This addition proved to increase the yield of 16 
from 10% to 30% after chromatography.  The reaction mixture was allowed for 
further 3 hours at room temperature.  The product, in the form of brown oil, 
was obtained through extraction with ethyl acetate.   This brown oil had at least 
5 different substances, which was applied to silica gel and purified by 
chromatography to obtain 16 as yellow crystals. 
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Scheme 4.4: Cyclisation of 16 to form product with 2 aromatic rings 17.  Reagents and 
conditions: (i) Fe, CH3CO2H, 70
oC, 1 h; 100oC, 1.5 hrs. 
 
To turn the molecule 16 into a product with two aromatic rings, 16 was 
dissolved in excess glacial acetic acid at 70
o
C followed by the addition of iron 
powder in batch-wise manner, which minimised the undesired reaction driven 
by this powerful reducing agent.  Here, iron was used as a reducing agent and 
glacial acetic acid provided H
+
 ion for the formation of an amine.  The reaction 
mixture was stirred at 70
o
C for 1 hour which reduces the nitrogen dioxide to 
amine, and 100
o
C for further 1.5 hours to complete the cyclisation.  The 
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reaction mixture was filtered hot through Kieselguhr to remove the iron 
powder.  17 was obtained with 60% yield. 

Scheme 4.5: Methylation of amine.  Reagents and conditions: (i) CH3I, NaH, DMA, 0
oC, 20 
min; r.t., 30 min. 
 
The final reaction in preparing the pyrimidine ring was to methylate the 
amine group.  17 was dissolved in dimethylacetamide (DMA) at -14oC 
followed by the addition of methyl iodide and sodium hydride in 60% mineral 
oil suspension; DMA is a strong solvent in dissolving and polarising 17, 
sodium hydride acts as a strong base triggering the addition of methyl group to 
the amine by methyl iodide.  The reaction mixture was stirred for 20 minutes at 
0
o
C which dehydrogenated the amine by sodium hydride and 30 minutes at 
ambient temperature for the addition of a methyl group by methyl iodide.  The 
raw product was applied to silica gel after the removal of the reaction catalysts 
and solvent, which was then purified by chromatography to obtain 18 as yellow 
oil with 60% yield. 
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Scheme 4.6: Synthesis of 1-methylpiperidin-4-amine 20.  Reagents and conditions: (i) LiAlH4, 
diethyl ether, reflux, 17 hrs. 
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After completing the synthesis of the region which functions as the adenine 
of ATP, we proceeded to the synthesis of the region which acts as the 
phosphate tail of ATP in BI 2536.  To obtain the piperidine ring required for 
the synthesis, ethyl 4-aminopiperidine-1-carboxylate 19 was employed as a 
starting material.  Under anhydrous conditions (nitrogen gas), Lithium 
aluminium hydride (LiAlH4) was used to reduce 19, its addition to the reaction 
mixture was under anhydrous condition (nitrogen gas), which then stirred in an 
ice-bath for half hour for mixing without initiating the reaction.  The reaction 
mixture was then placed into an oil bath and slowly heated to 44
o
C to reflux for 
17 hours, allowing reduction of 19 by LiAlH4 to occur.  The unreacted LiAlH4 
was quenched by the addition of 10% aqueous NaOH at the end of the reaction.  
The resulting slurry was filtered under vacuum and the filtrate washed with 
ether to elute 20.  The combined ether was dried with magnesium sulphate, 
filtered and evaporated resulting in 20 as yellow oil with 70% yield. 
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Scheme 4.7: Synthesis of 3-methoxy-4-nitrobenzoyl chloride 22.  Reagents and conditions: (i) 
SOCl2, CHCl3, reflux, 3hrs. 
 
To synthesise the other starting material of the phosphate antagonist region, 
a suspension of 3-methoxy-4-nitrobenzoic acid 21 was dissolved in chloroform 
under nitrogen followed by the addition of thionyl chloride.  Chloride ion has a 
higher polarity then hydroxide ion, which attack 21 at the hydroxide group for 
nucleophilic substitution.  The reaction mixture was refluxed for 3 hours until a 
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clear solution formed under nitrogen, which prevented the reaction to be 
reversed by the hydroxide ion from moisture.  The reaction mixture was 
evaporated at 60
o
C to remove the thionyl chloride, 22 was obtained as a yellow 
solid with 100% yield. 
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Scheme 4.8: Synthesis of 3-methoxy-N-(1-methylpiperidin-4-yl)-4-nitrobenzamide 23.  
Reagents and conditions: (i) Pyridine, THF, r.t., 2 hrs; reflux, 1.5 hrs. 
 
To combine 20 and 22, 20 was dissolved in tetrahydrofuran (THF) followed 
by the addition of pyridine.  Pyridine acted as a base to allow the substitution 
of amine on piperidin 20 to chloride on the alanine 22.  Followed by the 
addition of 22, the reaction mixture was stirred for 2 hours under nitrogen at 
ambient temperature, which prevented the conversion of 22 to 21.  1 hour 
reflux was followed allowing the completion of the reaction.  As 23 is a non-
polar molecule, re-crystallisation with ethanol is a better method than column 
chromatography for the purification of this compound, as a large amount of 
product would stay in the silica and the use of high polarity solvent may result 
in contamination by silica.  Re-crystallisation precipitated 23 as white solid 
with 65% yield.  
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Scheme 4.9: Reduction of 3-methoxy-N-(1-methylpiperidin-4-yl)-4-nitrobenzamide 23.  
Reagents and conditions: (i) Pd/C, EtOH, reflux, 1.5 hrs. 
 
Palladium in 10% carbon, which is a powerful agent in reducing large, non-
polar molecules
230-232
, was used to reduce the nitrogen dioxide on 23 to 
primary amine.  Tin chloride could replace palladium as the reducing agent
233
, 
but the yield would be reduced.  The reaction mixture was stirred at ambient 
temperature under hydrogen gas, which provided the source of hydrogen for 
the formation of amine.  Kieselguhr was used to filter out the palladium at the 
end of the reaction.  Re-crystallisation with hot ethanol was used again to 
purify the non-polar product.  24 precipitated as white solid, which was suction 
filtered out with 90% yield. 
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Scheme 4.10: Synthesis of BI 2536 racemic 25.  Reagents and conditions: (i) 160oC, overnight. 
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To combine 18 and 24 to form the final compound, both compounds were 
heated at 160
o
C overnight without any solvent and base (catalyst) to allow the 
occurrence of nucleophilic substitution by amine.  The completion of the 
reaction was checked by TLC (100% ethyl acetate, RF = 0.22).  The reaction 
mixture was purified by column chromatography; Purification by re-
crystallisation was followed, ethyl acetate was added to dissolve the product, 
followed by the addition of excess hexane until the formation of precipitate.  
The precipitate was filtered and washed with hexane yielding 25 as a yellow 
solid in 50% yield.  The chemical structure of this compound was confirmed by 
mass spectrometry (MS) and 1H nuclear magnetic resonance (NMR). 
 
4.3 Conclusion  
Plk1 is a kinase involved in multiple roles within mitosis and cytokinesis.  
Evidence has shown that over expression of Plk1 is associated with the 
formation of certain types of cancers.  As normal cells were found to survive 
without the expression of Plk1, targeting Plk1 as an anti-cancer drug has 
become a favoured topic in cancer research.  Since the claims of the first Plk1 
inhibitor a decade ago, about a dozen Plk1 inhibitors have entered clinical trials 
to date.  One of these compounds is BI 2536, one of the most potent and 
selective Plk1 inhibitor reported. 
Since BI 2536 is unavailable commercially, we aimed to synthesise this 
compound for use as a positive control in our project to design novel Plk1 
inhibitors.  Compound 25 was successfully prepared as the racemates of BI 
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2536.  However, by the time we completed the synthesis, the clinical 
compound BI 2536 has become available commercially.  Therefore, further 
purification and resolution of compound 25 was not carried out. 
 134
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Chapter Five 
General discussion, conclusion and 
future work 
5.1 General discussion and conclusion 
5.1.1 Elucidation of the mechanism of action of a 
novel CDK9 inhibitor 
Our mechanism studies of S-134 have shown that this novel inhibitor induced a 
nano-molar inhibition across a large range of cell lines using MTT assay with 
72 hours exposure.  In particular, S-134 was most potent in inhibiting HCT-116 
human colon and A2780 human ovarian carcinoma cell lines respectively.  S-
134 showed a micro-molar growth inhibition on the human malignant glioma 
cell line SNB19 and human astrocytoma cell line U373; these are actually 
promising results in comparison to some clinical drugs.  Using SNB19 cells as 
an example, one of the gold standard treatments for glioma is a small 
molecule inhibitor called temozolomide, which has a GI50 value of 30.70 µM 
in this cell line under similar experimental conditions (Personal communication 
with J.H. Zhang). 
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The data from kinase assays show S-134 to be most potent in inhibiting the 
activity of CDK9/cyclin T1, followed by CDK2/cyclin E and CDK7/cyclin H.  
Comparing these kinase assays with those from other CDK inhibitors in 
clinical trials, S-134 achieved a better selectivity and potency between these 
three CDKs than Roscovitine, but not Flavopiridol.  More importantly, the 
kinase assay data could not conclude which of these three compounds achieved 
the best potency and selectivity on CDK9 in cells. Firstly, there are numerous 
protein functions in conjunction with CDK9 during cell cycle, which could 
interfere with the binding between the inhibitors and CDK9.  Also, it is not 
possible to use this type of in vitro protein assay to verify whether other 
kinases and proteins inhibited by the compounds before CDK9, as large 
number of human kinases and proteins have still not being fully characterised. 
In terms of cell cycle, S-134 had no effect at its GI50 concentration but 
induced a G2/M transition block in HCT-116 cells at 10 times GI50 
concentration.  This inhibition was also observed with DRB, a known CDK9 
inhibitor with the same time points at the equivalent GI50 concentration.  
Flavopiridol has also been reported to induce this G2/M transition arrest in a 
number of cell lines
234
.  In addition, the inhibition of CDK7 could result in this 
cell cycle accumulation, as the concentration of compounds required for this 
blockage exceeded the IC50 for CDK7 in the kinase assay: RB activity is 
another possible candidate contributing to this arrest.  The cell cycle arrest 
induced by Flavopiridol has been found to be more potent in cell lines 
expressing RB to enhance resistance to apoptosis
234
.  The same study also 
pointed out the apoptosis caused by Flavopiridol did not relate to RB activity 
and this cell cycle arrest.  
5.1. General discussion and conclusion 
136 

Assays which aim to demonstrate that S-134 causes cell death include the 
Annexin-V assay, PARP cleavage by Western blot and the caspase-3 assay.  
Both Annexin-V and caspase-3 assays used HCT-116 cells.  The Annexin-V 
assay, which measures the percentage of total cell death, showed cell death 
reached a peak level at 36 hours with 1 µM S-134.  The caspase-3 assay, which 
only measures apoptotic cell death, showed the peak of caspase-3 activation at 
48 hours with 1 µM S-134.  Combining the data from both assays, we can 
conclude that S-134 induces both apoptosis.  Since the Annexin-V assay has 
shown a higher population of death cells that the other assays used, it is 
possible suggestion that S-134 also induces necrotic cell death.  In the same 
cell line, DRB was seen to induce a higher level of cell death than S-134 in 
caspase-3 assay, based on their GI50 concentrations.  In MTT assays, we 
demonstrate the cytostatic (i.e. growth inhibition) rather than cytotoxic effect 
(i.e. how effect of compound in killing the cells) of the compounds, hence the 
equivalent GI50 concentration is no reflection on the efficiency of compound in 
causing cell death.  Therefore, the difference in capase-3 activation by the two 
compound is possibly due to the compound concentration (i.e. 1 µM S-134 
compared to 60 µM DRB).  Alternatively, it could be an indication that S-134 
is a slower acting compound compared to DRB.   
To verify that S-134 targets CDK9 and to clarify its effect on CDK7 in cells, 
Western blot was used to detect the phosphorylation of RNAP II Ser 2 and Ser 
5 using A2780 cells, which indicates that S-134 specifically inhibits CDK9 up 
to 1 µM, followed by CDK7.  Compared to S-134, DRB appears to be a more 
specific CDK9 inhibitor as the phosphorylation of Ser 2 is always more 
severely reduced than Ser 5.  Since there is some evidence showing that 
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phosphorylation of Ser 5 could be related to CDK9 activity
181
, the reduced 
phosphorylation states of Ser 5 induced by S-134 could be due to the inhibition 
of CDK9, rather than an inhibition of CDK7.   
The effect of S-134 on anti-apoptotic proteins Mcl-1, Bcl-2 and XIAP was 
observed by Western blot.  The expression of Mcl-1 was reduced by S-134, 
followed by Bcl-2 and XIAP.  At 24 hours, Ser 2 phosphorylation was reduced 
by 1 µM S-134, the inhibition of these anti-apoptotic proteins, which started 
with 1 µM, was undoubtedly affected by the inhibition of CDK9.  This 
reduction also proved the apoptotic cell death observed by PARP cleavage, 
which appeared with 2.5 µM S-134, is a direct result of CDK9 inhibition. The 
level of reduction of the anti-apoptotic proteins observed by Western blot could 
be affected by  the half-life of the proteins; a shorter protein half-life would 
reduce the level of protein detected by Western blot, which may explain our 
observation on XIAP being more profoundly suppressed than Mcl-1 at 24 
hours
235
. 
p53 is an important tumour suppressor which responds to DNA damage and 
other genomic alterations; its inactivation and activity is closely linked to the 
development of tumours
236
.  In A2780 cells, p53 protein levels increased in a 
dose dependent manner.  The increase in p53 level should be caused by the 
altered transcription in the absence of CDK9
89
.  HDM-2, the negative regulator 
of p53, showed a very low level of reduction at 24 hours with 5 µM S-134.  
This indicates that S-134 stabilised, but not necessarily activates p53, at 
concentrations below 5 µM at 24 hours, as the negative feedback loop was not 
inhibited.  Flavopiridol has been reported to activate p53 by suppressing 
CDK9, which inhibited the transcription of HDM-2
237
.  As S-134 is a CDK9 
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inhibitor, it should also activate p53.  A higher concentration may be required 
to observe this significantly.  
The effect of S-134 on gene transcription was examined by RT-PCR.  The 
mRNA of Mcl-1, Bcl-2, XIAP and HDM-2 were investigated.  In A2780 cells, 
the transcription all the genes studied were found reduced.  The reduced 
patterns of Mcl-1, Bcl-2 and XIAP were similar to those observed in Western 
blot at the corresponding time point.  Comparing the effects of S-134 on these 
genes and the proteins detected by RT-PCR and Western blots respectively, the 
effect of the compound on the genes was more profound than on the proteins.  
Using HDM-2 as an example, the transcription at 24 hours was reduced from 
2.5 µM S-134, with protein expression reduced with 5 µM only.  This is 
possibly due to the RNA synthesis being suppressed by S-134, which led to the 
reduced expression in proteins.  Another example is the transcription inhibition 
of Bcl-2, which was much more profound than on protein expression, 
indicating that Bcl-2 protein might have a long half-life which delays the 
observation of reduced protein expression on Western blot
238, 239
. 
To summarise the mechanism of action of S-134, it is a novel CDK9 
inhibitor with nano-molar activity in vitro.  It primarily inhibits CDK9 at 
biochemical and cellular levels as well as affecting CDK7 at higher 
concentrations.  The inhibition of CDK9 leads to the alteration in transcription 
elongation. The inhibition of CDK9 results in reduction of anti-apoptotic 
factor, including Mcl-1, Bcl-2 and XIAP, which increases the sensitivity of 
cells to apoptotic signals.  The genomic abnormality in cells enhances the 
expression of p53, which possibly induces a G2/M transition accumulation in 
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the cell cycle.  Cell-cycle arrest is followed by significant cell death through 
apoptosis and necrosis. 
A therapeutic window of S-134 between tumour and normal cells has been 
demonstrated in a number of experiments.  An approximate eight fold 
selectively between HCT-116 and MRC-5 cell lines has been shown in MTT 
assays.  In terms of cell death, Annexin-V assays using MRC-5 cells and the 
same compound concentration and time points as with HCT-116 cells indicated 
that no cell death was induced.  In addition, Western blot only showed PARP 
cleavage induced at 24 hours with 5 µM S-134, double the concentration in 
A2780 cells.  For the effect on CDK9, Westerns blots using MRC-5 cells show 
a higher concentration of S-134, compare to A2780 cell, is required to affect 
the phosphorylation of RNAP II Ser 2, hence no effect on the anti-apoptotic 
proteins, while DRB showed the same phosphorylation pattern of Ser 2 in both 
A2780 and MRC-5 cells for the inhibition of Ser, resulting in a reduction in 
Mcl-1 was detected. 
The discovery of S-134 is only the beginning of the development of our 
novel CDK9 inhibitors.  From MTT assays, a number of other analogues in our 
novel CDK9 series modified from S-134 have proved better compounds in 
terms of potency and selectivity between cancer and normal cells.  The 
Cellomic Array Scan using HCT-116 to observe the effect of compounds on 
p53 stabilisation indicating a number of analogous performs better than S-134.  
The continuous biology mechanism studies and compound modification will 
hopefully produce a potential clinical candidate in the future.  
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5.1.2 Elucidation of the mechanism of action of 
ZJU-6 
A group of semi-synthetic compounds were screened in MTT assays to 
estimate their cellular growth inhibition.  These compounds were derived from 
a natural product known as Erianin, a small molecule produced by a plant 
species Dendrobium chrysotoxum
182
.  The aim of the synthetic modification 
was to enhance its activity, but all the modified compounds possessed reduced 
potency, by at least 20 fold compared to Erianin in cellular growth inhibition 
assays.  The most potent compound in this group, ZJU-6, was selected for 
further study.  ZJU-6 was screened using 10 cell lines for estimating its effect 
on cell growth; its GI50 values in most of the cell lines tested were reduced by 
at least 20 fold compared to Erianin, with a few exceptions including HCC-
2998, a human colon cell line. 
The image study showed Erianin and ZJU-6 induced similar physical effect 
on the cells using four times GI50 concentration of the corresponding 
compound.  Both compounds caused cell death by inhibiting cell division, in 
which the genetic material in cells failed to condense in order to form 
chromosomes.  As the formation of chromosomes is triggered by the formation 
of microtubules (i.e. polymerisation of tubulin) during mitotic prophase
56
, this 
observations confirmed Erianin, as reported from literature
182
, and ZJU-6 
inhibited the polymerisation of tubulin, hence resulting a cell cycle arrest at 
G2/M transition, which was proved by FACS. 
The mode of cell death induction by Erianin has not been reported.  Here, 
the cell death caused by Erianin and ZJU-6 had been observed by four different 
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experiments. The significant pre-G1 population from cell cycle analysis 
showed an early indication that both compounds induce similar level of cell 
death in MCF-7 cells, under the same equivalent GI50 concentration, which was 
further confirmed by Annexin-V assay.  However, Erianin induced significant 
caspase-3 activation at 10 times GI50 concentration, while ZJU-6 activated 
caspase-3 dose-dependently.  PARP cleavage, as detected by Western blot, 
revealed a similar pattern to caspase-3 assays for both compounds.  The data 
confirmed that both compounds induced cell death, possibly with different 
modes of cell death induction.  Erianin induced cell death possibly by caspase-
3 dependent and independent apoptosis, in addition to non-apoptotic cell death, 
such as necrosis, which has been reported
182
; while ZJU-6 induced specific 
caspase-3 dependent apoptosis.  As mention previously, Erianin has been 
reported to induce heavy toxicity to patients during clinical trials (S. Wang 
personal communication); the various mode of cell death employed by Erianin 
could be a possible factor responsible for this issue. 
The transcription of Bcl-2 has been found reduced by Erianin
184
, which 
responsible for cell death.  Therefore, ZJU-6 could possibly reduce the 
expression of Bcl-2.  The effect of compounds on Bcl-2 and Mcl-1 protein was 
examined by Western blot in MCF-7 cells.  No change on Mcl-1 expression 
was detected, while an extra band of protein was induced with treatment of 
Erianin and ZJU-6, but not with DMSO vehicle control, on the Western blot.  
This means both compounds affect Bcl-2 in the same manner.  Although the 
reduction of Bcl-2 is well linked to apoptosis (see section 1.3), however, from 
our observation, it does not necessarily apply to Erianin and ZJU-6.  If there is 
another possible mechanism that Erianin and ZJU-6 affect Bcl-2 other than a 
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simple reduction, one suggestion is that the compounds affect the 
phosphorylation status of Bcl-2, another suggestion is that both compounds 
alter the transcription machinery which then increases the length of the amino 
acid chain of Bcl-2
188
.   
The effect of compounds on transcription was examined by RT-PCR using 
the same time points and doses as in Western blot.  Both compounds reduced 
the transcription levels of Mcl-1 and Bcl-2.  Erianin inhibited Bcl-2 
transcription to a greater extent, while ZJU-6 was more effective in inhibiting 
Mcl-1 transcription.  The results from Western blot and RT-PCR showed the 
compounds affected the transcription machinery of the anti-apoptotic proteins 
rather than having direct interaction with the proteins.  For Mcl-1, the 
observable changes detected in transcription did not result in changes in protein 
level may be due to the longer half-life of these proteins than their RNAs
238-240
.  
This transcription inhibition of Mcl-1 by ZJU-6 could be one of the many 
possibilities triggering apoptotic cell death.   
There was no information about the effect of Erianin on p53 in the 
literature.  As Erianin inhibits the polymerisation of tubulin, which resulting in 
cell abnormality, this could trigger an increase in p53 protein in an attempt to 
repair the abnormality
241
.  Here, we proved both Erianin and ZJU-6 increase 
the level of p53 in MCF-7 cells by Western blot (section 3.7).  However, there 
is no reduction in HDM-2 protein or mRNA, proved by Western blot and RT-
PCR respectively, by either compound; hence, the p53 protein may not be fully 
active on its functions. 
Erianin clearly inhibited tubulin polymerisation, as reported in the 
literature
182
.  ZJU-6 should also have this property as indicated by the imaging 
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study.  A biochemical assay was used to confirm the effects of the compounds 
on tubulin polymerisation, which proved ZJU-6 was more effective than 
Erianin.  The concentration used was above the GI50 of Erianin and below that 
of ZJU-6.  Although it was a non-cellular detection, it is sensible to suggest 
that ZJU-6 may primarily function by inhibiting tubulin polymerisation, while 
Erianin may initially target other factors which lead to this inhibition. 
Erianin has already been proved to have anti-angiogenic effects by using an 
assay similar to our ex vivo chick embryo chorioallantoic membrane (CAM) 
assay
182
.  The CAM assay here indicated that ZJU-6 was more effective in 
suppressing angiogenesis than Erianin.  The use of GI50 concentration in MCF-
7 for this experiment was aim to achieve an observable result without killing 
the embryo, which minimised the possible problem of ZJU-6 entering into 
cells.  However, if this assumption was not correct and same concentrations of 
both compounds were used, we might not be able to conclude that ZJU-6 was 
more effective at anti-angiogenesis than Erianin. 
The aim of introducing a free radical into ZJU-6 was to introduce an anti-
oxidant property for cancer prevention.  Biochemical assays using DPPH and 
cellular assays with H2DCFDA analysed by FACS were used to examine the 
anti-oxidant properties of Erianin and ZJU-6.  Erianin has not been classified 
as anti-oxidant.  However, in the biochemical assays, Erianin was found to be a 
more potent anti-oxidant than ZJU-6.  In cellular assays, both compounds 
failed to reduce the oxidative state of cells and were unable to protect the cells 
against attack by oxygen radicals from hydrogen peroxide.  In chapter one, the 
anti-oxidant effect of EGCG (a polyphenol in green tea) was mentioned.  
However, a high dose of EGCG would be required for it to be observed in cells 
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and tissues
143
.  Biochemically, Erianin and ZJU-6 have anti-oxidant properties, 
but they were weaker than EGCG.  The concentrations of Erianin and ZJU-6 
used in assays determining their anti-oxidant properties were high enough to 
induce significant cell death.  Hence, unlike EGCG, it was not possible to 
examine the anti-oxidant effects of Erianin and ZJU-6 at high-doses.  
Therefore, Erianin and ZJU-6 would not be suitable compounds for the use as 
anti-oxidants in cancer prevention. 
A natural product and its derivatives should target a number of molecular 
targets.  However, based on the data collected from our study and from the 
available literature
182, 184
, we could only conclude the following: Erianin is a 
natural product with nano-molar activity in tumour cells.  It induces cell cycle 
arrest at the G2/M transition through inhibiting the formation of microtubules 
and induces cell death.  Erianin also inhibits the transcription of Bcl-2; it also 
has anti-angiogenic and anti-oxidant properties.  ZJU-6 is a micro-molar 
activity small molecule derived from Erianin, created with the intention of 
enhancing the activity of the molecule.  The addition of an extra structure may 
have reduced its effect on cellular growth inhibition and its ability to enter 
cells.  ZJU-6 evokes a similar cell cycle effects as Erianin.  However, unlike 
Erianin, the main pathway of cell death induced by ZJU-6 is apoptosis.  Its 
tubulin polymerisation inhibition, which is believed to be the primary mode of 
action of ZJU-6, and its anti-angiogenic properties were enhanced.  However, 
Bcl-2 suppression and the anti-oxidant property of the molecule were reduced.  
Both Erianin and ZJU-6 stabilise p53 though inhibiting the polymerisation of 
tubulin.  Neither compound would be a suitable anti-oxidant. 
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Throughout the mechanism studies on Erianin and ZJU-6, the ability of 
ZJU-6 to enter cells has been emphasised as the reason contributing to the 
reduced GI50 value.  Alternatively, the origins of Erianin and ZJU-6 could be 
used to form an alternative hypothesis to explain this difference.  Erianin is a 
natural product, which evolved together with the plant species; therefore 
Erianin should be more cytostatic and less cytotoxic.  ZJU-6 is a synthetic 
natural product derivative which aims to enhance the activity of Erianin; hence 
it is more cytotoxic and less cytostatic.  Accordingly, MTT assays indicated 
that Erianin performed better as a cytostatic agent, whereas ZJU-6 is a more 
cytotoxic agent as demonstrated in caspase-3 assays. 
 
5.1.3 Synthesis of BI 2536 racemate 
BI 2536 is one of the most selective and potent small molecule inhibitors of 
Plk1.  An alternative synthetic route was carried out which achieved synthesis 
of a racemic BI 2536; this route could potentially lead to synthesis BI 2536 
itself.  The synthetic routes used to synthesise the aromatic pyrimidine ring 18 
were similar to that described in the patent of BI 2536
224
. The synthetic route 
for alanine 24 was a combination of routes used for synthesis of similar 
molecules. 
The racemate had been tested for cellular growth inhibition (data not 
shown), which was ~600 times less effective in cell growth compare to the 
literature data of BI 2536.  This difference in cellular growth inhibition 
suggested the possibility of impurities.  Although 
1
H NMR and mass 
spectrometry data did not indicate the presence of impurities, but there are 
some exceptions of impurities which could not be detected by these analytical 
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methods.  This possible impurity was probably the main reason for the 
reduction in potency of our racemate, with the loss of stereo chemistry being a 
further reason
242
.  The interaction between the racemates itself is also an 
possibility, but less likely. 
 
5.2 Future work 
According to the biological assay results with S-134, we proved this molecule 
to be a potent and selective CDK9 inhibitor in vitro.  To fully study the 
cytotoxicity of the molecule across a large number of human cell lines from 
other origins, S-134 could be sent for screening against the NCI 60 cell panel.  
To test the selectivity of the molecule against other members of human CDKs, 
kinase assay screening against CDK1, 3, 4, 5, 6 and 8 should be done.  
Although a highly unlikely possibility, the effect of S-134 could vary between 
cell lines and cell cycle analysis should be done in a range of cell lines to 
investigate the possibility.  Although we have done a range of assays to test the 
effect of S-134 on cell death, further experiments could be done to interrogate 
cell death pathways, such as the caspase-7 activation assay.  In addition to the 
proteins and genes we screened in Western blot and RT-PCR, respectively, 
there are still a number of proteins affected by CDK9 inhibition, such as BAG-
1
243
.  Individual compound screening is an extremely time consuming process.  
The long term aim of the project is to obtain a potential drug candidate from 
large number of compounds; high-throughput screening (HTS) should be used 
to replace western blots and RT-PCR, which could generate data on the effect 
of a compound series with respect to a large number of molecular targets in a 
short period of time.  The most common HTS is the microarray technology 
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which screens the effects of compounds on hundreds of genes at the RNA level 
and could predict the effect of compounds on proteins.  For those genes whose 
transcription is significantly altered, the effect of compounds on protein 
expression could then be investigated using traditional technology such as 
Western blot.  The limitation of Western blot is the number of samples that can 
be tested at one time.  The Cellomic Array Scan used in p53 stabilisation 
screening could represent a way forward to increase the number of samples per 
assay, hence increasing the number of concentration points and compounds 
screened. 
From our data, S-134 seems to be a slow acting compound compared to 
other CDK9 inhibitors; other in vitro assays, such as time lapse cell imaging 
and diffusion assay studies, could be done.  In addition, further characterisation 
including stability studies and PK determination, should also be carried out.  
For in vivo animal studies, S-134 should be tested in mouse xenografts; as our 
data proved that the molecule is a promising inhibitor of cancer growth.  
Studies on the effect of S-134 on leukaemia cell death and HIV replication 
could also be done in the future.  After all these studies with S-134 and other 
promising analogues selected from SAR, compounds with promising in vitro 
and in vivo data will be obtained. 
In our study of natural products, the chemical modification of Erianin to 
ZJU-6 reduced the potency of the molecule; one of the hypotheses is the 
reduced transportation into cells.  A diffusion assay such as the lipophilicity 
test could be used; a more lipopholic molecule would have increased affinity to 
diffuse across the cell membrane.  Furthermore, imaging studies using labelled 
compounds could observe transportation/diffusion efficiency
244
.  In terms of 
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further direction for in vitro assays, growth inhibition assays could be done in 
additional tumour cell lines.  Cell cycle analysis could be done in these cell 
lines, expanding time points and concentrations to further elucidate the cell 
cycle perturbation effects of Erianin compounds.  Other assays could also be 
done to consolidate the evidence on cell death induction, such as the red green 
staining in conjunction with cell imaging.  The effects on tubulin 
polymerisation could be researched using cellular assays such as the collagen 
gel migration assay.  For angiogenic assays, the CAM assay could be repeated 
using the same concentration with all compounds; this was not carried out as it 
was a time consuming assay with a potentially low success rate.  Alternatively, 
Western blot and PCR could be used to test for proteins involved in 
angiogenesis, such as VEGF.  Erianin has been reported to inhibit endothelial 
tube formation, migration and adhesion using HUVECs cell, which indicated 
Erianin may work in more than one step in the process of angiogenesis.  This 
assay can be performed to prove the anti-angiogenic property of ZJU-6.   
Although natural products are a good source from which to search for 
potential drug candidates, it is hard to predict and verify primary targets.  
Therefore, modern technology such as microarray could be a quick method in 
the search for these target proteins.  However, availability of compounds is a 
fundamental limitation in these suggestions; the yield after modification to 
ZJU-6 was low, restricting the number of experiments that could be done.  
High yield and ease of synthesis are fundamental aims of semi-synthetic 
compounds.  Further detailed studies in the mechanism of action of Erianin are 
also necessary to guide synthesis of more promising compounds. 
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Chapter Six 
Materials and Methods 
6.1 Suppliers of reagents 
 
Amersham Pharmacia Biotech (Little Chalfont, Buckinghamshire, UK) 
ECL
TM
 Western blotting detection kit, Hyperfilm
TM
 ECL 
 
Beckman Coulter (London, UK) 
COULTER CLENZ® Cleaning Agent, IsoFlow Sheath Fluid  
 
Bioline (London, UK) 
Oligo (dT)18 Primers 
 
Bio-Rad Laboratories (Hertfordshire, UK) 
Bio-Rad DC protein assay kit, bovine serum albumin (BSA) standard solution, 
polyvinylidene difluoride (PVDF) membrane 
 
Calbiochem (Nottingham, UK) 
Seliciclib, 5,6-dichloro-1-ȕ-d-ribofuranosylbenzimidazole (DRB) 
 
Cell Signalling Inc. (Beverly, MA, USA) 
Rabbit anti-Mcl-1 monoclonal antibody, rabbit anti-XIAP monoclonal 
antibody, rabbit anti-PARP polyclonal antibody 
 
Champion Photochemistry International Limited (CPIL) (Brentwood, 
UK) 
X-ray films processing solutions (Developers and Fixers) 
 
Covance Research Products (Berkeley, CA, USA) 
Mouse anti-RNAP II monoclonal antibody (clone 8WG16), mouse anti-RNAP 
II Ser 2 monoclonal antibody (clone H2), mouse anti-RNAP II Ser 5 
monoclonal antibody (clone H5) 
 
Cytoskeleton Inc (Denver, Colorado, USA) 
Microtubules/tubulin Biochem Kit, HTS tubulin 
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Dako (Glostrup, Denmark) 
Mouse anti-Bcl-2 monoclonal antibody, mouse anti-p53 monoclonal antibody, 
goat anti-mouse IgG-HPR conjugated antibody, swine anti-rabbit IgG-HPR 
conjugated antibody 
 
Fisher Scientific (Loughborough, Leicestershire, UK) 
Acetone (analytical reagent grade), Acetonitrile (HPLC grade), chloroform, 
concentrated HCl (analytical reagent grade), denatured ethanol (IMS), 
dichloromethane, ethanol, ether, ethidium bromide (EtBr) solution, ethyl 
acetate, glacial acetic acid (analytical reagent grade), hexane, magnesium 
sulphate, methanol (analytical reagent grade), potassium carbonate (K2CO3), 
pyridine, silica, sodium chloride (NaCl), sodium hydroxide (NaOH), sodium 
hydrogen carbonate (NaHCO3), tetrahydrofuran (THF) 
 
Invitrogen Ltd (Paisley, UK) 
High resolution agarose 
 
Joice and Hill Poultry Ltd (Peterborough, UK) 
Fertilised chicken eggs 
 
Millipore Corporation (Billerica, MA, USA) 
CDK9/cyclin T1, ATP, PDK 
 
MWG-Biotech AG (Ebersberg, Germany) 
Forward and reverse primers for ȕ-Actin  
 
Oxoid limited (Hampshire, UK) 
Phosphate buffer saline (PBS) tablet 
 
Perkin Elmer (Massachusetts, USA) 
Easy-lite reagent 
 
Qiagen Ltd (Crawley, West Sussex, UK) 
RNeasy mini kit  
 
Roche Diagnostics (Lewes, East Sussex, UK) 
Reverse transcriptase, nucleotide mix (dNTP), Taq DNA polymerase, protease 
inhibitor cocktail tablet 
 
Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA) 
Annexin V-FITC kit 
Severn Biotech Ltd, (Worcestershire, UK) 
30% acrylamide solution 
 
Sigma-Aldrich (St Louis, MO, USA) 
Acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin (Ac-DEVD-AMC), 4-
aminopiperidine-1-carboxylate, ammonium persulfate (AMPS), aprotinin, 
boric acid, bozine serum albumin (BSA), briji-35, bromoplecol Blue, calcium 
chloride (CaCl2), caspase-3 fluorimetric assay kit, 2, 4-dichloro-5-
nitropyrimidine, 3-[(3-Cholamidopropyl)dimethylammonio]-1-
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propanesulfonate (CHAPS), ColorBrust
TM
 electrophoresis markers, DL-
Alanine ethyl ester hydrochloride, D-2-aminobutyric acid, 2,7-
dichlorodihydrofluorescein diacetate (H2DCFDA), 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT), cyclopentanone, 1,1-diphenyl-2-
picrylhydrazyl (DPPH), dimethylacetamide (DMA), dimethylsulphoxide 
(DMSO), dithiothreitol (DTT), Direct load
TM
 PCR 100bp low ladder, 
ethylenediamine tetra-acetic acid (EDTA), ethyl 4-aminopiperidine-1-
carboxylate, ethylene glycol-bis(ȕ-aminoethylether)-N,N,N,N-tetra-acetic 
acid (EGTA), fetal bovine serum (FBS), forward and reverse primers for Mcl-
1, Bcl-2, XIAP and HDM-2, gel loading solution (for nucleic acid product), L-
glutamine, glycerol, glycerol-2-phosphate, ȕ-glycerophosphate, N-[2-
hydroxyethyl]piperazine-N-[2-ethanesulfonic acid] (HEPES), hydrogen 
peroxide (H2O2), iron powder, Kieselguhr, leupeptin, lithium aluminium 
hydride (LiAlH4), magnesium chloride (MgCl2), ȕ-mercaptoethanol, 3-
methoxy-4-nitrobenzoic acid, methyl iodide, minimum essential medium, 
molecular grade H2O, MOPS-NaOH, mouse anti-MDM2 monoclonal antibody, 
mouse anti-ȕ-actin monoclonal antibody, non-essential amino acids, palladium 
in 10% carbon, penicillin, phenylmethylsulfonyl fluoride, 
polyoxyethylenesorbitan monolaureate (Tween 20), potassium chloride (KCl), 
propidium iodide (PI), ribonuclease A, RPMI-1640 liquid medium (with L-
glutamine and sodium bicarbonate), sodium acetate, sodium bicarbonate, 
sodium citrate, sodium deoxycholate, sodium dodecyl sulphate (SDS), sodium 
hydride (NaH), sodium orthovanadate (Na3VO4), sodium 
triacetoxyborohydrate, sucrose, N,N,Nƍ,Nƍ-Tetramethylethylenediamine 
(TEMED), tert-butyl-methyl-ether, thionyl chloride, thymidine, Trizma® base 
[Tris(hydroxymethyl)aminomethane], Trizma® hydrochloride (Tris.Cl) 
[Tris(hydroxymethyl)aminomethane hydrochloride],  triton X-100, 
trypsin/EDTA solution, water (molecular biology grade) 
 
6.2 General cell culture 
 
A2780 and WI38 cells were purchased from European Collection of Cell 
Cultures (ECACC, UK).  All other cell lines were obtained from the cell bank 
at Centre for Biomolecular Sciences (Division of Medicinal Chemistry and 
Structural Biology, School of Pharmacy, University of Nottingham).  MRC-5 
and WI38 cells were cultured in minimum essential medium with 10% fetal 
bovine serum (FBS), 1% 7.5% Sodium bicarbonate, 1% 0.1 mM non-essential 
amino acids, 1% 1 M Hepes, 1% 200 mM L-glutamine and 1% penicillin.  All 
other cell lines were maintained in RPMI-1640 with 10% FBS. 
 
6.3 In vitro biological assays 
 
6.3.1 Preparation of sample compounds  
 
The novel CDK9 inhibitors tested in this thesis were synthesised by Mr S. Shi 
(University of Nottingham, UK), while the nature product derivatives were 
6.3. In vitro biological assays 
152 

synthesised by Dr H. Mao (Zhejiang University, China).  All solid compounds 
were weighted in mini gram scales; the compounds were dissolved in DMSO 
to make up a 10 mM concentration stock solution and stored at -20
o
C. 
 
6.3.2 MTT cell viability assay 
 
Dependent on the cell line, cells were seeded at 1.5-3x10
3
 per well in a 96 well 
plate.  The volume of each well was made up to 180 ȝl with cell culture media 
and incubated at 37
o
C in a 5% carbon dioxide (CO2) atmosphere overnight.  
Before the addition of compounds, the T0 plate was treated with 50 ȝl MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution (2 mg/ml 
in phosphate buffered saline) per well and incubated for further 2-6 hours at 
37
o
C in a 5% CO2 atmosphere.  Light absorbencies were read at 550 nm on an 
Anthos Labtec Systems plate reader after the removal of media and MTT 
mixture, addition of 150 ȝl DMSO per well was followed.  Data was 
automatically transferred to a computer with software Deltasoft 3
TM
.  Chemical 
inhibitor(s) from a 10 mM stock were added to the cells in a concentration 
range between 0.1 nM - 100 µM and incubated for further 72 hours at 37
o
C 
with 5% CO2.  All plates were treated and analysed in the same manner from 
the addition of MTT after 72 hours.  All data was transferred to Microsoft 
Excel, which was used to analyse the data and used to calculate the GI50 value 
of each compound. 
 
6.3.3 Kinase assay 
 
This assay was carried out both internal and externally.  For the internal assay, 
inhibitor(s) were diluted in a concentration range of 0.11 nM to 250 nM in 10% 
DMSO.  To carry out this assay, a white 96 well plate was used and 5 ȝl of 
inhibitor were added per well, followed by 5 ȝl CDK9/Cyclin T1 [40 ng in 
dilution buffer (20 mM MOPS-NaOH at pH 7.4, 0.1 mM EGTA, 150 mM 
Sodium chloride, 270 mM Sucrose, 0.03% Briji-35, 0.07% ȕ-mercaptoethanol) 
1:10] and 5 ȝl reaction buffer (20 nM MOPS-NaOH at pH 7.4, 25 mM 
Glycerol-2-phosphate, 5 mM EGTA, 1 mM DTT).  The reaction was started by 
the addition of 5 ȝl 75 mM MgCl2, 100 nM ATP and 5 ȝl PDK (5 µM).  The 
reaction was preceded at room temperature for 1 hour and consequently 
stopped by the addition of 25 ȝl Easy-lite reagent (PerkinElmer).  The plate 
was incubated for 1 minute at room temperature with gentle shaking and was 
read on Victor 2
TM
 plate reader for luminescence detection.  All data was 
transferred to Microsoft Excel, which was used to analyse the data.  The 
external assays were performed by Millipore (Billerica, MA, USA). 
 
6.3.4 Cell cycle analysis 
 
Cells were seeded at a density of 3x10
5
 and incubated at 37
o
C in a 5% CO2 
atmosphere overnight.  Cells were treated with compounds at the appropriate 
concentrations and harvested with the medium at appropriate time points, 
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washed with PBS (Phosphate Buffered Saline) and transferred into FACS tube.  
All samples were centrifuged at 1200 rpm for 5 minutes at 4
o
C and the 
supernatants were discarded.  Following the disregard of the supernatant, 300 
ȝl fluorochrome solution (50 ȝg/ml propidium iodide, 0.1 mg/ml ribonuclease 
A, 0.1% sodium citrate, 0.1% triton X-100) were added to each samples.  Cells 
were suspended, protected from light and stored at 4
o
C overnight.  Cell cycle 
status was analysed using flow cytometer (Beckman Counter FACS). 
For synchronisation assays, cells were seeded at a density of 5x10
5
 and 
incubated at 37
o
C in a 5% CO2 atmosphere overnight.  Thymidine was added 
to the medium at a final concentration of 2 mM followed by 18 hours 
incubation at 37
o
C 5% CO2 atmosphere.  Thymidine containing media was 
removed and the cells washed with PBS.  Following this wash, medium 
without thymidine was added and the cells incubated for a further 8 hours at 
37
o
C with 5% CO2 atmosphere.  Thymidine was added after this incubation 
period to the media at a final concentration of 2 mM followed by 16 hours 
incubation at 37
o
C in a 5% CO2 atmosphere.  After the second incubation with 
thymidine, cells were used to start the experiment by removing the thymidine 
containing medium and replaced with the medium with appropriate compound.  
Post-processed were carried out as previously described. 
 
6.3.5 Annexin-V assay 
 
Cells were seeded at a density of 3x10
5
 and were treated with compounds after 
overnight culture. Cells were collected, together with the media at an 
appropriate length of time, washed with PBS, placed in a FACS tube and 
centrifuged at 1200 rpm for 5 minutes at room temperature.  The supernatants 
were discarded and suspended with 1 ml fresh medium.  For each sample, the 
cell number was counted using a haemocytometer and 1x10
5
 cells were 
transferred into a fresh FACS tube with 1 ml PBS, and centrifuged at 1200 rpm 
for 5 minutes at room temperature. Supernatants were again discarded followed 
by the addition of 100 ȝl Annexin V binding buffer [0.01 M Hepes (pH 7.4), 
0.14 M NaCl, 2.5 mM CaCl2] and 5 ȝl Annexin V-FITC.  After 15 minutes 
incubation in the dark at room temperature, there was the addition of 400 ȝl 
Annxin V buffer and 10 ȝl propidium iodide in PBS (50 ȝg/ml).  Samples were 
placed in ice and dark for a further 10 minutes and analysed using FACS 
within 1 hour. 
 
6.3.6 Caspase-3 assay 
 
Caspase-3 activity was determined using the caspase-3 fluorimetric assay kit 
(cat no. CASP3F) and used under manufacturer instruction.  Briefly, cells were 
seeded at 2x10
4
 cells per well in a 96 well plate and incubated at 37
o
C and 5% 
CO2 atmosphere for a further 48 hours.  Compounds were added to cells and 
incubated for the appropriate length of time.  Cell culture media was removed 
after the incubation period, and placed on ice.  25 ȝl lysis buffer (50 mM 
HEPES (pH 7.4), 5 mM CHAPS, and 5 mM DTT) were added per well 
followed by a further 15-20 minutes incubation on ice.  200 ȝl assay buffer [20 
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mM HEPES (pH 7.4), with 0.1% CHAPS, 5 mM DTT, 2 mM EDTA, and 0.66 
mM Acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin (Ac-DEVD-AMC)] 
were added per sample.  200 ȝl from each sample was transferred into 96 well 
fluorimeter plates.  Fluorescence was measured at 460 nm in a kinetic mode 
every 10 minutes for 60 minutes at room temperature using EnVision 
multilabel plate reader (PerkinElmer).  The data was calculated in comparison 
to the AMC standard curve according to manufacturer recommendation. 
 
6.3.7 Western blot analysis 
 
Cells were seeded at a density of 3x10
5
 on a 10 cm tissue culture plate and 
were treated with compounds after 2 days culture at 37
o
C with 5% CO2 
atmosphere.  Cells were collected at appropriate time points and lysed in buffer 
[25 mM Hepes (pH 7.5), 300 mM NaCl, 1.5 mM MgCl2, 0.5% sodium 
deoxycholate, 20 mM ȕ-glycerophosphate, 1% Triton X-100, 0.1% sodium 
dodecyl sulphate, 0.2 mM EDTA (pH 8), 0.5 mM DTT, 1 mM sodium 
orthovanadate (pH 10), 1 mM phenylmethylsulfonyl fluoride, 20 µg/ml 
aprotinin, 20 µg/ml leupeptin].  
Protein content in the lysates was determined using the Bio-Rad DC protein 
assay kit operated according to the manufacturers instructions (Bio-Rad, 
Hercules, CA).  
Dependant on the size of the protein of interest, the percentage of 
acrylamide used in the gels varies between 7-15%.  Acrylamide solution was 
mixed with 25% resolving gel buffer solution (1.5 M Tris.Cl, pH 8.8, 0.4% SDS) 
and water.  After the addition of AMPS, polymerisation initiated with the 
addition of TEMED in a gel cassette.  After the resolving gel had polymerised, 
stacking gel (for 5 ml: 0.67 ml 30% acrylamide, 0.63 ml stacking gel buffer (1 
M Tris.Cl, pH 6.8, 0.8% SDS), and 3.70 ml H2O) was added after the addition 
of AMPS and TEMED. A comb for the sample wells was added immediately.   
Each cell lysate sample (250 µg protein) with loading buffer (three times) 
[For 10 ml: 2.4 ml 1 M Tris.Cl (pH 6.8), 3ml Glycerol, 3 ml 20% SDS, 1.6 ml 
ȕ-Mercaptoethanol, 0.006 g Bromoplecol Blue) were denatured at 95oC for 5 
minutes and separated by SDS-polyacrylamide gel electrophoresis at a voltage 
between 70-150V.  At the end of electrophoresis, the gel was removed from the 
cassette and transferred for post-processing as required.  
Separated cell lysates were electrotransferred onto a PVDF membrane (Bio-
Rad, Hercules, CA).  Dependant on the primary antibody, the membrane was 
blocked in TBST (Tris buffered saline with 0.1% Tween 20) with either 5-10% 
BSA or 10% non-fat dry milk for a minimum of 1 hour, followed by incubation 
with primary antibodies solutions overnight at 4
o
C.  Incubation of appropriate 
secondary antibodies conjugated to horseradish peroxidase for a minimum of 1 
hour were followed and washes with TBST at an appropriate length of time.  
Antibodies for Mcl-1, PARP, XIAP were purchased from Cell signalling 
technology.  Antibodies for Bcl-2 and p53 were obtained from Dako (Dako 
Denmark A/S).  Antibodies for total RNA (8WG16), phosphorylated CTD at 
Ser 2 (H5) or Ser 5 (H14) were purchased from Covance research Products 
(Berkeley, CA).  Antibody for HDM-2 and ȕ-actin were purchased from Sigma 
(Sigma-Aldrich, USA).  Both anti-mouse and anti-rabbit Immunoglobulin G 
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(IgG) horseradish peroxidase-conjugated antibodies were obtained from Dako 
(Dako Denmark A/S). 
All blots were visualised using enhanced chemiluminescence according to 
the manufacturers instruction (Amersham plc, GE healthcare) and exposed to 
X-ray films (Amersham plc, GE healthcare) at an appropriate length of time.  
The X-ray films were processed by developers and fixers solutions (CPIL). 
For membrane stripping, blots were washed three times with TBST for 10 
minutes each.  Stripping buffer (To prepare 100 ml, mix 0.76 g Trizma® base, 
2 g SDS and 700µl ȕ-mercaptoethanol. Bring to 100ml with dH2O and adjust 
pH to 6.8 with HCl) were incubated with blots for 30 minutes at 50
o
C.  Blots 
were washed three times with TBST for 10 minutes each and membranes were 
used as fresh for appropriate applications. 
 
6.3.8 Reverse transcription polymerase chain 
reaction (RT-PCR) 
 
Cells were seeded at a density of 3x10
5
 on 10 cm tissue culture plate and were 
treated with compounds after 2 days culture at 37
o
C with 5% CO2 atmosphere.  
Cells were collected at appropriate time points following the removal of culture 
medium.  RNA was extracted using Qiagen RNeasy® mini kit (Qiagen) and 
used under manufacturers instruction. 
The concentration of RNA samples were estimated by NanoDrop® ND-
1000 Spectrophotometer (Thermo Fisher Scientific, USA), which was used 
under manufacturers instruction.  Resultant RNA content was calculated at ng 
per ȝl by software provided by the manufacturer. 
To obtain a cDNA template from the RNA samples, 4 µg of RNA for each 
individual sample were mixed with 10 µM oligo (dT)18 primers (Bioline) and 
diluted with H2O (Sigma) to a final volume of 13 µl.  Addition of 0.5 µl 
transcriptor reverse transcriptase (20 U/µl) (Roche) and 4 µl transcriptor RT 
reaction buffer (5x) (Roche) was followed with the final addition of 20 mM 
PCR grade nucleotide mix (Roche) and 7.5 µl of H2O (Sigma).  Samples were 
incubated at 25
o
C for 10 minutes followed by 30 minutes at 55
o
C in thermal 
cycler (PTC-100
TM
, MJ Research INC).  Reactions were stopped by heating at 
85
o
C for 10 minutes and cooled down at 4
o
C.  For long term storage, the 
cDNAs were kept at -20
o
C. 
To quantify the mRNA product, 100 ng cDNA from each individual sample 
was mixed with 25 µM forward and reverse primers, followed with the 
addition of 10 mM PCR grade nucleotide mix (Roche).  Addition of 0.25 µl 
Taq DNA polymerase (5 U/µl) (Roche) and 5 µl PCR reaction buffer (10x) 
(Roche), H2O was added to make up the final volume of 50 µl.  The PCR 
reactions were heated in thermal cycler at 94
o
C for 2 minutes and 30 cycles of 
denaturation anneling elongation (94
o
C for 30 seconds, 55
o
C for 60 s, and 72
o
C 
for 3 minutes).  The final elongation for 7 minutes at 72
o
C and cooled down at 
4
o
C.  The PCR products were stored at -20
o
C. 
The primers for amplifying ȕ-Actin were purchased from MGW Biotech 
AG (Ebersberg, Germany), other primers were custom designed by Dr Scott 
Roberts and produced by Sigma.  The sequences of these primers were listed 
below (Table 6.1). 
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Oligo Forwardprimer Reverseprimer
Mcl ?1 5GAAGGCGCTGGAGACCTTAC3 5CATTCCTGATGCCACCTCT3
Mcl ?1LT 5TAAGGACAAAACGGGACTGG3 5GCTCCTACTCCAGCAACACC3
Bcl ?2 5ATGTGTGTGGAGAGCGTCAA3 5GCCGTACAGTTCCACAAAGG3
XIAP(1)
5TCACTTGAGGTTCTGGTTGC3 5CGCCTTAGCTGCTCTTCAGT3
XIAP(2) 5TGCAAAGCTTCTCCTCTTGC3
HDM ?2 5TGGTGCTGTAACCACCTACA3 5TTTTTGTGCACCAACAGACTTT3
 
Table 6.1: Sequences of custom designed PCR primers  
 
The PCR products were analysed using agarose gel electrophoresis.  The 
agarose gel was prepared at a concentration of 2.5% agarose with TBE buffer 
(0.89 M Trizma® base, 0.89 M Boric acid, 0.02 M EDTA).  Reaction mixture 
was heated in microwave to dissolve the agarose.  The clear mixture was 
cooled down to room temperature and ethidium bromide (EtBr) was added to 
make up the concentration of 0.2 µg/ml.  The mixture was poured into the gel 
container with the combs added.  After the gel was set, combs were removed 
and load with 5 µl PCR product with 1 µl gel loading solution (Sigma) per 
samples.  Samples were separated with TBE buffer at 100 V for 30 minutes. 
Gel with separated PCR products were visualised under UV light.  Images 
were recorded digitally and to estimate the relative effect on nucleic acids 
between samples, intensity of bands was measured using software Image J
TM
. 
 
6.3.9 Cellomics Array Scan protein expression 
assay 
 
Cellomics Array Scan protein expression assay was used to determine the 
stabilisation of p53 protein by compounds.  Samples were prepared by Dr 
Carol Midgley (Open University, Cambridge, UK).  Plates were read in the 
University of Nottingham using ImageXpress Micro (Molecular Devices) 
available in the institute of cell signalling.  Images were analysis by software 
MetaXpress
TM
 (Molecular Devices) to give the statistical data.  
 
6.3.10 Cell imaging studies 
 
Cells were seeded at a density of 1x10
5
 in 6 well tissue culture plates and were 
treated with compounds after overnight culture at 37
o
C with 5% CO2 
atmosphere.  At the time point required, images were observed under light 
microscope (Olympus) at 40 times magnification and recorded by digital 
camera (Nikon). 
 
6.3.11 Biochemical tubulin polymerisation assay 
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HTS-Tubulin Polymerisation Assay Kit (Cytoskeleton, Inc.) was used to 
determine the effect of drug on tubulin polymerisation and the kit was used 
under manufacturers instruction.  Briefly, compounds were diluted into desire 
concentration with General tubulin buffer (PEM) supplied [80 mM Na-PIPES 
(pH 6.9), 1 mM MgCl2 and 1 mM EGTA].  HTS-Tubulin was diluted with 
PEM to give a final concentration of 4mg/ml.  Compounds were added to each 
well of the 96 well plate followed by the addition of PEM buffer with 1mM 
GTP.  The assay starts following the addition of tubulin solution.  The reaction 
occurred at 37
o
C for 1 hour.  The optical density was measured every minute at 
the absorbance wavelength of 340 nM in a spectrophotometer. 
 
6.3.12 Ex vivo angiogenesis assay  
 
Chorioallantoic Membrane (CAM) Assay is the ex vivo assay to determine the 
anti-angiogenic effect of compounds.  Appointed on the arrival of fertilised 
chicken eggs (Henry Stuart, Joice and Hill Poultry Ltd, Peterborough, UK), 
eggs were placed horizontally and incubated at 37
o
C for 4 days.  After the 
incubation period, eggs were placed under a detectable light source to check 
the blood vessels formations that have occurred around the embryo.  The 
position of the embryo was marked by pencil on the shell of eggs.  Eggs were 
placed horizontally at all times.  A sterile 19 g needle and 10 ml syringes (BD, 
USA) were inserted into the egg at the 9 oclock position of the embryo to 
remove 6-10 mls of albumin.  The puncture hole was sealed by sterile masking 
tape after removal of needle.  An approximate 1x1.5 cm
2
 window was cut by a 
band-saw with shells removed.  Viability of the embryo was checked before 
addition of compounds.  Compounds were soaked in sterile filter paper with 
size 2x3 mm
2
 and placed at a site of vasulisation approximate 1-2 cm away 
from the embryo.  The window was sealed with sterile masking tape after the 
addition of compounds and egg were incubated at 37
o
C for a further 6 days.  
Eggs were removed from incubator after 6 days incubation followed by 
additional shells removed from the window.  Stereomicroscope (Lecia, 
model no. MZ16F) was used to capture the images of embryos.  Retrieved 
specimens were disposed according to ethical guidelines. 
 
6.3.13 DPPH assay 
 
The mixture containing 20 ȝL of sample solution (different concentrations) and 
180 ȝL of DPPH (1,1-diphenyl-2-picrylhydrazyl, 150 ȝȂ) 7 was taken in a 96 
well plate and incubated at 37
o
C for 30 minutes.  The absorbance was 
measured at 517 nm by a microplate reader.  Radical scavenging activity was 
calculated by the following equation: 
 
I ( %) =100× (Ablank-Asample)/Ablank 
 
Where Ablank is the absorbance of the control mixture excluding the test 
compounds, and Asample is the absorbance of the mixture with the tested 
6.3. In vitro biological assays 
158 

compounds.  IC50 values represent concentration of compounds to scavenge 
50% of DPPH radicals.  
 
6.3.14 In vitro oxidation states analysis with FACS 
 
Cells were seeded at a density of 3x10
5
 and were treated with compounds at 
37
o
C with 5% CO2 atmosphere after overnight culture.  Cells were treated with 
5 ȝM hydrogen peroxide as required 1 hour before the collation of samples.  30 
minutes prior to the end of the experiment, 5 ȝM 2ƍ,7ƍ-dichlorofluorescin 
diacetate (H2DCFDA)  were added to the cells.  Cells were collected together 
with the media at appropriate length of time, washed with PBS, placed in 
FACS tube and centrifuged at 1200 rpm for 5 minutes at room temperature.  
Supernatants were discarded and suspended in FACS tube with 300 ȝl PBS 
containing 50 ȝg/ml propidium iodide.  All samples were analysed using FACS 
within 1 hour. 
 
6.3.15 Statistical analysis 
 
GraphPad Online Software (GraphPad Software, Inc.) was used for calculation 
of p values.  Microsoft Excel was used in generate statistical data, such as 
mean values and standard deviations, from all data set demonstrated.  It was 
also used in calculating all graphic related statistics.   
 
6.4 Compound synthesis  
 
General. 
1
H-NMR spectra were obtained using a Bruker-400 spectrometer.  
Chemical shifts are reported in parts per million relative to internal 
tetramethylsilane standard.  Coupling constants (J) are quoted to the nearest 0.1 
Hz.  The following abbreviations are used: s, singlet; d, doublet; t, triplet; q, 
quartet; qu, quintuplet; m, multiplet and br, broad.  Mass spectra were obtained 
using a Waters 2795 single quadrupole mass spectrometer with electrospray 
ionization (ESI).  Microwave assisted chemistry was carried out using CEM 
Discovery model (Biotage Ltd. UK).  TLC (thin-layer chromatography) was 
performed using alumina plates coated with silica gel G60. Developed plates 
were air dried and analysed under a UV lamp (254 / 365 nm).  Silica gel (EM 
Kieselgel 60, 0.040-0.063 mm, Merck) or ISOLUTE pre-packed columns was 
used for flash chromatography.  
 
Methyl 2-(cyclopentylamino)butanoate 14 
 

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DL-alanine ethyl ester hydrochloride 12 and 1 equivalent of cyclopentanone 13 
were dissolved with dichloromethane (10 equivalents) at 0
o
C.  1 equivalent of 
sodium acetate and 1.5 equivalents of sodium triacetoxyborohydrate were 
added and the reaction mixture was stirred for 12 hours.  20% aqueous sodium 
hydrogen carbonate solution was added to the reaction mixture until hydrogen 
gas was no longer generated.  The reaction mixture was extracted into 
dichloromethane twice and the combined organic phase collected, washed with 
water and dried over magnesium sulphate.  The organic phase was evaporated 
to give [14, colourless oil]. 
1
H NMR (400 MHz, DMSO-d6) į 3.63 (s, 3H), 3.12-3.08 (m, 1H), 2.90-2.88 
(m, 1H), 1.90 (s, 1H), 1.60-1.43 (m, 8H), 1.29-1.22 (m, 2H), 0.86-0.81 (t, 
J=8.4Hz, 3H) 
(MS-ES) m/z 186.14 (MH
+
, C10H19NO2 requires m/z 186.26) 
 
Methyl 2-((2-chloro-5-nitropyrimidin-4-yl)(cyclopentyl)amino)butanoate 
16 
 
 
 
While cooling on ice, 1 equivalent of 14 was suspended in acetone (30 
equivalents).  1 equivalent of 2,4-dichloro-5-nitropyrimidine 15 was added into 
the reaction mixture followed by the addition of potassium carbonate (1.1 
equivalents).  The reaction mixture was returned to room temperature and 
stirred for a further 12 hours.  0.1 equivalents of 2,4-dichloro-5-nitrpyrimidine 
were added after 12 hours and the reaction mixture was stirred for further 3 
hours.  The reaction mixture was evaporated down, taken up in ethyl acetate 
and water (4:3) and the aqueous was extracted with ethyl acetate.  The 
combined organic phase was washed with water, dried with magnesium 
sulphate and evaporated down.  The product in the form of brown oil was 
applied to silica gel and purified by chromatography to obtain [16, yellow 
crystal]. 
1
H NMR (400 MHz, DMSO-d6) į 8.84 (s, 1H), 2.08 (s, 3H), 1.92-1.64 (m, 9H), 
1.42-1.35 (m, 1H), 0.96-0.92 (t, J=7.4Hz, 3H), 0.89-0.80 (m, 2H) 
(MS-ES) m/z 343.12 (MH
+
, C14H19ClN4O4 requires m/z 343.78) 
 
2-chloro-8-cyclopentyl-7-ethyl-7,8-dihydropteridin-6(5H)-one 17 

N
N
H
N
NCl
O
 
 
5 equivalents of 16 was dissolved in excess glacial acetic acid at 70oC, 1 
equivalent of iron powder was added batch-wise.  The reaction mixture was 
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stirred at 70
o
C for 1 hour and 100
o
C for further 1.5 hours.  The reaction 
mixture was filtered hot through Kieselguhr.  The reaction mixture was 
evaporated resulted in brown oil. [17, brown oil]. 
1
H NMR (400 MHz, DMSO-d6) į 7.56 (s, 1H), 2.08 (s, 1H), 1.99 (s, 1H), 1.94-
1.54 (m, 9H), 1.19-1.16 (m, 2H), 0.81-0.76 (t, J=9.4Hz, 3H) 
(MS-ES) m/z 281.12 (MH
+
, C13H17ClN4O requires m/z 281.75) 
 
2-chloro-8-cyclopentyl-7-ethyl-5-methyl-7,8-dihydropteridin-6(5H)-one 18 
 

 
1 equivalent of 17 was dissolved in dimethylacetamide at -14oC.  After 1 
equivalent of methyl iodide and 1 equivalent of sodium hydride in 60% mineral 
oil suspension were added, the reaction mixture was stirred for 20 minutes in 
0
o
C and 30 minutes at ambient temperature.  To stop the reaction, ice was 
added and the reaction mixture was evaporated down.  The reaction mixture 
was diluted with water and suction filtered after the formation of precipitate.  
The precipitate was re-dissolved in dichloromethane, applied to the silica gel 
and purified with chromatography to obtain 18.  [18, yellow oil]. 
1
H NMR (400 MHz, DMSO-d6) į 7.87 (s, 1H), 4.36-4.34 (q, J=3.5, 1H), 4.18-
4.14 (t, J=8.2Hz, 1H), 4.05-4.00 (q, J=7.1Hz, 1H), 1.99 (s, 3H), 1.94-1.77 (m, 
8H), 1.73-1.67 (m, 1H), 1.56-1.53 (m, 2H), 1.19-1.15 (t, J=7Hz, 3H), 0.75-0.71 
(t, J=7.6Hz, 3H) 
(MS-ES) m/z 295.12 (MH
+
, C14H19ClN4O requires m/z 295.78) 
 
1-methylpiperidin-4-amine 20 
 
N
NH2
 
 
1 equivalent of ethyl 4-aminopiperidine-1-carboxylate 19 was dissolved in dry 
ether and cooled in ice bath.  Under anhydrous conditions (nitrogen gas), 2.5 
equivalents of lithium aluminium hydride (LiAlH4) was added and the reaction 
mixture was stirred in an ice-bath for another half hour.  The reaction mixture 
was placed into oil bath after 30 minutes and slowly heated up to 44
o
C to allow 
reflux for 17 hours.  To stop the reaction, the reaction mixture was cooled in 
ice and the unreacted LiAlH4 was quenched by the addition of 10% aqueous 
NaOH until the effervescence subsided.  The resulting slurry was filtered under 
vacuum and the filtrate washed with ether.  The combined ether was dried with 
magnesium sulphate, filtered and evaporated. [20, yellow oil]. 
 
3-methoxy-4-nitrobenzoyl chloride 22 
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A suspension of 3-methoxy-4-nitrobenzoic acid 21 (1 equivalent) was 
dissolved in chloroform under nitrogen.  Thionyl chloride (3 equivalents) was 
subsequently added and the reaction mixture was reflux for 3 hours under 
nitrogen until a clear solution formed and then concentrated to dryness at 60
o
C. 
[22, yellow solid]. 
 
3-methoxy-N-(1-methylpiperidin-4-yl)-4-nitrobenzamide 23 
 
 
 
1 equivalent of 20 was dissolved in Tetrahydrofuran (THF) and 1.5 equivalents 
of pyridine were added.  The reaction mixture was added to the 1 equivalent of 
22 and stirred for 2 hours under nitrogen at ambient temperature, followed by 1 
hour reflux.  The reaction mixture was cooled down and evaporated.  The 
resulting solid was re-dissolved in hot ethanol.  After the formation of 
precipitate, the reaction mixture was suction filtered and participate collected. 
[23, white solid].  
1
H NMR (400 MHz, DMSO-d6) į 8.92-8.91 (d, J=6.8 Hz, 1H), 7.97-7.95 (d, 
J=8.4, 1H), 7.79, (s, 1H), 7.62-7.60 (d, J=8.0Hz, 1H), 4.01 (s, 1H), 3.43-3.36 (t, 
J=15.4Hz, 4H), 3.10 (s, 2H), 2.71 (s, 3H), 1.99 (s, 4H) 
(MS-ES) m/z 294.13 (MH
+
, C14H19N3O4 requires m/z 294.32) 
 
4-amino-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide 24 
 
 
 
23 (10 equivalents) was dissolved in excess ethanol followed by the addition of 
palladium in 10% carbon (1 equivalent).  The reaction mixture was stirred at 
ambient temperature under hydrogen gas.  After 4 hours, the reaction mixture 
was filtered through Kieselguhr.  The reaction mixture was evaporated and re-
dissolved in hot ethanol.  After the formation of precipitate, the reaction 
mixture was suction filtered, and participate were collected. [24, white solid] 
1
H NMR (400 MHz, DMSO-d6) į 8.15-8.13 (d, J=7.2 Hz, 1H), 7.36-7.34 (q, 
J=2.1, 2H), 6.62-6.60 (d, J=8.8Hz, 1H), 5.28 (s, 2H), 4.02-3.99 (m, 1H), 3.81 
(s, 3H), 3.38-3.35 (d, J=12.0Hz, 2H), 3.06 (s, 2H), 2.68 (s, 3H), 1.95-1.94 (d, 
J=2.8H) 
(MS-ES) m/z 264.17 (MH
+
, C14H21N3O2 requires m/z 264.34) 
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4-(8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-
ylamino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide 25 
 
N
N
N N
HN
O
O
HN
O
N
 
 
1.1 equivalents of 18 and 1 equivalent of 24 were heated at 160oC overnight 
without any solvent and base.  After the reaction completed (checked by TLC, 
100% ethyl acetate, RF = 0.22), the reaction mixture was dissolved in methanol 
and applied to silica for column chromatography, the fraction with product was 
evaporated down, and a small amount of ethyl acetate added followed by the 
addition of excess hexane until the formation of precipitate.  The precipitate 25 
was filtered and washed with hexane. [25, yellow solid]. 
1
H NMR (400 MHz, DMSO-d6) į 7.82-7.80 (t, J=4.0Hz,1H), 7.72 (s, 1H), 
7.29-7.27 (m, 2H), 6.60-6.57 (m, 1H), 5.22-5.18 (d, J=16.0Hz, 2H), 4.56-4.53 
(d, J=13.6, 2H) 4.56-4.00 (m, 6H), 3.80-3.75 (m, 2H), 3.19 (s, 3H), 2.94-2.91 
(t, J=6.0Hz, 3H), 1.99-1.78 (m, 6H), 1.77-1.72 (m, 6H) 1.62-1.33 (m, 9H), 
1.23-1.15 (m, 5H), 0.85-0.73 (m, 5H) 
(MS-ES) m/z 522.00 (MH
+
, C14H21N3O2 requires m/z 522.65) 
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It is now a well established fact that natural products can provide compounds having either 
immediate drug potential or which provide inspiration for synthetic drug discovery. It is 
estimated that over 60 percent of the current anticancer drugs are derived from natural 
sources. Erianin, a known natural product of Dendrobium chrysotoxum, possesses potent anti-
tumour activity and is currently in clinical development for the treatment of haematological 
malignancies in China. Erianin has been shown to disrupt endothelial tube formation and to 
inhibit the polymerised both F-actin and ȕ-tubulin. In this study, we report that ZJU-6, a 
novel semi-synthetic derivative of Erianin, demonstrated excellent anti-proliferative and anti-
angiogenic activities. The anti-proliferative activity of ZJU-6 was evaluated against several 
human tumour cell lines by 72 hrs MTT assay which gave low to sub-µM GI50 values. The 
cellular mode of action was further investigated. FACS analyses revealed that treatment of 
MCF-7 cells with 5µM ZJU-6 for 48 hrs resulted in G2/M phase cell cycle block.  
Microtubule polymerisation assays showed that ZJU-6 inhibits polymerisation of tubulin 
more effectively than Erianin. Furthermore, when MCF-7 cells are treated with 5µM ZJU-6 
for 24hrs, Western blots showed that Bcl-2 protein expression was significantly inhibited 
while the level of Mcl-1 was not affected. PARP cleavage indicated the cells undergoing 
apoptosis in the presence of ZJU-6. The effect of ZJU-6 on angiogenesis was also 
investigated in the chick embryo chorioallantoic membrane assay. The compound possessed 
potent anti-angiogenic property, being more effectively than Erianin, by blocking the blood 
vessel formation during embryonic development. In conclusion, we have identified a novel 
anti-tumour agent ZJU-6 which inhibited tubulin polymerisation, causing accumulation of 
cells within G2/M cell cycle phase. The compound was able to suppress the expression of 
Bcl-2 anti-apoptotic protein and induce apoptosis in cancer cells. Furthermore ZJU-6 has 
demonstrated potent anti-angiogenic activity. These data suggest that ZJU-6 is a potential 
drug candidate for cancer therapy. 
 
